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SUMMARY
A study was undertaken to investigate the radiochemical stability of the ~-iodoethoxyl moiety,
a relatively novel prosthetic group employed in radiopharmaceutical chemistry, in which an
oxygen atom in a ~-position relative to the radioiodine atom has a stabilising effect on the
aliphatic carbon-iodine bond. The investigation was started as a pilot study by synthesising
various model compounds containing a ~-radioiodoethoxyl moiety, as well as two reference
compounds lacking such a moiety. The purpose was to determine the influence of various
groups in the vicinity of the ~-oxygen atom on the stability of the abovementioned moiety.
Radiochemical stability tests were carried out in vitro at 37°C in human blood serum. The
results confirmed the superior stability of such a moiety compared to that of the reference
compounds and also showed that the branching of such an aliphatic unit resulted in a
considerable improvement in its stability, especially over a longer period.
The investigation was extended to the synthesis of other compounds containing a few selected
~-iodoethoxyl moieties that showed improved stability in the pilot study work. Reference
compounds containing the classical iodovinyl unit, as well as those lacking a stabilising ~-
oxygen atom, were also prepared. The carrier molecules used in this part of the work was a
benzamide containing a phenolic oxygen atom which acted as the ~-oxygen atom, as well as
two heterocyclic amines, benzotriazole and 2-methyl-5-nitroimidazole, in which the ~-
iodoethoxyl moiety was linked to a secondary nitrogen atom. Various suitable alkylating agents
were prepared, chemically linked to the carrier molecules, the resulting intermediate
compounds converted into tosylate or triflate iodination precursors and labelled with
radioiodine by means of iodide-for-tosylate/triflate exchange. In vitro stability tests of these
compounds showed similar trends to those obtained with the model compounds. Moreover, the
stability of the stabilised ~-iodoethoxyl moiety compared favourably with that of the iodovinyl
unit, especially when incorporated into a heterocyclic amine. The results of this study have
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shown that some of the radioiodinated compounds synthesized in this work, especially the
nitroimidazole derivatives, have the potential to be considered as novel radiopharmaceuticals.
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OPSOMMING
'n Studie is onderneem om die radiochemiese stabiliteit van die ~-jodium-etoksi-eenheid te
ondersoek. Dié eenheid is 'n relatief nuwe prostetiese groep wat in radiofarmaseutiese chemie
gebruik word. Die suurstofatoom wat in 'n ~-posisie relatief tot die radiojodiumatoom
voorkom, oefen 'n stabiliserende invloed op die alifatiese koolstof-jodiumbinding uit. Die
ondersoek het met 'n loodsstudie begin deur verskillende modelverbindings te sintetiseer wat 'n
~-radiojodium-etoksi-eenheid bevat, asook twee verwysingsverbindings waarin so 'n eenheid
ontbreek. Die doel hiermee was om die invloed van verskillende groepe, wat in die omgewing
van die ~-suurstofatoom voorkom, op die stabiliteit van die eenheid te bepaal. Radiochemiese
stabiliteitstoetse is uitgevoer deur middel van inkubering in menslike bloedserum by 37°C. Die
resultate het die groter stabiliteit van so 'n eenheid in vergelyking met dié van die
verwysingsverbindings aangetoon, en het ook uitgewys dat vertakking van so 'n alifatiese
eenheid 'n aansienlike verbetering in die stabiliteit tot gevolg gehad het, veraloor 'n langer
periode.
Die ondersoek is vervolgens uitgebrei deur verdere verbindings te sintetiseer wat beskik oor
bepaalde uitgesoekte ~-jodium-etoksi-eenhede, wat verbeterde stabiliteit in die loodsstudie
getoon het. Verwysingsverbindings wat die klassieke jodiumvinieleenheid bevat het, sowel as
dié waarin 'n stabiliserende ~-suurstofatoom ontbreek het, is ook berei. Die draermolekules
wat in hierdie deel van die studie gebruik is, was 'n bensamied met 'n fenoliese suurstofatoom
wat as die ~-suurstofatoom gedien het, sowel as twee heterosikliese amiene, bensotriasool en 2-
metiel-5-nitroimidasool, waarin die ~-jodium-etoksi-eenheid aan 'n sekondêre stikstofatoom
geheg is. Verskillende geskikte alkileermiddels is berei, aan die draermolekules geheg, die
tussenprodukte omskep in tosilate of triflate en met radiojodium gemerk deur middel van
jodium-vir-tosilaatltriflaat-uitruiling. Stabiliteitstoetse van hierdie verbindings in bloedserum
het soortgelyke tendense as dié van die aanvanklike modelverbindings getoon. Daarbenewens
het die stabiliteit van die gestabiliseerde ~-jodium-etoksi-eenheid gunstig vergelyk met dié van
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die jodiumviniel-eenheid, veral wanneer dit deel gevorm het van 'n heterosikliese amien. Die
resultate van die studie het getoon dat sommige van die radiogejodeerde verbindings wat berei
is, veral die nitroimidasoolderivate, die potensiaal het om as nuwe radiofarmaseutiese
verbindings gebruik te kan word.
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CHAPTERl
INTRODUCTION AND OBJECTIVES
1.10VERVIEW OF RADIOPHARMACEUTICALS
1.1.1 Radiopharmacy: Definitions and History
Radiopharmaceuticals can be defined as radioactive nuclide-containing drugs that are used in
nuclear medicine for noninvasive diagnostic organ or tumour imaging, metabolism studies or
therapy. The purpose for which it is used depends on the energy of the radiation emitted by the
radionuclide. The radionuclide acts as the "active ingredient", while the drug or organic
compound to which it is attached merely acts as a vehicle or carrier that delivers the
radionuclide to its biological target. Diagnostic imaging is carried out using gamma-emitting
nuclides in the energy range of 150 to 300 keY, and a sophisticated scanning module called a
gamma camera. These cameras are equipped with large sodium iodide-crystal detectors with
which the emitted gamma photons interact. All data are recorded simultaneously and
continuously, resulting in well-defined images of the organ or tumour.
Radiopharmacy is the science and art of preparing and dispensing these radiopharmaceuticals,
while radiopharmacology refers to their utilisation for demonstrating their distribution,
deposition, kinetics of metabolism, turnover, and their fmal excretion from the body. The
practice of radiopharmacy as a specialised medical tool began early in the twentieth century. It
all perhaps started in consequence of a report on the injections of radium into the skin lesions
of lupus (Wickham & Degrais, 1911), followed shortly afterwards by another report on the
intravenous injection of radium for the therapy of various diseases (Proescher, 1914). In 1928 a
natural radionuclide, a preparation from thorium dioxide, was introduced in Germany as an
intravenously administered contrast medium for diagnostic radiology (Casper, 1967). The
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artificial production of radionuclides began in the early 1930s. In 1934, E.O. Lawrence, the
inventor of the cyclotron, first produced radioactive nuclides by bombarding stable atoms with
artificially accelerated particles (Lawrence, 1965). His brother, J.H. Lawrence, made the first
clinical therapeutic application of an artificial radionuclide when he used 32p to treat leukemia
in 1937 (Lawrence, 1940). In 1946, radionuclides such as 14C (as barium carbonate), which
were produced in the Oak Ridge reactor in Tennessee, USA, were made available for
biological and medical purposes (Andrews, 1976).
The late 1940s and early 1950s saw the beginning of rapid growth in the medical applications
of radionuclides. Before this stage, most radionuclides had been used in rather simple chemical
forms. In some cases, the nuclides had been attached as labels to molecules already familiar in
their stable form. Relatively little was done with regard to creating entirely new labelled
compounds. In 1946, Abbott Laboratories started to develop and produce radioactively labelled
compounds for medical use. One of the first radioiodine-labelled compounds reported was 1311_
labelled diiodofluorescein (Andrews, 1976), which was used for the detection of brain tumours,
using Geiger-Muller tubes that were placed on the scalp of the patient, as detection device. This
very primitive type of detection apparatus was soon replaced by more modem scanners, and
eventually by the gamma camera. The emergence of other radioiodine-labelled
radiopharmaceuticals, such as serum albumin, antibodies and quinoline derivatives, soon
followed. Today, a vast number of established radiopharmaceutical compounds is available,
and extensive research is still continuing in order to develop improved products.
1.1.2 Design and Synthesis of Radiopharmaceuticals
Radiopharmaceuticals are designed according to the same principles that are applied to the
development of non-radioactive pharmaceuticals. One of these principles is the all-important
relationship between structure and activity. The affinity of a radiopharmaceutical for a specific
biological target depends largely on the structure of the carrier. The radiopharmaceutical
usually binds to a specific organ or tumour in the body through interaction with a receptor.
2
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However, binding can also take place at so-called non-receptor sites, resulting in errors in
receptor binding measurements (Katzenellenbogen et al., 1981). The optimal design of a
radiopharmaceutical is therefore of critical importance in order to obtain images of high quality
that will provide the correct information. In this thesis, structure-activity relationships will-not
be discussed in further detail, as this issue was deemed to be beyond the scope of the present
research project.
When designing new radiopharmaceuticals, other factors should also be taken into
consideration. The choice of radionuclide, as well as its physical properties such as mode of
decay and energy associated with it, is also crucial with regard to the intended application of
the radiopharmaceutical. Modem radiopharmaceuticals are classified into two types, namely
so-called SPECT (single photon emission computed tomography) and PET (positron emission
tomography) tracers. SPECT tracers contain medium- to relatively long-lived radionuclides
with predominant gamma emission and are the most general tracers used in nuclear medicine.
PET tracers contain mostly accelerator-produced short-lived positron emitters, are generally
more expensive than SPECT tracers, and require much more sophisticated scanning equipment
for diagnostic imaging. Positron emitters such as 18p and IlC are incorporated in molecules
designed for PET tracers, and gamma emitters such as 1231, 1311 and 99mTcin SPECT tracers.
Due to its more favourable decay characteristics and principal gamma-ray energy of 159 keY,
1231 is predominantly used in diagnosis, while 1311 with its higher principal gamma energy of
364.5 keY is mostly used in therapy and to a lesser extent in diagnosis.
An orgamc radiopharmaceutical is produced by incorporating a radionuclide into
pharmaceuticals, biochemical substrates and metabolic intermediates. This process is generally
carried out by substituting a stable atom or leaving group in an organic compound with a
radionuclide, and is called radiolabelling or labelling. The radionuclide can be an isotope of the
substituted atom, or it can be a completely different atom. Por example, a stable carbon atom
can be substituted with its radioisotopes IIC or 14C. A stable hydrogen atom can likewise be
substituted with a 3H atom (tritium labelling), or with a radioactive iodine (1231, 131 I) or fluorine
3
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(!8F) atom. Another way to incorporate a radionuclide into an organic structure is by means of
complex formation. This type of labelling process is usually utilised for incorporating
radiometals into organic compounds. Technetium- and gallium-labelled compounds are
produced this way. The radionuclide 99mTcis obtained from a 99Mol9mTcgenerator system as
the pertechnetate anion. In this chemical form it is in its highest oxidation state. A prerequisite
for complex formation is the lowering of the oxidation state of the metal. In order to carry out a
labelling process, the generator eluate is simply mixed with a suitable ligand in the presence of
a suitable chemical reductant at room temperature. Such ligands are usually marketed as so-
called "cold! kits", and are kept in sealed, aseptic glass vials in a lyophilised form. Today,
99mTc-Iabelledcompounds are the most frequently used SPEeT tracers in nuclear medicine due
to their relative ease of preparation, as well as the ready availability and relatively low cost of
the isotope.
For the purpose of this study, emphasis will be placed solely on diagnostic type of
radiopharmaceuticals containing radioactive iodine. There is a wide range of radioiodinated
radiopharmaceuticals due to the relative ease with which iodine can react with many organic
compounds. Examples of these are the following: radioiodinated benzylguanidine for the
imaging of tumours associated with the adrenal glands (McEwan et al., 1986), radioiodinated
hippuric acid or long-chain fatty acids for kidney or heart muscle imaging respectively
(Zielinski et al., 1977; Machulla et al., 1980b) and radioiodinated benzamides for brain
imaging (Kung et al., 1988a).
The most commonly used radiolabelling methods employed for the production of
radioiodinated compounds are the following:
(1) Exchange of a stable iodine atom in the molecule with a radioactive iodine atom (isotope
exchange).
(2) Exchange of a stable chlorine or bromine atom in the molecule with radioiodine (halogen
exchange in a so-called Finkelstein substitution).
IThe term "cold" refers to non-radioactive compounds
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(3) Substitution of a stable hydrogen atom with radioiodine (direct iodination).
(4) Substitution of a good leaving group, pre-introduced into the molecule, with radioiodine.
The exchange reactions, as well as the leaving group substitution, can be carried out on aryl-X
as well as on alkyl-X compounds, where X is the atom to be exchanged or substituted. Direct
iodination is limited to aryl-X compounds only, which requires activation of the aromatic ring
towards electrophilic substitution.
All of these methods result in products with different compositions. The isotope exchange
reactions produce products that have so-called low specific activities. The term specific activity
is defined as the activity per unit mass of an element or compound containing the radioactive
nuclide. It can also be said that the mass or molar ratio between the radioiodinated compound
and its stable precursor' is low due to the small percentage of stable atoms that is exchanged.
The mass associated with the radioactivity is only in the order of nano- to picograms, while the
mass of the precursor is in the order of milli- to micrograms. In isotope exchange reactions the
radiolabelled compound obviously cannot be separated from its stable precursor because of
their identical chemical properties. The other radiolabelling methods, on the other hand, can
lead to products with higher specific activities. For example, when a bromine atom is
exchanged with a radioiodine atom in the Finkelstein reaction, the radioiodinated species can
be fairly well separated from its non-radioactive brominated precursor by chromatographic
means. The substitution reactions invariably result in radiopharmaceuticals with much higher
effective specific activities, as the radioiodinated species can be quite effectively separated
from their respective precursors. Having the precursor as an impurity in a radioligand would,
on the other hand, reduce the effective specific activity of the radiopharmaceutical (Pike et al.,
1991). The specific activity of radiopharmaceuticals is important, especially in receptor
imaging. If the specific activity is too low, the receptor can easily be saturated with stable
precursor (Pike et al., 1991), resulting in the exclusion of the radiopharmaceutical. This
2 A precursor is the starting material used for the synthesis of a radioiodinated compound
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prerequisite does not apply to all types of radiopharmaceuticals, and the isotope exchange
method is therefore fairly commonly used in radiochemistry.
To summarise, the chemical structure of a chosen target molecule (i.e. the molecule to be
radiolabelled) must not only be in line with structure-activity requirements, but must also allow
relatively fast labelling, which would result in high radiochemical yield and, when needed,
high specific activity. Other important requirements regarding the design of
radiopharmaceuticals will be discussed in the following paragraph.
1.1.3 Radiochemical Stability of Radiopharmaceuticals
The properties of a radiopharmaceutical are not only important with regard to its efficiency of
binding to a receptor or organ, but also with regard to its radiochemical stability. A
radiopharmaceutical is of no use if it cannot retain its radioactive nuclide, as the biological
pathway of the unbound nuclide is completely different to that of the covalently bound nuclide.
For example, free radioiodine will accumulate in the thyroid, while radio iodinated hippuric
acid will migrate to and be excreted by the kidneys. Deiodination can therefore result in
unwanted radiation of healthy organs (Warren et al., 1990). The radioiodine should therefore
be introduced regioselectively into an organic compound to ensure optimum stability of the
covalent carbon-iodine bond. However, the relatively poor biochemical stability of the C-I
bond often leads to dehalogenation and a high blood background which could seriously affect
imaging (Coenen et al., 1983).
Deiodination of radioiodinated compounds can occur "in vitro" (outside the body), as well as
"in vivo" (inside the body). Storage of such compounds in solution at room or elevated
temperatures might result in the gradual decomposition of the carbon-iodine bond due to
radiolysis, a process that accompanies the radioactive decay of the radionuclide (Verbruggen,
1987; Chattopadhyay et al., 2001). Radiolysis is mostly pronounced at high activity levels
(more than 225 MBq/ml) (Eersels & Herscheid, 2001) and when dealing with a-emitting
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nuclides or nuclides which decay during processes followed by an Auger process and the
emission of a high number of electrons (Coenen et al., 1983). Radiopharmaceuticals with high
specific activities can also exhibit radiolytic decomposition (Coenen et al., 1983). This process
can be diminished by the addition of radical absorbers and bactericidal agents such as benzyl
alcohol, para-hydroxybenzoic acid, etc. (Saha, 1983; Wafelman et al., 1994). The stability of
radiohalogenated pharmaceuticals (tracers) under physiological conditions is very important for
their in vivo application. In vivo deiodination is probably of bigger concern to nuclear
pharmacists because the breakdown of the molecule cannot be controlled. The deiodination of
radioiodinated antibodies can be caused by three processes (Warren et al., 1990), namely by
hydrolytic, enzymatic (Eary et al., 1988) and catabolic biochemical means (Leninger, 1982).
These deiodination processes can be limited by introducing various structural changes to
compounds. Warren et a!. postulated that hydrolytic deiodination can be minimised by
employing stronger aryl-iodine bonds, while enzymatic deiodination could be inhibited by the
elimination of adjacent hydroxyl groups in aromatic compounds. The presence of a hydroxyl
group in the aromatic ring of a radioiodinated antibody ortho to an iodine atom can also lead to
some in vivo deiodination (Vaidyanathan et a!., 1995). Krummeich et a!. (1994) claimed that
O-methylation, as well as methylation in the alpha-position of tyrosine, increase the in vivo
stability of the radioiodinated product towards deiodination.
The chemical as well as physical nature of carbon-iodine bonds, for example, the C-I bond
energy, are important factors regarding the stabilities of radioiodinated tracers (Coenen et al.,
1983). The bond energy of aryl halides is generally 40 to 80 kJ/mole higher than that of alkyl
halides, while vinyl iodides exhibit slightly higher C-I bond energies than aryl iodides.
Furthermore, halogens on aromatic rings are usually metabolically stable, and vinyl compounds
are more stable in vivo than aliphatic ones (Chenoweth & McCarty, 1963). Generally,
compounds having Sp2carbon-bonded iodine have a higher metabolic stability than those with
iodoalkyl functionalities (Seevers & Counsell, 1982; Musachio & Lever, 1992). The chemical
environment surrounding the labelled tracer is also important. Mazaitis et al., (1980) have, for
example, found that iodoethynyl derivatives are stable under synthetic conditions but were
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completely deiodinated in blood plasma within one hour. co-Halogenated long-chain fatty acids
show no decomposition when stored for one hour in blood (Kupfernagel, 1978), while half of
the bonded iodine is released from 17-[1231]-iodoheptadecanoic acid in the heart muscle cells of
mice 30 seconds after i.V. injection (Kupfernagel, 1978; Stocklin et al., 1980). This implies that
the metabolic process which degrades the iodinated fatty acid is relatively fast (Kloster &
Stocklin, 1982). On the other hand, the halogen in halophenyl fatty acids is metabolically stable
(Stocklin et al., 1980; Machulla et al., 1980a).
To summanse, there are numerous factors that can prevent a radiotracer from reaching its
target inside the body. Not only can it lose its radionuclide before being administered, but this
can also take place inside the body. Radiopharmaceuticals are normally administered as soon
as possible after they are synthesised due to the relatively short half-lives of their incorporated
radionuclides. For this reason, radiochemists are not too concerned about their shelf stability,
as this, to a certain extent, can be controlled. Their biological breakdown poses a much bigger
problem, and this has been the topic of extensive research.
The preceding arguments imply that the position of a radionuclide in a molecule, as well as the
presence of neighbouring groups, largely influences the stability of the tracer. Ideally,
radioiodine should be introduced into an aromatic moiety of a target molecule due to the
relatively higher stability of the aromatic carbon-iodine bond (Mennicke et al., 2000). Direct
electrophilic radioiodination is most commonly used, but many molecules do not possess
aromatic rings or are not suited to this procedure because they lack activating functionality or
lose biological activity when iodinated at the chemically favoured site (Musachio & Lever,
1992). For example, molecules like the neuroreceptor ligand diprenorphine (a 4,5-
epoxymorphinan) contain a highly activated aromatic (phenolic) ring suitable for direct
electrophilic radioiodination. However, direct substitution of the aromatic ring with heavy
halogens leads to a substantial reduction in potency of 4,5-epoxymorphinans (easy & Parfitt,
1986; Wang et al., 1995). For all these reasons, radiochemists have to make use of alternative
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methods to introduce a radionuclide into an organic molecule. This will be discussed in the
following section.
1.2 PROSTHETIC GROUPS IN RADIOPHARMACEUTICAL CHEMISTRY
1.2.1 Introduction
It was mentioned in the previous section that the aromatic portion of a molecule is the most
commonly used site for the introduction of radioiodine, but that, due to certain restrictions, the
scope for this technique is limited. In order to circumvent this problem, radio chemists make
use of so-called prosthetic groups that act as a "bridge" between the parent molecule (i.e. the
unmodified molecule to be radiolabelled) and the radionuclide. Prosthetic groups usually are
relatively small organic units that can easily be attached to the parent molecule without
significantly changing its chemical, physical or biological properties. Prosthetic groups can
also fulfil other functions, such as enhancing the reactivity of a molecule, improving its
stability, controlling regiospecificity and preventing harsh labelling reaction conditions
(Musachio & Lever, 1992). The reagents used for the introduction of prosthetic groups into
radiopharmaceuticals typically contain two functional groups, one for attaching the unit to the
parent molecule via an established chemical method (e.g. nucleophilic addition), and the other
to serve as a good leaving group that can be substituted by a suitable radionuclide (e.g. in
radioiododestannylation reactions) (Musachio & Lever, 1992). In most cases the attachment
step will precede the displacement step as it is advisable to incorporate the radionuclide in the
final step of any synthesis. It also follows from previous arguments that the carbon-
radionuclide bond in a prosthetic group should be very stable in order to prevent loss of the
radionuclide.
1.2.2 Types of Prosthetic Groups
Various types of prosthetic groups of varying size, have been used. One classical example is
the so-called Bolton-Hunter reagent, a radioiodinated 3-(p-hydroxyphenyl)propionic acid N-
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hydroxysuccimide ester, tailored for conjugation to proteins, antibodies and glycocides
(Musachio & Lever, 1992; Bolton & Hunter, 1973; Lowndes et al., 1988; Wilbur et aI., 1989;
Lin et al., 1989; Vaidyanathan & Zalutsky, 1990). However, due to its relatively large size, it is
of limited applicability to small molecules (Musachio & Lever, 1992). A vast number of other
radiolabelled reagents has been used for protein conjugation and has been reviewed by Wilbur
(1992). These include activated esters, imidate esters, aldehydes, isocyanates and
isothiocyanates. All of these reagents react with protein amines to form different types of bond
linkages (amides, amidines, imines, ureas and thioureas). para-Iodobenzylbromide is one of the
few prosthetic groups chiefly intended for radiolabelling small molecules with either I251 or 1231
(Wilson et al., 1986), but it has also been applied to the synthesis of radioiodinated glucose
analogues (Saji et al., 1987). This reagent is particularly appropriate when the benzyl unit is an
integral part of the target (i.e. the molecule to be radiolabelled) (Musachio & Lever, 1992). For
radioiodination of small molecules, prosthetic groups, which impart less bulk and lipophilicity,
are desired (Musachio & Lever, 1992). The lithiated vinylstannane 1.1 is the smallest prosthetic
group that has been used in radioiodinations (Musachio & Lever, 1992).
1.1
After nucleophilic addition to carbonyl groups and subsequent halodemetalation this group
yields iodovinyl derivatives (Hanson & Seitz, 1982; Hanson, Seitz & Botarro, 1982). (E)- and
(Z)-3-(Tributylstannyl)prop-2-en-l-yl tosylates are other allylic bifunctional alkylating agents
which render vinylstannanes for radioiodination (Musachio & Lever, 1989). The relatively high
stability of vinyl iodides has already been referred to. These bifunctional agents can be attached
to an OH-group in a target molecule such as diprenorphine via a coupling reaction involving
the tosylate group, followed by an electrophilic radioiododestannylation reaction, involving the
tributylstannyl group, to produce O-iodoallyl compounds with the oxygen atom in a gamma
position relative to the iodine (Musachio & Lever, 1992; Wang et al., 1995). This type of
prosthetic group is present in compound 1.2. The derivatisation of the OH group with an
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alkynylic halide such as propargyl bromide, followed by hydrostannylation of the triple bond
and subsequent radioiododestannylation is an alternative synthetic route towards these
compounds (Van Dort et al., 1999).
I~
O-DIPRENORPHINE
1.2
Secondary ammo groups m molecules can also be functionalised to produce N-iodoallyl
compounds (Chumpradit et al., 1995; Waterhouse et al., 1996; Waterhouse et al., 1998). The
synthesis of an 125I-labelled 2-nitroimidazole derivative is an interesting example of the
introduction of an oxygen atom into an iodoallylic prosthetic group in a gamma position
relative to the iodine (Hasan et al., 1991). The propargyloxymethylation of 2-nitroimidazole
was followed by hydrostannylation and radioiododestannylation as previously described, to
produce the N-CH20-iodoallyl compound (1.3). Another example featuring this type of
prosthetic group, is the (iodovinyl)misonidazole derivative (E)-5-(2-nitroimidazolyl)-4-
hydroxy-l-iodopent-l-ene (1.4) (Biskupiak et al., 1991). The nitrogen atom in a cyclic amide
structure such as hydantoin has also been functionalised with an iodoallyl group (1.5) (Van
Dort & Hagen, 2001). The allylic bifunctional alkylating agent in this case was (E)-1-chloro-3-
(tri-n-butylstannyl)-2-propene. Iodovinyl groups can also be attached to a carbon atom that
forms part of a cyclic structure to produce iodovinyl derivatives. The radioiodine-labelled
iodovinylestradiol derivatives 1.6a & b (Hanson, Seitz & Botarro, 1982; Kabalka et al., 1991;
Napolitano et al., 1995) and iodovinyltetrabenazine (1.7) (Canney et al., 1993) are examples of
such compounds.
1.3 1.4 1.5
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H3CO
HO
H3CO
RI =H; R= -(CH2)x-CH=CH-I (x = 0 - 8) 1.6a
RI = -CH=CH-I; R=H 1.6b
1.7
Aliphatic prosthetic groups containing either radioiodine or radio fluorine but lacking the
stabilising effect of a vinyl bond or other groups have also been described. The alkylation of
secondary amines or amides with fluoroalkyl groups has been well documented, and a few
similar iodoalkyl derivatives have also been reported. In the synthesis of
[1251]iodoethylspiperone,a radioligand used for the exploration of central dopamine receptors
in the brain, the iodoethyl group is introduced at the laetam nitrogen atom of spiperone (1.8)
(Chalon et al., 1990). Surprisingly, this compound exhibited good in vivo stability in rats,
which was indicated by the slow uptake of radioactivity in the thyroid. No explanation for this
unusual stability of the C-I bond is given, but it is possible that the nearby laetam carbonyl
group could have a stabilising effect. A similar 18P-labelled spiperone derivative,
[18P]fluoroethylspiperone, was also documented (Kiesewetter et al., 1986; Chi et al., 1986).
Other compounds containing the N-fluoroalkyl unit are 1-(2-fluoroethyl)-2-nitroimidazole and
1-(2-fluoroethyl)-2-methyl-5-nitroimidazole (1.9) (Jerabek et al., 1986), [18P]fluororaclopride
(1.10) (Kiesewetter et al., 1989), N- fluoropropyltetralin- (1.11) (Zijlstra et al., 1993a; Shi et
al., 1999), N-fluoropropylapomorphine derivatives (Zijlstra et al., 1993b), ro-fluoroalkylated
derivatives of l-phenylpiperazine (1.12) (Chi et al., 1986) as well as N-
fluoropropylnormetazocine- and N- fluoropropyllorazepam derivatives (Shiue et al., 1986). A
few C-fluoroalkyl compounds such as 11~-(2-fluoroethyl)estradiol derivatives (French et al.,
1993) and 4-fluoromethylcyclohexyl derivatives (Windhorst et al., 1999) have also been
documented. Other examples of radioiodine-labelled compounds with the radionuclide in an
apparently non-stabilised aliphatic position are 1311-labelledornidazole [1-iodo-3-(2-methyl-5-
nitroimidazol-Lyljpropan-Zeol (1.13) (A~ikoglu et al., 1998), 1251-labelled5-(1-hydroxy-2-
12
Stellenbosch University http://scholar.sun.ac.za
iodoethyl)-2'-deoxyuridine (1.14) (Iwashina et al., 1990) and 1311-labelled"Flagyl" [1-(2-
iodoethyl)-2-methyl-5-nitroimidazole] (1.15) (Tubis et al., 1975). In the case of the labelled
omidazole, allegedly an inflammation or infection detecting agent (Asikoglu et al., 2000), the
radioiodine is incorporated into a propan-2-o1 unit, attached to the terminal carbon adjacent to
the OH-bearing carbon. No information regarding radiochemical stability was given. However,
positive results were reported in imaging and biodistribution studies in rabbits and rats
respectively (Asikoglu et al., 2000). In the case of the labelled deoxyuridine, the radioiodine is
present in the 2-iodoethanol unit, attached to a terminal carbon adjacent to an OH-bearing
carbon similar to that in the omidazole derivative. No radiochemical stability data or any
biodistribution results for this compound were given.
o ~I /CH3
F o 0+,CJb ( Cl />CJNH H " N
, J Ó N02N--CyCH3 OH )Cl
F
1.8 1.9 1.10
~ fY'~\
1.11 1.12 1.13
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1.14 1.15 1.16
In another study, fluoromisonidazole (1.16), a l8F-Iabelled compound similar in structure to
omidazole, except for a nitro group replacing the methyl group in the 2-position of the
imidazole ring and without any other ring substituents, was claimed to be unstable in vivo
(Dolbier et al., 2001; Rasey et al., 1999). Predominantly polar metabolites were identified
following renal clearance. These metabolites were not identified, but most probably included
free radiofluoride. As it is unlikely that the ring substituents could affect the stability of such a
compound, the stability of the l3ll-labelled omidazole must also be questioned. The syntheses
of other l8F-Iabelled nitroimidazole derivatives with improved biological stabilities were also
reported. In these compounds the l-fluoropropan-Z-ol group (as in fluoromisonidazole) was
replaced with various other prosthetic groups such as an N-(2- fluoroethyl)acetamide group
(compound 1.17) (Rasey et al., 1999; Tewson, 1997), an N-(3-fluoropropyl)acetamide group
(compound 1.18) (Kachur et al., 1999), and an N-(2,2,3,3,3-pentafluoropropyl)acetamide group
(compound 1.19) (Dolbier (Jr.) et al., 2001). Other examples of N-fluoroalkylated amides are
fluoroethyl and fluoropropyl derivatives of spiroperidol (Shiue et al., 1986). In the case of the
radioiodine-labelled "Flagyl", the iodine is attached to the terminal carbon of an N-ethyl unit.
The labelled compound was claimed to have a long shelf-life at room temperature with no
significant release of free radioiodide (Tubis et al., 1975). In the only reference to its stability
under physiological conditions it was stated that some radioiodide was metabolically released,
but this release was not quantified. The fact that more radiopharmaceuticals containing
fluoroalkyl rather than iodoalkyl groups have been documented, can most probably be ascribed
to the general higher bond strengths of alkyl fluorides (444 kJ/mole on average) as opposed to
alkyl iodides (222 kJ/mole on average) (Coenen et al., 1983; Weast, 1982).
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1.17
fNH~F
('rNO'
1.18
1.2.3 Radiopharmaceuticals containing the p-Haloethoxyl Moiety.
Another type of prosthetic group that has come to the attention in recent years, and of which
the advantages have been described (Hamant et al., 1994), is the so-called p-iodoethoxyl
moiety. The unusual stability of p-iodoethyl ethers was pointed out more than a century ago
(Baumstark, 1874; Demole, 1876) and was later confirmed by Tasker and Purves (1949). A
direct comparison of the radiochemical stabilities of two radioiodine-labelled ro-iodo
carboxylic acids showed a remarkable difference in their respective in vitro stability in human
serum albumin (Hamant et al., 1994; Robinson (Jr.) & Lee, 1975). 6-lodohexanoic acid (1.20)
showed more than 85% deiodination after one hour, while its analogue, in which a methylene
group situated in a P-position relative to the radiohalogen had been substituted by an oxygen
atom (1.21), showed less than 5% deiodination after two days.
I~ r=.
\__O eOOH
1.20 1.21
The radiosynthesis of the fatty acid 1.21, carried out by isotope exchange in acetone, required
heating at a high temperature (105°C). This in itself reflected the stability of this type of C-I
bond towards displacement reactions (Hamant et al., 1994), which can be attributed to the P-
effect of the oxygen substituent (Fleet, 1989). This p-effect can be better understood in the
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light of the arguments raised by French et al., (1993). During the development of a series of
18F-Iabelled estrogen derivatives used for non-invasive diagnostic investigations of breast
cancer, several observations regarding metabolic defluorination of some of their compounds
were made. The compounds containing fluoroethyl groups showed significantly higher levels
of defluorination than those containing fluoroethoxy groups. On the other hand, the estrogens
containing fluoropropoxy groups (with the ether oxygen situated gamma with respect to the
C-F bond) showed somewhat higher levels of defluorination than those with fluoroethoxy
groups. In another publication, French et al., (1991) speculated that the positioning of a
heteroatom (oxygen or nitrogen) beta to a carbon-fluorine bond might protect this bond from
metabolic cleavage. The metabolism of halogenated alkanes generally involves a preferred
hydroxylation at the halogen-bearing carbon, followed by elimination of the halide ion (Anders
& Pohl, 1985). The metabolic lability of the C-F bond will therefore be determined by the
reactivity of the C(F)-H bond towards hydroxylation (French et al., 1991). Two mechanisms
could play a role in the activating effect of fluorine towards hydroxylation at this site. A
resonance mechanism will cause electron donation that will stabilise an incipient radical or
carbenium ion intermediate in the hydroxylation process. This mechanism outweighs electron
withdrawal by an inductive mechanism, which destabilises such intermediates, and therefore
the first mechanism will predominate. However, when a ~-heteroatom substituent is present, it
will provide an additional metabolically deactivating inductive effect as it is too far removed to
increase electron density by resonance (French et al., 1991). This will result in a reduction of
the reactivity of the beta-situated C-H bonds towards oxidative hydroxylation (French et al.,
1993). These arguments are most probably also applicable to other halogens such as iodine,
and this is indeed confirmed by the ever-increasing number of documented examples of
radiopharmaceuticals containing the ~-iodoethoxy moiety.
Various examples of radiopharmaceuticals containing this moiety are documented. Besides the
labelled fatty acids mentioned above, in which the moiety forms part of a straight aliphatic
carbon chain, the syntheses of radiolabelled co-iodoalkyl glucosides (1.22 and 1.23)(Bignan, et
al., 1993), two D-glucose analogues, namely 4-deoxy-4-iodo-D-glucose (1.24) (Abbadi et al.,
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1997) and 6-deoxy-6-iodo-D-glucose (1.25) (Charronneau et al., 1998), as well as N-
substituted radioiodinated nitroimidazole analogues such as iodoazomycin acyclonucleoside
(1.26) (Srivastava et al., 1990; Srivastava et al., 1991), and an iodo-~-D-arabinofuranosyl-2-
nitroimidazole analogue (1.27) (Mannan et al., 1991) are also documented. In the compounds
1.22 and 1.23, the ~-iodoethoxyl moiety is not included in the glucoside ring, but forms part of
the aliphatic substituent X at C-l. In the glucose analogue 1.24, the iodine label is attached
directly to the ring at a secondary carbon, having replaced the OH-group at the C-4 position,
while the glucoside ring oxygen atom serves as the ~-oxygen atom. In the second glucose
analogue, 1.25, the iodine is attached to an exocyclic methylene group, but is also in a ~-
position relative to the ring oxygen. In the imidazole derivative 1.26, the ~-iodoethoxyl unit is
linked to the N-l nitrogen via a methylene bridge, while in 1.27 it forms part of the
arabinofuranosyl ring that is linked to the N-l nitrogen. In the 125I-Iabelling of the 5-(1-
hydroxy-2-iodoethyl)-2'-deoxyuridine (1.14) described earlier, a l-methoxy derivative (1.28)
was also labelled (Iwashina et al., 1990). The I-methoxy-2-iodoethyl unit in this derivative can
also be classified as a ~-iodoethyl ether moiety.
OH OH
HO
OH
OH
HO
1.24
HO
1.25
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1.26 1.27 1.28
In addition to these radioiodinated compounds, some radiofluorinated compounds containing
this moiety are also documented. In the l8F-Iabelled tyrosine derivative [O-(2-fluoroethyl)-L-
tyrosine (1.29)], for example, the tyrosine hydroxyl group is derivatised by fluoroalkylation
(Wester et al., 1999). In this compound, the hydroxyl oxygen atom serves as the p-oxygen.
C8F]Fluoroethoxy-benzovesamicol (1.30), a radiotracer for cholinergic neurons, is another
example of this type of substitution. This type of C8F]fluoroethyl ether was first reported by
French et al., (1993). No examples of similar radioiodo-ethoxy compounds could be found in
literature, presumably because the facile incorporation of an iodine atom into a phenolic ring
by means of electrophilic substitution is a more attractive alternative, especially when the ring
is activated by an electron-donating hydroxyl group, in contrast to electrophilic substitution
with fluorine which results in low yields (Wester et al., 1999). Finally, another interesting
example in which radio fluorine is incorporated into a P-position relative to an aliphatic oxygen
atom is shown in compound 1.32. A 2-nitroimidazole nucleoside analog, 1-[2-hydroxy-1-
(hydroxymethyl)ethoxy]methyl-2-nitroimidazole (1.31) was converted into its 2-[l8F]fluoro
analog (1.32) by firstly protecting one of the two equivalent hydroxyl groups by acetylation,
converting the other one to a tosylate, followed by substitution with l8F and subsequent
deprotection (Wada et al., 2000). This radiopharmaceutical was developed as an alternative to
the previously reported C8F]fluoromisonidazole (1.16) in order to improve its biological
properties. No mention, however, was made of the in vivo stability of this new
radiopharmaceutical. The application of this 2-[l8F]fluoro analog for imaging ischemic but
viable myocardium was documented recently (Kaneta et al., 2002).
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~COOH
F~O~ ~H2
1.29 1.30 R= OH 1.31
R= F 1.32
1.2.4 Concluding Remarks on Prosthetic Groups
The use of prosthetic groups in radiopharmaceutical chemistry has become an increasingly
important tool for the radiochemist. Their most important feature should be to impart optimum
radiochemical stability to a radiopharmaceutical without significantly affecting its biological
properties. Small aliphatic units such as iodoallyl groups would be mostly preferred, especially
when designing radiopharmaceuticals with relatively low molecular masses. Additional
features such as the high stability of vinyl iodides and the facile labelling of their precursors
make iodoallyl groups particularly attractive. It is possible, however, that certain structural
requirements with regard to a target compound could restrict or rule out the use of these
groups. There will therefore be a need for alternative prosthetic groups that might not
necessarily possess the advantageous features of the iodovinyl unit, but could structurally be
more reconcilable with the parent compound. The ~-iodoethoxyl moiety offers the
radiochemist such an alternative option. Many target molecules, such as glucose derivatives,
already contain an aliphatic oxygen atom in their structures, which makes the use of a ~-
iodoethoxyl prosthetic group very attractive for radio labelling purposes. Since this type of
prosthetic group has been utilised relatively infrequently, little information is available,
especially, on its radiochemical stability. Some contradictory statements have also been made
about the in vivo stability of a radioiodinated nitroimidazole derivative containing such a
moiety. According to Srivastava et al., (1990), the injected radio labelled compound
iodoazomycin acyclonucleoside (1.26) resulted in low in vivo deiodination in mice, whereas
Hasan et al., (1991) claimed that the same compound resulted in high levels of radioactivity in
the blood, spleen and lungs, probably due to in vivo deiodination. This could also be as a result
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of the compound having been metabolised (Srivastava et al., 1991). Apparently more research
is needed in order to determine the stability of a radiolabelled ~-iodoethoxyl moiety by
comparing it with the so-called "gold standards" such as the iodovinyl unit (which forms part
of the iodoallyl group), as well as to find methods to further stabilise the moiety.
1.3 OBJECTIVES OF THIS STUDY
The pnmary objective of this research project was to investigate the utilisation of
radioiodinated prosthetic groups in radiopharmaceutical chemistry with particular regard to
their radiochemical stabilities under semi-physiological conditions. The emphasis was placed
on the ~-iodoethoxyl moiety. The synthesis of compounds containing other moieties such as
the iodovinyl unit was only done for reference purposes. The aim was to compare the stabilities
of the ~-iodoethoxyl compounds with these iodovinyl compounds, which are referred to as the
"gold standards". In order to avoid using these small units on their own because of their
unacceptable physical properties such as their high volatilities, it was decided to couple them to
various carrier or model compounds before radioiodination. The following tasks were therefore
undertaken: (As a rule-of-thumb, the term "~-iodoethoxyl" refers to the position of the iodine
atom (~) relative to the ether oxygen atom, while the term "~-oxygen" refers to the position of
the oxygen atom (~) relative to the iodine atom).
(i) In a pilot study, a systematic comparative investigation of the in vitro radiochemical
stabilities of model compounds containing radioiodinated ~-iodoethoxyl units and
derivatives thereof, as well as those of control references lacking a ~-oxygen atom, was
undertaken. These target derivatives were designed to investigate how various
neighbouring alkyl and aryl groups situated in various positions relative to the ~-oxygen,
would affect the radiochemical stability of the radioiodinated compounds. At this stage no
deliberate attempts were made to improve the stability of the prosthetic groups by altering
the structures of these moieties. The aim was to investigate stability trends. For the
purpose of this study, aromatic ethers or ethers containing an aromatic group were
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selected as model compounds to avoid complications arising from the high volatility of
aliphatic ethers. All of this was done on phenolic or benzyloxy compounds in which the
phenolic or benzyloxy oxygen served as the ~-oxygen atom.
(ii) Based on the results obtained in the pilot study, a few ~-iodoalkoxyl moieties with certain
structural features, as well as the unmodified ~-iodoethoxyl moiety, were selected for
coupling to various carrier molecules', hereafter called carriers. In addition to the moieties
emerging from the pilot study, another slightly different unit, the iodo-analogue of the 1-
[2-fluoro-l-(hydroxymethyl)-ethoxy ]methyl moiety present In 1-[(1-fluoro-3-
hydroxyprop-2-yloxy)methyl]-2-nitroimidazole 1.32, was also selected. It was decided to
attach it only to a heterocyclic amine as explained in objective (iii). Finally, two units
lacking a ~-oxygen were also selected. The reason for their selection is explained in
Section 2.3, but they were supposed to serve a similar function as the control references
used in the pilot study.
(iii) Three earners, belonging to two different types of compounds, namely a benzamide
containing a phenolic group, and two heterocyclic amines, were selected in order to
determine the selected moieties' behaviour in different chemical environments. With the
exception of one of the heterocyclic amines, namely benzotriazole, these carriers were not
model compounds, in contrast to the compounds used in the pilot study, but had the
chemical features of established radiopharmaceutical compounds. The rationale behind
this was that, if the prosthetic moieties linked to these compounds showed appreciable
levels of stability, their radioactively labelled analogues could be considered to be
radiopharmaceuticals.
A benzamide containing a phenolic hydroxyl group was selected as the first type of
carrier. The phenolic group present in these molecules was also present in some of the
selected model compounds. Such a structure was chosen because radioiodinated
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benzamides are widely used as radiotracers. Benzamides furthermore are easy to prepare.
(S)-(-)-N- [(1-Ethyl-2-pyrrolidin yl)methyl]-2-hydroxy- 3-iodo-6-methoxybenzamide
(IBZM) (1.33) (Kung & Kung, 1989; Kung et al., 1991; Bobeldijk et al., 1990), 2,3-
dimethoxy-(S)-N-[(I-ethyl-2-pyrrolidinyl)methyl]-5-iodobenzamide (Epidepride) (1.34)
(Clanton et al., 1991; Mulligan et al., 1999), 4-iodo-N-(2-piperidin-l-ylethyl)benzamide
(IPAB) (1.35) (John et al., 1993), 3-iodo-4-methoxy-N-(2-piperidin-l-ylethyl)benzamide
(PIMBA) (1.36) (John et al., 1999) and N-(2-diethylaminoethyl)-3-iodo-4-
methoxybenzamide (IMBA) (1.37) (Nicholl et al., 1997) are but a few of the
radioiodinated benzamides that have been reported in the literature. Radioiodinated
benzamides have an affinity for melanocytes (Mohammed et al., 1997) and can therefore
be used for radioimaging of various types of tumours such as melanoma (John et al.,
1993; Nicholl et al., 1997; Mohammed et al., 1997) and breast cancer (John et al., 1999).
Compounds such as IBZM display significant antidopaminergic activity (Hogberg et al.,
1987) and are used for dopamine D-2 receptor imaging in the central nervous system.
Many structure-activity relationship studies have been carried out on benzamides in order
to establish optimum biological characteristics. Of these, structural variations on the
phenyl ring, such as introduction of a methoxy group, resulted in considerable
improvements in their biological characteristics, for instance high melanoma affinity and
excellent melanoma/non-target tissue ratios (Mohammed et al., 1997). A few
[18P]fluoroalkyl- as well as [18P]fluoroalkoxy substituted benzamides (compounds 1.38 to
1.40) have been documented (De Paulis et al., 1991); however, no iodinated analogues of
a similar kind could be found. In all the documented examples of radioiodinated
benzamides, the radioiodine atom is directly attached to the aromatic ring as shown in
compounds 1.33 to 1.37. In this study, however, it was decided to synthesise
radioiodinated benzamides with the iodine attached to an aliphatic carbon, as in the
fluorinated analogues 1.39 and 1.40, with the phenolic oxygen serving as the stabilising ~-
heteroatom. The synthetic strategy was the O-alkylation of the free phenolic hydroxyl
group of a pre-synthesised benzamide derivative with the appropriate prosthetic group
3 The term carrier molecule or carrier refers to the parent molecule to which the moiety is coupled
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containing suitable active sites for the condensation as well as iodination steps. While the
primary purpose of this exercise was to investigate the radiochemical stabilities of these
compounds and not necessarily to improve on existing benzamide radiotracers, the
stability results were expected to indicate whether there might be any advantages in
pursuing this method of benzamide labelling.
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A heterocyclic aromatic amine with a ring nitrogen atom for N-alkylation was selected as
the second type of carrier. Although no information regarding the use of benzotriazoles as
radiopharmaceuticals could be found in the literature, benzotriazole was chosen to serve
as a model compound. The objective was to attach a few of the prosthetic moieties,
similar to those used in the pilot study and in the benzamide compounds, to the nitrogen
atom of benzotriazole in order to establish whether similar stability trends would be
observed when the prosthetic groups are present in different chemical environments. 2-
Methyl-5-nitroimidazole was also selected as a heterocyclic amine because of the
widespread utilisation of nitroimidazoles in radiopharmaceutical chemistry as discussed in
Sections 1.2.2 and 1.2.3. The infection-seeking compound iodo-ornidazole 1.13 also has a
2-methyl-5-nitroimidazole heterocyclic ring in its structure. In addition to its condensation
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with a few of the stabilised moieties identified in the pilot study, it was also decided to
condense the nitroimidazole with the 1-[2-halo-l-(hydroxymethyl)-ethoxy]methyl moiety
as discussed in objective (ii). In the light of the questionable stability of radioiodinated
ornidazole (as mentioned in Section 1.2.2), this study might result in the development of
an alternative prosthetic group with improved stability. This could create an opportunity
to develop improved radiopharmaceuticals with structures closely related to those of
existing ones. Similar synthetic methods were used in the preparation of some of the N-
alkylated prosthetic moieties, using the two different heterocyclic amines as starting
materials.
(iv) In addition to the synthesis of the 0- and N-alkylated ~-iodoalkoxyl compounds, their
respective iodoallyl analogues were also synthesised for reference purposes. The synthesis
of 1-(3-e23I]iodo-2-propen-l-yl)benzotriazole was carried out in a separate study (Visser,
2002), but the results regarding its radiochemical stability will be presented and discussed
in this work.
1-(3-iodo-2-propen-l-yl)benzotriazole
(v) The optimisation of reaction conditions in organic synthesis with the aim to improve
product yields was not an objective of this study, neither was the investigation of various
labelling techniques of the prosthetic groups with the aim to optimise radiochemical
yields. With the exception of the comparative radioiodinations of two different
nitroimidazole precursors (see Section 3.4.5.3), the kinetics of the labelling reactions were
not studied.
(vi) In this study, only in vitro stability tests in human blood serum were carried out on the
vanous radioiodinated compounds. This technique has already been used by other
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workers (Harapanhalli et al., 1998; Robinson (Jr.) & Lee, 1975) to make an approximate
estimate of the radiochemical stability of a radiolabelled compound. The testing of the in
vitro serum stability of a chemical does not necessarily reflect its in vivo characteristics
(Harapanhalli et al., 1998). The various biological processes such as metabolism and
catabolism that occur in the body can also result in deiodination (Coenen et al., 1983). It
was, however, not intended to develop radiopharmaceuticals that would necessarily be
biologically stable, but to observe stability trends. This method of stability evaluation
does not produce quantifiable, but only relative results, which were expected to give a fair
indication of the expected in vivo stability trends.
To summarise, this study comprised three components, namely: (a) organic synthetic chemistry
(b) radiochemistry (radiolabelling) and (c) stability evaluation. The first objective was to
synthesise precursor molecules suitable for labelling with radioiodine. These precursors
consisted of a suitable carrier molecule (parent molecule) covalently bonded to the appropriate
prosthetic group, which in tum had a leaving group in an appropriate position that could be
substituted with iodine. The leaving group mostly used in this work was the p-
toluene sulphonate (tosylate) group. It was anticipated that an iodide-for-tosylate substitution
reaction would occur more readily than, for instance, halogen exchange in a Finkelstein
substitution reaction. For this reason, a few bromo compounds were rather converted to
hydroxy compounds, followed by tosylation, instead of directly iodinating the bromo
compounds. In some cases the more reactive trifluoromethanesulphonate (triflate) group was
also used as a leaving group, while one of the reference compounds (a vinyl derivative) was
equipped with a tri-n-butylstannyl group. The second objective was to convert the precursors to
radioiodinated compounds by introducing the radioiodine atom regioselectively at the position
of the leaving group. Finally, the labelled compounds were incubated in blood serum at 37°C to
determine their in vitro radiochemical stability. The extent of release of free radioiodine was
used as an indicator for stability assessment.
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CHAPTER2
SYNTHESIS OF LABELLING PRECURSORS AND NON-RADIOACTIVE
IODO DERIVATIVES
2.1 PILOT STUDY
Simple model compounds were selected for this preliminary investigation of the stability of ~-
iodoalkylethers. The model compounds were all ~-hydroxy ethers, a few of which were
commercially available. They were composed of either phenolic or benzyloxy groups attached
to aliphatic chains containing the free hydroxyl group. The ~-hydroxy ethers were converted to
the required precursors by tosylation of the free hydroxyl group. The tosylates, prepared
according to the method of Argentini et al. (1981), were converted to the corresponding iodo
derivatives by heating them with sodium iodide in acetone as solvent. These iodinated
compounds only served as reference materials for characterisation and identification of the
radioiodinated species. The synthesis of the model compounds that were not commercially
available, the precursors, and the iodinated compounds was carried out according to the
reaction schemes shown in Scheme 2.1. The ~-hydroxy ether 2.2was synthesised by hydrolysis
of ~-bromophenetole 2.1 in a mixture of H20/HMPT according to the method of Hutchins and
Taffer (1983). Subsequent tosylation of the hydroxy group, followed by iodination of the
tosylate, gave 2-phenoxyethyl p-toluenesulphonate 2.3 and l-iodo-2-phenoxyethane 2.4
respectively. Commercially available 2-benzyloxyethanol 2.5 was likewise converted into 2-
benzyloxyethyl p-toluenesulphonate 2.6 and I-benzyloxy-2-iodoethane 2.7 respectively. 2-
Phenoxy-l-propanol 2.10 was obtained by the condensation of potassium phenoxide 2.8 with
ethyl 2-bromopropionate in the presence of a crown ether catalyst, according to the method of
RaIl et al. (1976), followed by reduction of the resulting ethyl 2-phenoxypropionate 2.9 with
lithiumaluminiumhydride in THF. Tosylation of 2.10 resulted in 2-phenoxyprop-l-yl p-
toluenesulphonate 2.11. Iodination of 2.11 gave l-iodo-2-phenoxypropane 2.12. Similar
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treatment of commercially available l-phenoxypropan-z-ol 2.13 gave I-phenoxyprop-2-yl p-
toluenesulphonate 2.14 and 2-iodo-l-phenoxypropane 2.15 respectively. 2-Phenoxy-l-butanol
2.17 was obtained by reduction of 2-phenoxybutyric acid 2.16. Its respective tosylated and
iodinated analogues 2.18 and 2.19 were prepared as before. The same method was used for the
preparation of 2-methoxy-2-phenylethyl p-toluenesulphonate 2.21 and its iodinated analogue
2.22 from commercially available 2-methoxy-2-phenylethanol 2.20. In addition to these ~-
iodoalkoxy compounds, two reference compounds, one containing an ether oxygen in a gamma
position relative to the iodine (1-iodo-3-phenoxypropane 2.26), and the other without an ether
oxygen (l-iodo-2-phenylethane 2.30), were also prepared. Compound 2.26 was prepared by
hydrolysis of I-bromo-3-phenoxypropane 2.23 in aqueous HMPT, followed by tosylation of
the formed 3-phenoxy-l-propanol 2.24 and subsequent iodide-for-tosylate exchange of 3-
phenoxyprop-I-yl p-toluenesulphonate 2.25. Compound 2.30 was prepared in a similar fashion,
starting from I-bromo-2-phenylethane 2.27, and subsequent tosylation and iodination of 2-
phenylethyl alcohol 2.28 and 2-phenylethyl p-toluenesulphonate 2.29, respectively.
0-0 a 0-' ° b o-~° c 0-'~~_ ~~_ ~~ _v
Br OH OTs --\
2.1 2.2 2.3 2.4
b- c- c-.
~I
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a. 15 % H20IHMPT; 130°C
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c. Nalldioxane/acetone; heat under reflux
d. (i) 18-crown-6 / CH3CN (ii) ethyl 2-bromopropionate
e. LiAIH4/THF /ether; reflux
Scheme 2.1 Synthesis of the model alcohols, followed by tosylation and iodination to yield 13-
iodoalkylether derivatives and reference compounds.
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As mentioned in the statement of objectives, a few of these ~-iodoalkoxyl moieties that showed
enhanced stability, together with their non-stabilised parent moieties, were selected as
prosthetic moieties for coupling to the selected carriers. It is important to mention that methods
used to couple them to the simple model compounds would not necessarily be suitable for their
coupling to the more complex carriers. The presence of sensitive groups (amides) in the latter
type of compounds could be vulnerable to the synthetic conditions required for these
transformations. The challenge was therefore to design suitable synthetic procedures.
The stabilised moieties selected were of the type displayed in l-iodo-2-phenoxypropane 2.12
and 2-iodo-l-phenoxy-propane 2.15. As mentioned before, two different types of carriers were
used. The respective amines were readily available commercially, but the benzamide had to be
synthesised, using conventional methods. No efforts were made to optimise the yields of the
intermediates or the final products, but where necessary they were purified to the highest level
possible, especially for characterisation purposes.
2.2 SYNTHESIS OF THE BENZAMIDE DERIVATIVES
The analytical chromatographic methods that are been referred to from here onwards are
described in Section 6.2.
In this section the synthetic procedures for the various benzamide derivatives containing the
pre-selected prosthetic moieties are discussed. The synthetic routes leading to the benzamide
carrier 2.33, all the desired reagents, precursors and iodinated compounds are summarised in
Schemes 2.2 to 2.4, and are followed by a detailed discussion of the synthetic procedures.
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Scheme 2.2 Synthesis of the benzamide carrier 2.33
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Scheme 2.3 Synthesis of the alkylating agents for O-alkylation of the benzamide carrier
4 The drawing programme automatically terminates an aliphatic chain with a methyl group
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c. (E)-3-(Tributylstannyl)prop-2-en-l-yl p-toluenesulphonate 2.40
d. NaI
e. Iodine
Scheme 2.4 Synthesis of the benzamide precursors and iodinated compounds
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The type of benzamide carrier was selected arbitrarily. The main criterion was that it should
contain a free hydroxyl group somewhere on the aromatic ring. It was also decided to have a
methoxy group on the ring, as many established radiopharmaceuticals of this class contain this
group. The relative position of the OH group with regard to the amide side chain was regarded
as irrelevant as it was unlikely that this would affect the stability of the prosthetic groups. The
starting material also had to contain a carboxylic group that could be converted to an amide
group. 3-Methoxysalicylic acid 2.31 was chosen as the starting material.
2.2.1 Synthesis of Carrier 2.33
The reaction sequence is illustrated in Scheme 2.2, which is represented below. The synthesis
was based on the method proposed by John et al. (1993). The carboxylic function of 3-
methoxysalicylic acid 2.31 was converted to the acid chloride by means of thionyl chloride,
affording the acyl chloride intermediate 2.32. Subsequent condensation of 2.32 with 1-(2-
aminoethyl)piperidine gave 2-hydroxy-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.33. In
a similar sequence, Kung et al. (1988b) converted 3-iodo-6-methoxysalicylic acid via the acid
chloride to a benzamide without protecting the phenolic hydroxyl group. This group was
therefore also not protected in this synthesis.
Some by-products were formed during the synthesis, presumably due to reactions with the
phenolic hydroxyl group. Silica gel column chromatography gave a moderate yield of
approximately 38%, which was sufficient for the subsequent steps.
2.2.2 Synthesis of the Benzamide Precursors
The term "benzamide precursors" refers to the iodination precursors containing a benzamide
group. On the basis of the previously mentioned considerations, the benzamide derivatives
mentioned below were selected as precursors for radioiodination:
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The strategy was to O-alkylate the phenolic hydroxyl group of the earner 2-hydroxy-3-
methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.33 with various alkylating agents to produce
precursors, each having a good leaving group in the ~-position. Nucleophilic substitution of
this leaving group with iodine was expected to result in the regioselective incorporation of an
iodine atom in a ~-position relative to the phenolic oxygen atom. Various reaction routes and
alkylating agents were considered. In the pilot study, l-iodo-2-phenoxypropane 2.12 was
synthesised by condensing potassium phenoxide with the ethyl ester of 2-bromopropionic acid
under phase transfer conditions, followed by reduction of the ester 2.9 to the corresponding
alcohol 2.10, subsequent tosylation to give 2.11 and substitution with iodide to give 2.12. Such
a strategy would probably not be feasible for the transformation of benzamide carrier 2.33 to
the various precursors due to the relatively harsh reaction conditions that have to be used.
Conversion to the potassium salt could probably result in hydrolysis of the amide, while the
reduction step could also result in reduction of the amide. One viable option appeared to be the
alkylation of the OH group with bifunctional agents such as 2-bromo-l-ethanol, 2-bromo-l-
propanol or I-bromo-2-propanol, followed by conversion of the free hydroxyl group to a
tosylate group, to give precursors 2.41, 2.43 and 2.45 respectively. Another, shorter, route
would be to make use of ditosylates such as ethylene di-p-toluenesulphonate 2.35 or propylene
1,2-di-p-toluenesulphonate 2.37 as alkylating reagents. According to the method proposed by
Mulholland et al. (1993), the phenolic hydroxyl group of (-)-(2R,3R)-trans-2-hydroxy-3-(4-
phenylpiperidino )-5-hydroxytetralin was alkylated with an excess of ethylene di-p-
toluenesulphonate after formation of the phenoxide with tetrabutylammonium hydroxide.
Being a symmetrical ditosylate, this reagent could be expected to yield only one condensation
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product, namely (-)-(2R,3R)-trans-2-hydroxy-3-( 4-phenylpiperidino )-5-[2-(P-
toluenesulphonyloxy)ethoxy]tetralin, while condensation of the formed product with another
molecule of the phenoxide would be countered by the large excess of ditosylate used. The
advantage of this method was that it is essentially a one-step reaction, without the need for a
tosylation step. A possible disadvantage was that, when using un-symmetrical ditosylates such
as propylene 1,2-di-p-toluenesulphonate, inseparable isomeric mixtures could be formed.
Nevertheless, it was decided to investigate this method because of its anticipated simplicity.
In addition to these ~-tosyloxyalkoxyl precursors, a precursor for the synthesis of an iodoallyl
compound was also needed to serve as a reference, as explained in the objectives of this thesis.
This precursor, 3-methoxy-N-(2-piperidin-l-ylethyl)-2-[3-(tributylstanny1)prop-2-en-l-yloxy]-
benzamide 2.47, was prepared according to the method of Wang et al. (1995). The
tributylstannyl group served as the leaving group for displacement with electrophilic iodine. It
is important to note that, after such a displacement, the iodine atom would be situated in a
gamma position relative to the phenolic oxygen atom and would therefore be stabilised, not by
the ~-effect of an ether oxygen atom, but by the vinyl group. As in the previous cases, the
strategy for the synthesis of compound 2.47 was based on O-alkylation of the phenolic
hydroxyl group of 2-hydroxy-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.33 with a
suitable bifunctional vinylstannane moiety. The prosthetic group (E)-3-(tributylstannyl)prop-2-
en-I-yl p-toluenesulphonate (TBS-PROP-TOS) 2.40, employed by Musachio and Lever (1992)
for the preparation of, amongst others, iodoallyl analogues of spiperone, was used for this
purpose.
O~Sn(BU)3
2.47
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2.2.2.1 Synthesis of the precursor 3-methoxy-N-(2-piperidin-I-ylethyl)-2-[2-(p-toluene-
sulphonyloxy)ethoxy]benzamide 2.41
Ethylene di-p-toluenesulphonate (TET) 2.35 was easily prepared from ethylene glycol 2.34
where a two-molar excess of p-toluenesulphonyl chloride (p-TsCI) was used, as shown in
Scheme 2.3. The mixture was refluxed in dichloromethane in the presence of triethylamine
(TEA), after which the formed TEA.HCI was filtered off and the filtrate concentrated and
chromatographed over silica gel. The coupling of TET to the benzamide is shown in Scheme
2.4. Tetrabutylammoniumhydroxide (TBAH) was used to form the phenoxide of 2-hydroxy-3-
methoxy-N-(2-piperidin-I-ylethyl)benzamide 2.33, and this was subsequently refluxed with a
nine- to ten-fold molar excess of purified TET in acetonitrile, according to the method of
Mulholland et al. (1993). Thin-layer chromatography (TLC) (Method 4) indicated total
consumption of 2.33 after 1.5 hours, after which the reaction mixture was evaporated to
dryness, the residue re-dissolved in chloroform, washed with water, and again evaporated to
dryness. The residue was re-dissolved in acetonitrile, excess TET was partially removed by
crystallisation at -10°C, and the concentrated mother liquor was chromatographed twice over
silica gel to give the purified product in a yield of approximately 57%.
2.2.2.2 Synthesis of the precursors 3-methoxy-N-(2-piperidin-I-ylethyl)-2-[I-(p-
toluenesulphonyloxy)prop-2-yloxy]benzamide 2.43 and 3-methoxy-N-(2-piperidin-
l-ylethyl)-2-[2-(p-toluenesulphonyloxy)prop-I-yloxy ]benzamide 2.45
In order to synthesise these two isomeric compounds, it was decided to follow the same
synthetic route that was used for the synthesis of precursor 2.41. The unsymmetrical propylene
1,2-di-p-toluenesulphonate (TPT) 2.37 was selected as the alkylating agent. It was expected
that if the two isomers were formed simultaneously, they might be separable by
chromatography over silica gel. As no example of a similar condensation reaction could be
found in the literature, no information was available on the expected ratio in which the isomers
would be formed.
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TPT was prepared in a similar way as TET, as shown in Scheme 2.3, using propane-1,2-diol
2.36 as the starting material. The reaction mixture was refluxed at an oil bath temperature
ranging between 80° and 120°C. Condensation with the phenoxide of the benzamide 2.33,
using a nine- to ten-fold molar excess of purified TPT, was carried out as before (Scheme 2.4).
TLC indicated completion of the reaction after 20-30 minutes, after which the reaction mixture
was evaporated to dryness. As the removal of excess TPT by crystallisation was unsuccessful,
the whole mixture was chromatographed to remove all the excess TPT. This gave the target
product containing some residual polar impurities. TLC (Method 5) showed a partial resolution
of what was expected to be two isomeric products. Analytical HPLC (Method 1) gave
acceptable resolution of the two expected isomers, thereby enabling their relative
quantification. The ratio between the more polar compound and the less polar one was
approximately 37:63. The two isomers were subsequently separated by column
chromatography over silica gel, using diisopropylether/isopropanol/ammonia (85: 15:0.5) as
mobile phase. A large fraction consisting of a mixture of the two compounds was obtained
since a complete separation could not be achieved. Only the fractions highly enriched in a
specific isomer were combined separately, resulting in a recovery of approximately 19% of the
less polar compound and 14% of the more polar one. The correct structure assignments of the
two compounds were made possible by means of proton magnetic resonance spectroscopy (1H
NMR). The methine proton adjacent to the phenoxide in compound 2.43 was expected to
resonate slightly further upfield (lower 8) than the one adjacent to the tosylate group in
compound 2.45. The spectrum of the less polar compound had a lower chemical shift (8 4.70-
4.73) for the methine proton than that of the more polar one (8 4.98-5.03). This difference was
quite subtle due to the small difference in chemical shifts caused by the tosylate and phenoxide
functional groups, respectively. More evidence was obtained from the IH NMR spectra of the
iodinated analogues prepared from the respective tosylates. The less polar tosylate yielded an
iodinated compound of which the 1H NMR spectrum showed a pair of methylene protons
resonating at relatively higher field (8 3.44-3.51). The more polar tosylate, on the other hand,
gave an iodinated compound of which the 1H NMR spectrum showed a pair of methylene
proton signals at lower field (8 4.12-4.26). Due to the shielding effect exerted by an iodine
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atom, it would be expected that the methylene protons resonating at 8 3.44-3.51 would be
geminal to an iodine atom (such as in structure 2.44), rather than an oxygen atom, while those
at lower field would be geminal to an oxygen atom (such as in structure 2.46). The tosylate
structure 2.43 was therefore assigned to the less polar tosylate, which gave the iodo compound
2.44, and 2.45 to the more polar tosylate, which gave the iodo compound 2.46. Based on steric
considerations, the formation of 2.45 was expected to be probably slightly more favoured than
2.43. However, the respective yields of the two compounds show that 2.43 was the more
favoured isomer. These results show that the isomer ratio is not controlled by steric factors, but
rather by the higher reactivity of a tosylate attached to a secondary carbon atom because of the
greater stability of the substitution transition state.
2.2.2.3 Synthesis of the precursor 3-methoxy-N-(2-piperidin-l-ylethyl)-2-[3-( tributylstannyl)-
prop-2-en-l-yloxy]benzamide 2.47
The precursor 2.47 contains the tributylstannylpropenyl prosthetic group. The starting material
required for the introduction of this prosthetic group, (E)-3-(tributylstannyl)prop-2-en-l-yl p-
toluene sulphonate (TBS-PROP- TOS) 2.40, was synthesised in a two-step synthesis (Scheme
2.3) starting with the treatment of propargyl alcohol 2.38 with tributyltin hydride (Musachio &
Lever, 1992; Jung & Light, 1982), followed by the separation of the geometrical isomers 2.39a
and 2.39b by means of silica gel column chromatography. The hydroxy group of the E-isomer
2.39a was then tosylated with p-toluenesulphonyl chloride according to the strategy of
Musachio and Lever (1992). The IH NMR data of the vinylic and allylic protons of the final
product 2.40 corresponded to those quoted in literature (Musachio & Lever, 1992), confirming
the compound's structure and configuration (Table 2.1).
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TABLE 2.1 Assignment of IHNMR (300 MHz) data for vinylic and allylic protons in (£)-3-
(tributylstannyl)prop-2-en-1-yl p-toluenesulphonate 2.40
Protons Assignmentof resonances
Synthesised Literature [Musachio and Lever, 1992]
8 (ppm) J (Hz) 8 (ppm) J (Hz)
CfuOTs 4.56 (2H)dd 5.5, 1.2 4.53 (2H) dd 5.3, 1.2
CHCH2 5.88-5.98(lH) dt 19.1,5.5 5.90 (lH) dt 19.0,5.3
SnCH 6.29-6.36(lH) dt 19.1,1.2 6.29 (lH) dt 19.0, 1.2
The tetrabutylammonium phenoxide of 2-hydroxy-3-methoxy-N-(2-piperidin-1-
ylethyl)benzamides 2.33 was reacted with TBS-PROP-TOS 2.40 under the same conditions
employed in the synthesis of the benzamide precursors 2.41, 2.43 and 2.45, except for using
equimolar amounts of substrate and reagent (Scheme 2.4). The use of an excess of the reagent
was unnecessary, as only the tosylate functional group in TBS-PROP-TOScould react with the
phenoxide. Chromatography on a silica gel column gave the pure benzamide precursor 2.47 in
an overall yield of 85%.
2.2.3 Synthesis of the Iodinated Benzamides 2.42, 2.44, 2.46 and 2.48
In order to obtain "cold" iodinated compounds for NMR and MS characterisation, portions of
the precursors were reacted with stable iodide or iodine as shown in Scheme 2.4. In the case of
the tosylates 2.41, 2.43 and 2.45, the respective precursors were dissolved in acetone and
heated in a sealed vial in the presence of a slight molar excess of sodium iodide. In the case of
the tributylstannyl precursor 2.47, the precursor was dissolved in dichloromethane and stirred
at room temperature in the presence of an equimolar amount of molecular iodine. The product
mixtures were chromatographed over silica gel to give pure 2-(2-iodoethoxy)-3-methoxy-N-(2-
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piperidin-l-ylethyl)benzamide (2.42), 2-( l-iodoprop-2-yloxy)-3-methoxy-N-(2-piperidin-l-
ylethyl)benzamide (2.44), 2-(2-iodoprop-l-yloxy)-3-methoxy-N-(2-piperidin-l-ylethyl)-
benzamide (2.46) and 2-(3-iodoprop-2-en-l-yloxy)-3-methoxy-N-(2-piperidin-l-ylethyl)-
benzamide (2.48).
0 0 0 0 0 00 NH NHNH \_j \_j NH
\_/ \_/
o 1 0)-11 O~_< 0\J"I\_j
o H3C 0-CH3 CH3/ 0-CH3O-CH3 H3C
2.42 2.44 2.46 2.48
2.3 SYNTHESIS OF THE HETEROCYCLIC AMINE DERIVATIVES
In this section, the synthetic procedures for the vanous heterocyclic amme derivatives
containing the selected prosthetic moieties are discussed. As mentioned before, benzotriazole
and 2-methyl-5-nitroimidazole were selected as examples of carriers containing a heterocyclic
amine. Both of these compounds are commercially available. The benzotriazole derivatives 1-
[(2-p-toluenesulphonyloxyethoxy)methyl ]benzotriazole 2.65, 1-[(l-p- toluenesulphonyloxy-
prop-2-yloxy)methyl]benzotriazole 2.69, 1-(2-p-toluenesulphonyloxyprop-l-yl)benzotriazole
2.73 and 1-(2-methyl-3-p-toluenesulphonyloxyprop-l-yl)benzotriazole 2.77 were selected as
precursors for radioiodination:
CH3 CH3 8~OT'N 8~OZOT' N~"N~Nf" "N~o O~OT' bOT,
;)
2.65 2.69 2.73 2.77
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In the nitroimidazole series, the 2-methyl-5-nitroimidazole derivatives 2-methyl-5-nitro-l-[(l-
p-toluenesulphonyloxyprop-2-yloxy)methyl]imidazole 2.84, 2-methyl-5-nitro-l-[(I-trifluoro-
methanesulphonyloxyprop-2-yloxy)methyl]imidazole 2.86, 2-methyl-5-nitro-l-[(2-trifluoro-
methanesulphonyloxyprop-l-yloxy)methyl]imidazole 2.91, 1-[( I-benzoyloxy-3-trifluoro-
methanesulphonyloxyprop-2-yloxy)methyl]-2-methyl-5-nitroimidazole 2.96 and 1-[(I-benzoyl-
oxy-3-p-toluenesulphonyloxyprop-2-yloxy)methyl]-2-methyl-5-nitroimidazole 2.98 were
initially considered as precursors. However, based on steric considerations, it was expected that
the N-3 atom on the 2-methyl-5-nitroimidazole heterocyclic ring would probably be
preferentially alkylated. This would result in 2-methyl-4-nitroimidazole derivatives. The N-
alkylated nitroimidazole target compounds prepared in this study were therefore in fact the 2-
methyl-4-nitroimidazole derivatives 2.83, 2.85, 2.90, 2.95 and 2.97 respectively. This will be
discussed in greater detail in paragraph 2.3.2.
Rl = N02; R2 =H; R3 = OTs 2.83
Rl = H; R2= N02; R3 = OTs 2.84
Rl =N02; R2 = H; R3 = OTf 2.85
Rl = H; R2 = N02; R3 = OTf 2.86
Rl = N02; R2 = H 2.90
Rl = H;R2 = N02 2.91
rR3(o\_ _
R2~N'y-CH' );--0
~ II °N
Rl
Rl = N02; R2 = H; R3 = OTf 2.95
Rl =H; R2 =N02; R3 =OTf 2.96
Rl =N02; R2= H; R3 =OTs 2.97
Rl = H; R2 = N02; R3 = OTs 2.98
To obtain the iodinated analogues of all of these compounds, the substitution of their tosylate
or triflate groups with iodine was envisaged. The l-benzoyloxy group in the iodinated
analogues of 1-[(l-benzoyloxy-3-trifluoromethanesulphonyloxyprop- 2-yloxy )methyl]- 2-
methyl-4-nitroimidazole 2.95 and 1-[(I-benzoyloxy-3-p-toluenesulphonyloxyprop-2-
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yloxy)methyl]-2-methyl-4-nitroimidazole 2.97 were intended to be converted to a hydroxy
group (see Section 2.3.4).
The prosthetic moieties III the benzotriazole-derived precursors 1-[(2-p-
toluenesulphonyloxyethoxy)methyl ]benzotriazole 2.65 and 1-[(1-p-toluenesulphonyloxyprop-
2-yloxy)methyl]benzotriazole 2.69 are of a similar nature to those present in the benzamides 3-
methoxy-N-(2-piperidin-1-ylethyl)-2-[2-(p-toluenesulphonyloxy)ethoxy]benzamide 2.41 and 3-
methoxy-N-(2-piperidin-1- ylethyl)- 2- [l-(p-toluenesulphonyloxy )prop- 2-yloxy ]benzamide 2.43
respectively, while those in 1-(2-p-toluenesulphonyloxyprop-1-yl)benzotriazole 2.73 and 1-(2-
methyl-3-p-toluenesulphonyloxyprop-1-yl)benzotriazole 2.77, both having branched chains,
lacked a p-oxygen atom. The radioiodinated analogues of 2.73 and 2.77 were selected to serve
as reference compounds, i.e. 2.74 and 2.78 (similar to the model compound 1-iodo-2-
phenylethane 2.30). Their radiochemical stabilities were to be compared with those of the
radioiodinated analogues of 1-[(1-p-toluenesulphonyloxyprop-2-yloxy)methyl]benzotriazole
2.69, i.e. 2.70, and 2-methyl-4-nitro-1-[(2-trifluoromethanesulphonyloxyprop-1-
yloxy)methyl]imidazole 2.90, i.e. 2.92, both having p-oxygen atoms in their branched chains,
in order to determine the influence of branching in the prosthetic group on the radiochemical
stability. This exercise was expected to give an approximate indication of the contribution of
steric factors, caused by branching, towards the expected higher stability of the radioiodinated
analogue of 1-[(1-p-toluenesulphonyloxyprop-2-yloxy)methyl]benzotriazole 2.69, in contrast to
the radioiodinated analogue of 1-[(2-p-toluenesulphonyloxyethoxy)methyl]benzotriazole 2.65,
i.e.2.66b.
The prosthetic group III the nitroimidazole precursor 2-methyl-4-nitro-1-[(1-p-
toluenesulphonyloxyprop-2-yloxy)methyl]imidazole 2.83 was identical to that in the
benzotriazole precursor 2.69, while the prosthetic group III 1-[(1-benzoyloxy-3-
trifluoromethanesulphonyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.95 or its
tosylated analogue 2.97 resembled the prosthetic group of 1-[2-[18p]fluoro-1-
(hydroxymethyl)ethoxy]methyl-2-nitroimidazole 1.32 reported in Chapter 1. As methods for
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the synthesis of 1.32 or its intermediate 1-[2-hydroxy-l-(hydroxymethyl)ethoxy]methyl-2-
nitroimidazole 1.31 are not described in the literature, novel methods had to be developed
during the course of this work to synthesise the intermediates required for the preparation of
2.95 and 2.97.
The prosthetic group III 2-methyl-4-nitro-l-[(2-trifluoromethanesulphonyloxyprop-l-
yloxy)methyl]imidazole 2.90 resembled the one in 3-methoxy-N-(2-piperidin-l-ylethyl)-2-[2-
(p-toluenesulphonyloxy)prop-l-yloxy]benzamide 2.45. The triflate precursors 2-methyl-4-
nitro-l-[(1-trifluoromethanesulphonyloxyprop-2-yloxy)methyl]imidazole 2.85, 2.90 and 2.95
differed from all the others with respect to the nature of their leaving groups. According to
Fleet (1989), triflates are preferred to tosylates as leaving groups for nucleophilic substitutions
at secondary carbons in carbohydrates. The reason is that the ~-oxygen atom slows down SN
reactions dramatically, and that triflate is an extremely good leaving group (Fleet, 1989;
Wheeler et al., 1987). Therefore the triflate was used as leaving group in precursor 2.90. In
addition to the tosylate precursor 2-methyl-4-nitro-l-[(1-p-toluenesulphonyloxyprop-2-
yloxy)methyl]imidazole 2.83, its triflate analogue 2.85 was also prepared in order to compare
their respective reactivities towards nucleophilic displacement with iodide. Because the triflate
precursor 2.95 was only used for the in situ synthesis of the "cold" iodinated compound 2.99,
while its more stable tosylate analogue 2.97 was used in radioiodinations, both of these
precursors were prepared. Tosylate 2.97 was prepared according to the method of Wada et al.
(2000), which is similar to the tosylation method used by Argentini et al. (1981).
A different strategy had to be followed in order to attach the various prosthetic moieties to the
nitrogen atom in the synthesis of the ~-oxygen-containing precursors 2.65, 2.69, 2.83, 2.85,
2.90, 2.95 and 2.97. In contrast to the benzamide derivatives in which the carrier compound
already contained the ~-oxygen atom, this atom had to be incorporated into the prosthetic
moieties used for the synthesis of the amine derivatives. It was decided to follow the method of
Srivastava et al. (1991) in which a nitroimidazole (azomycin) was condensed with the
alkylating agent 2-chloromethoxyethyl benzoate 2.51, according to Scheme 2.5.
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2.51 -..,
Azomycin
Scheme 2.5 Condensation of azomycin with 2-chloromethoxyethyl benzoate 2.51
Hydrolysis of the ester function of this condensation product resulted in the formation of an
OH group two carbons removed from the methyloxy oxygen atom that served as the ~-oxygen
atom. Various methods are available for the substitution of an OH group with "cold" iodine,
amongst others iodination with the reagent methyltriphenoxyphosphonium iodide. Isotope
exchange radiolabelling of the "cold" iodinated compound gives the radioiodinated compound
(Srivastava et al., 1991). In the present investigation it was decided to rather convert the OH
group to a tosylate or other good leaving group in order to obtain the same type of precursors
as those prepared from the benzamides.
Initially a major problem in the synthesis of the mentioned derivatives was that the appropriate
alkylating agents were not commercially available. Srivastava et al. (1991) did not report a
method for the synthesis of 2-chloromethoxyethyl benzoate 2.51. Methods therefore had to be
developed to synthesise all the relevant alkylating agents. A feasible general strategy was to
chloromethylate the free hydroxy group of the monobenzoate ester of a glycol. The following
section describes attempts to synthesise these reagents.
2.3.1 Synthesis of Alkylating Agents
The following alkylating agents were synthesised in order to prepare the various N-alkylated
heterocyclic amine derivatives: 2-chloromethoxyethyl benzoate 2.51, 2-chloromethoxyprop-l-
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yl benzoate 2.56, l-chloromethoxyprop-2-yl benzoate 2.57 and 1,3-dibenzoyloxy-2-
chloromethoxypropane 2.61.
0-\0 0-\0 CH3 /CIo-{ °A~o 0))--CH3La ° 0yo 0yo° \__CI\__CI Ph Ph
2.51 2.56 2.57 2.61
2.3.1.1 Synthesis of 2-chloromethoxyethyl benzoate 2.51
The synthetic pathway is given in Scheme 2.6. The starting material for this synthesis was 2-
hydroxyethyl benzoate 2.50, prepared by heating a mixture of ethylene glycol 2.34 and benzoic
acid 2.49 in a molar ratio of 3: I, respectively, in the presence of a catalytic amount of
concentrated sulphuric acid and 3Á molecular sieves. After work-up, TLC (Method 8) showed
only a trace of an impurity suspected to be ethylene dibenzoate in the product 2.50. The
product 2.50 was pure enough to use without further purification. The chloromethyl ether was
initially prepared according to the method of Hakimelahi et al. (1987). According to this
method, aqueous hydrochloric acid, adsorbed on silica gel, converts alcohols in aprotic solvents
to the corresponding chloromethyl ethers in the presence of an aldehyde. The
chloromethylation is carried out in chloroform at room temperature, using the dried HClIsilica
gel mixture and 1,3,5-trioxane as a source of aldehyde. However, despite numerous attempts,
2-hydroxyethyl benzoate 2.50 could not be converted to its chloromethyl ether by using this
method. TLC- and HPLC analysis of the reaction mixtures showed the formation of products,
but according to qualitative tests for halogen (Furniss et al., 1989), not one of the products
isolated on a silica gel column by chromatography contained a chlorine atom. Attempts to
alkylate amines with either of these products also failed. Alternative methods for
chloromethylation were subsequently considered. The method described by Guédin-Vuong and
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Nakatani (1986) seemed promising. This method, designed for the chloromethylation of long-
chain alcohols, involves the reaction of the alcohol with paraformaldehyde and gaseous
hydrogen chloride at a low temperature of not higher than -lODe (Scheme 2.6). According to
the authors, it is imperative that the temperature be maintained below -lODe to avoid a
dismutation leading to a mixture of the symmetrical acetal and methylene chloride. It has been
stated that the product should not be distilled or chromatographed over silica gel, which
possibly partially explains the failure of the attempts at using the method proposed by
Hakimelahi et al. Guédin-Vuong and Nakatani's method gave the target chloromethyl ether
2.51 in high yields of 93-100%. The product showed a positive halogen test. Due to its
instability, it was not purified or characterized. It was either used on the day of its preparation,
or stored in methylene chloride at about -lODe for a few days only.
0{
2.49
+ HO~
\__OH
a 0-<
2.50 ~OH
b 0{
--~ ~O
2.51 La2.34
a. H2S04
b. (CH20)n, HCI(g), -lODC
Scheme 2.6 Synthesis of 2-hydroxyethyl benzoate 2.50 and 2-chloromethoxyethyl benzoate 2.51
2.3.1.2 Synthesis of 2-chloromethoxyprop-l-yl benzoate 2.56
The synthetic pathway for the synthesis of 2-chloromethoxyprop-l-yl benzoate 2.56 from the
corresponding monoester 2-hydroxyprop-l-yl benzoate 2.54 is outlined in Scheme 2.7. At first
glance, propane-l,2-diol appeared to be the obvious starting material for the synthesis of the
monoester 2.54, but the regioselective esterification of the primary OH group was expected to
be problematic. Instead, it was decided to use a halohydrin such as I-bromo-2-propanol 2.52,
in which the halogen could be selectively substituted with a benzoate group in a dipolar aprotic
solvent(March, 1992). Unfortunately, the best quality commercially available l-bromo-Z-
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70%
Sodium benzoate + ",c--(_
Br
2.52 2.53
+
2.54 2.55
+
2.56 2.57
a. 60o-130oe, DMF or HMPA
b. (eH20)n , Hel (g), -lOoe
Scheme 2.7 Synthesis of 2-chloromethoxyprop-l-yl benzoate 2.56 containing the isomeric impurity
l-chloromethoxyprop-2-yl benzoate 2.57
propanol 2.52 contains about 30% of the isomeric 2-bromo-l-propanol 2.53 as an impurity. It
was anticipated that all the intermediate products would therefore be contaminated with
isomeric impurities such as I-hydroxyprop-2-yl benzoate 2.55. Some exploratory experiments
to synthesise 2-hydroxyprop-I-yl benzoate 2.54 were nevertheless initially carried out with the
impure material. It was, however, also attempted to synthesise I-bromo-2-propanol of a better
quality than the commercial material. The exploratory experiments, using the impure material,
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will now be discussed, followed by a discussion of the synthesis of the better quality l-bromo-
2-propanol 2.52 and its conversion to pure 2-hydroxyprop-l-yl benzoate 2.54.
Dry sodium benzoate was heated with the mixture of bromohydrins 2.52 and 2.53 in
dimethylformamide (DMF) at 120c-130cC. HMPA was recommended as solvent because of its
alleged superior efficiency as solvent for esterification by halogen displacement (March, 1992;
Shaw et al., 1973; Pfeffer & Silbert, 1976), but the dipolar aprotic DMF was used instead
because it is cheaper and more readily available. The assumption was that both isomers present
in the bromohydrin mixture would react quantitatively with the benzoate, resulting in a product
containing about 30% of the undesired isomer l-hydroxyprop-Z-yl benzoate 2.55. Work-up and
silica gel chromatography gave a product (68%) that showed only a single spot on TLC
(Method 7). On HPLC analysis of this product [Method 3(a)], two well resolved peaks were
obtained in a ratio of 65:35. The peak with the shorter retention time (the more polar
component) was the most prominent and was deemed to be the desired 2-hydroxyprop-I-yl
benzoate 2.54. The esterification of propane-l ,2-diol with benzoic acid under acidic conditions,
using a three-fold excess of the diol to suppress the formation of the di-ester, incidentally also
resulted in the formation of 2.54 and 2.55 in approximately the same ratio. As the ester could
not be crystallised, it was impossible to separate the two isomers by crystallisation.
Furthermore, it was unlikely that they would be separable by column chromatography because
TLC on silica gel gave only one spot. At this stage it was decided to continue the synthesis of
the subsequent intermediate products, using the 65%-pure 2-hydroxyprop-l-yl benzoate 2.54,
in the hope that steric influences would promote the elimination of the undesired isomers.
Investigation of the synthesis of pure l-bromo-Z-propanol 2.52 was started by exploring the
method proposed by Dawe et al. (1984) and Bonini and Righi (1994). These authors claim that
the reaction of propylene oxide with freshly prepared Li2NiBr4 in dry THF at room temperature
should produce the two isomers 2.52 and 2.53 in a ratio of ca. 95:5 respectively, according to
Scheme 2.8. Several attempts to synthesise 2.52 by using this method gave impure products.
Using lower reaction temperatures and different work-up procedures again gave isomer ratios
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of between 79:21 and 86:14. This synthetic route to the 1-bromo-2-propanol 2.52 was
therefore abandoned.
OH Br
0 Li2NiBr4 H,C--\__ H,C--\__H3C~
Br OH
Propylene oxide 2.52 2.53
95 5
Cl attack Cj attack
Scheme 2.8 Synthesis of I-bromo-2-propanol 2.52 according to Dawe et al. (1984) and Bonini and
Righi (1994).
Bonini et al. (1992) claimed a ratio of C1:C2 of between 75:25 and 99:1 for different
unspecified halogen derivatives using lithium bromide as the source of bromide, Amberlyst 15
as the acidic catalyst and dry acetonitrile as the solvent, according to Scheme 2.9. However,
several variations of the method of Bonini et al. (1992) did not yield better than 75:25 ratios.
R 0
~
LiBr
R= alkyl, aryl Cl attack C2attack
Scheme 2.9 Synthesis of I-bromo-2-hydroxy derivatives according to Bonini et al. (1992)
The synthesis of 1-bromo-2-decanol according to Eisch et al. (1992), as depicted in Scheme
2.10, gave this compound in a high degree of purity. Unfortunately the long-chain 1,2-
epoxydecane was the only starting material that was used by Eisch et al. to demonstrate the
selectivity of this synthesis. A Grignard reagent is treated with a non-nucleophilic amine, and
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the resulting compound is reacted with an epoxide. Although it is difficult to remove the amine
used in this synthesis, 2,2,6,6-tetramethylpiperidine, from the product, it was possible to
synthesise I-bromo-2-propanol 2.52 in a yield of 41% and a high degree of purity of more than
99% with the use of this method. Extended storage and distillation of the crude product at high
temperatures should be avoided because the target product can react with 2,2,6,6-
tetramethylpiperidine and can eventually produce the starting epoxide. Most of the unreacted
amine was removed from the product by means of the ammonium chloride solution that is used
to hydrolyse the intermediates. The removal of THF from l-bromo-Z-propancl is also difficult
because the boiling point of the target compound is relatively low. Substituting
diisopropylamine for the expensive 2,2,6,6-tetramethylpiperidine also gave an acceptable
product in a yield of 43%.
---c., ---(OHR 0~ Mg(TMP)Br
R= l-octyl TMP = 2,2,6,6-tetramethylpiperidine 100 o
Scheme 2.10 Synthesis of I-bromo-2-decanol according to Eisch et al. (1992)
GC-MS analysis of the product (Method 1) confirmed the identity of I-bromo-2-propanol. The
molecular ions (m/z 138 and 140) arising from the two stable bromine isotopes were present in
a low concentration (0.5% each), but the m/z peak of 45, characteristic of secondary alcohols,
was present as base peak. According to GC analysis (Method 1), the purest fraction showed an
overall purity' of approximately 85% and contained only 0.3% 2-bromo-l-propanol. Using this
fraction as starting material, an additional synthesis of 2-hydroxyprop-l-yl benzoate 2.54 was
carried out in an attempt to prepare an isomer-free product. HMP A, instead of DMF, was used
5 The solvent is included in calculating the overaJl purity. In this case, for example, the product contained ca. 15% solvent
and co-eluting volatile material
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as solvent for this synthesis. Preliminary pilot experiments had indicated that the reaction
proceeded very slowly at room temperature, while prolonged heating at higher temperatures
(700-100°C) resulted in the formation of increasing amounts of the undesired I-hydroxyprop-2-
yl benzoate 2.55, presumably due to rearrangement. Work-up and silica gel chromatography of
a reaction product obtained under optimised reaction conditions (reaction temperature = 60°C,
reaction time = 2 hours) gave compound 2.54 in an isomeric purity of 97% and a yield of
approximately 58%.
2-Chloromethoxyprop-I-yl benzoate 2.56 was prepared from both the 65%- and 97%-pure 2-
hydroxyprop-l-yl benzoate 2.54. Guédin-Vuong and Nakatani's method (1986) for the
synthesis of 2-chloromethoxyethyl benzoate 2.51 was utilised. As before, this method proved
to be very successful and gave the product in quantitative yield. This chloromethyl ether was
used without purification in the next step of the preparation of the N-alkylated heterocyclic
amme.
2.3.1.3 Synthesis of I-chloromethoxyprop-2-yl benzoate 2.57
2-Bromo-Lpropanol 2.53 was needed as the halohydrin source for the synthesis of the
monoester I-hydroxyprop-2-yl benzoate 2.55, the required starting material for the synthesis of
I-chloromethoxyprop-2-yl benzoate 2.57, as shown in Scheme 2.7. Since 2-bromo-I-propanol
2.53, the contaminating isomer present in the commercial I-bromo-2-propanol 2.52, is not
commercially available, it had to be synthesised. The strategy chosen for the synthesis of this
bromohydrin was based on the reduction of 2-bromo-propionic acid to the corresponding
alcohol. Lithium aluminiurnhydride (LiAIH4) is mostly used as reducing agent for the reduction
of carboxylic acids or esters to alcohols, but aluminium hydride was preferred in order to
prevent dehydrobromination as a possible side reaction. This agent was generated in situ by
treating LiAIH4 with concentrated sulphuric acid at 0° to 5°C, according to the method of Shah
et al. (1996). The 2-bromopropionic acid was treated with the resulting H2S04/AIH3 mixture.
Work-up gave a product in low yield (approximately 20%). GC analysis (Method 1) of this
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product showed a major peak with a retention time similar to that of the smaller peak in the GC
chromatogram of the commercial l-bromo-2-propanol, i.e. the contaminant 2-bromo-l-
propanol, as well as a smaller peak with a retention time similar to that of the major peak in the
commercial l-bromo-2-propanol. This suggested that the required product (2-bromo-1-
propanol) had been formed. The ratio of 2-bromo-1-propanol 2.53 to 1-bromo-2-propanol 2.52
in this product was approximately 95:5, while its overall purity was approximately 70% (GC).
Itwas not distilled to avoid possible isomerisation.
This preparation of l-hydroxyprop-2-yl benzoate 2.55 from the bromohydrin 2.53 was carried
out in DMF. Experiments were carried out to find the optimum reaction conditions such as
reaction temperature and reaction time. HPLC analysis of the reaction mixtures [Method 3(a)
or 3(b)] showed the presence of a higher than expected amount of2-hydroxyprop-I-yl benzoate
2.54, formed as a result of the presence of 1-bromo-2-propanol 2.52 in the starting material
2.53. In one experiment, the reaction temperature was maintained between 100° and 117°C.
The ratio of 2.55:2.54 changed from = 82:18 to 66:34 over a period of approximately six hours.
In another experiment, in which the reaction temperature was maintained at 100°C over a
period of approximately 2.5 hours, the final ratio of 2.55:2.54 was 80:20. These results
suggested that some rearrangement had taken place during prolonged heating, as the starting 2-
bromo-I-propanol 2.53 contained only 5% I-bromo-2-propanol 2.52. The reason for the
extended heating was to optimise the yield of the product. Unfortunately, optimum isomeric
purity had to be sacrificed in order to obtain an acceptable yield. No further attempts were
made to optimise reaction conditions in order to ensure optimum isomeric purity. Crude
reaction products were worked up and chromatographed over silica gel. Purified products
obtained from various experiments were combined to give a final product containing the two
monoesters 2.55 and 2.54 in a ratio of 70:30. Despite this lower isomeric purity of 1-
hydroxyprop-2-yl benzoate 2.55, it was nevertheless decided to use it as substrate for the
preparation of chloromethyl ether 2.57 according to the method of Guédin-Vuong and Nakatani
(1986).
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2.3.1.4 Synthesis of 1,3-dibenzoyloxy-2-chloromethoxypropane 2.61
This reagent, required for the alkylation of 2-methyl-5-nitroimidazole, was synthesised
according to the reaction pathway depicted in Scheme 2.11. The starting material 1,3-dibromo-
2-propanol 2.58 is commercially available in a purity of 95%. It was heated in HMPA or DMF
with a two- to three-fold molar excess of sodium benzoate to produce 1,3-dibenzoyloxy-2-
propanol 2.59. Firstly, in an adaptation of the method described by Shaw et al. (1973), sodium
benzoate was formed in situ by treating benzoic acid with sodium hydride in
hexamethylphosphoramide (HMPA). 1,3-Dibromo-2-propanol 2.58 was then added to the
mixture. In contrast to the method described by Shaw, in which the reaction was carried out at
room temperature using an excess of the halide, the synthesis under investigation had to be
carried out at an elevated temperature (110°C) in order to dissolve all of the benzoate.
Br\ /r
2 Sodium benzoate + /
HO
~ Q-{~~ +
HO 0
2.58 2.59 2.60
{,b
a. 110°-165°C, DMF or HMPA
b. (CH20)n, HCI (g), -8°C
2.61
Scheme 2.11 Synthesis 1,3-dibenzoyloxy-2-propanol 2.59 and 1,3-dibenzoyloxy-2-
chloromethoxypropane 2.61
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In a second procedure, in which a mixture of previously prepared sodium benzoate and DMF
was used, a higher reaction temperature (165°C) was needed to dissolve the benzoate.
According to HPLC-analysis (Method 4) of the products obtained in these experiments, the
products contained two major constituents in a ratio of ca 3:7. As the starting material was 95%
pure, the formation of an impurity in a concentration of 30% was somewhat unexpected. The
impurity was presumed to be the hydroxydibenzoate 2.60 formed by a rearrangement
analogous to the formation of 2-hydroxyprop-I-yl benzoate 2.54 as a by-product of the
synthesis of l-hydroxyprop-Z-yl benzoate 2.55 described in Section 2.3.1.3.
The products obtained in all of these experiments were combined and purified by column
chromatography over silica gel. In contrast to the mixture of the monoesters 2-hydroxyprop-l-
yl benzoate 2.54 and l-hydroxyprop-2-yl benzoate 2.55, the two constituents of this mixture,
1,3-dibenzoyloxy-2-propanol 2.59 and 2,3-dibenzoyloxy-l-propanol 2.60, could be fairly well
separated by means of silica gel chromatography, although a large fraction of the eluted
material contained both compounds. The less polar, major constituent was isolated in a 24%
yield and a purity of 95%. The more polar, minor constituent was isolated in a yield of 3%, but
in a similar purity. IH NMR data (TABLE 2.2) confirmed the less polar compound to be 1,3-
dibenzoyloxy-2-propanol 2.59. The IH NMR spectrum of the more polar compound is in good
agreement with the proposed structure, 2,3-dibenzoyloxy-I-propanol 2.60. While the
chemically equivalent methylene protons in 2.59 have the same chemical shift, the chemical
shifts of the non-equivalent methylene protons in 2.60 differ by approximately 0.7 ppm, with
those geminal to the hydroxyl group resonating at higher field. Likewise, the chemical shift of
the methine proton at 8 5.5 in the spectrum of the hydroxydiester 2.60, being geminal to a
carboxylic ester oxygen atom, resonates at a lower field than the analogous proton of
hydroxydiester 2.59 (8 4.4).
The reaction conditions used for the preparation of the alkylating agents 2.51, 2.56 and 2.57
were also employed to synthesise the alkylating agent 1,3-dibenzoyloxy-2-
chloromethoxypropane 2.61 from 1,3-dibenzoyloxy-2-propanoI2.59. However, the preparation
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TABLE 2.2 IH NMR (300 MHz) data for the hydroxydibenzoates 2.59 and 2.60
Protons PhCOO-CH2-CH(OH)-CH2-OCOPh HO-CH2-CH(OCOPh)-CH2-OCOPh
2.59 2.60
8 (ppm) 8 (ppm)
OH 2.91 (IH) d 2.48 (lH) broad m
CHOH 4.38 - 4.44 (lH) m -
CfuOH - 3.98 (2H) d
CfuOCO 4.49 - 4.59 (4H) dd 4.70 (2H) d
CHOCO - 5.48 - 5.55 (lH) quintet
of 2.61 was much less successful than that of the others. The purity of this type of chloromethyl
ether cannot be easily determined chromatographically because of its instability (Guédin- Vuong
& Nakatani, 1986). However, an idea of its purity can be obtained by observing the yield of the
condensation product (e.g. 1-[( 1,3-dibenzoyloxyprop-2-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.93 obtained by the reaction of the chloromethyl ether (e.g. 2.61) with an
amine such as 2-methyl-5-nitroimidazole). A poor condensation yield can most probably be
attributed to an impure chloromethyl ether. The yields of the various condensation products,
using the various chloromethyl ethers, are discussed in Section 2.3.2.1.1. Alkylated products in
modest to fairly good yields were given by 2-chloromethoxyethyl benzoate 2.51, 2-
chloromethoxyprop-l-yl benzoate 2.56 and l-chloromethoxyprop-2-yl benzoate 2.57. In
contrast to these yields, 1,3-dibenzoyloxy-2-chloromethoxypropane 2.61 gave the alkylated
amine 2.93 in widely varying yields, ranging from very poor to modest. This phenomenon can
probably be explained in terms of possible steric hindrance caused by the two geminal
benzoyloxymethyl groups at the secondary hydroxy group in the precursor, 1,3-dibenzoyloxy-
2-propanol 2.59, which might impede the ease of chloromethylation at this reaction site.
54
Stellenbosch University http://scholar.sun.ac.za
2.3.2 Preparation of N-alkylated Amines
In order to synthesise the amine precursors, a nitrogen atom had to be alkylated in the
heterocyclic rings of benzotriazole and 2-methyl-5-nitroimidazole, respectively. Initially, it was
not clear at which nitrogen atom in the heterocyclic ring of benzotriazole alkylation would
preferentially occur. In the case of 2-methyl-5-nitroimidazole, it was easier to predict the
preferred site of N-alkylation. Tautomer II, 2-methyl-4-nitroimidazole, would not exist in
significant quantities because of the stabilisation of tautomer I, 2-methyl-5-nitroimidazole,
through hydrogen bonding between the NH proton and the negatively polarised oxygen atom of
the adjacent nitro group. However, after abstraction of the proton from the nitrogen atom with
base, there will be no difference in the stability between the two resonance structures (shown in
Scheme 2.12), and the site of N-alkylation should be ruled by a steric influence exerted by the
nitro group on the adjacent N-l atom of 2-methyl-5-nitroimidazole. N-alkylation of this
compound would therefore probably preferentially occur at the more accessible N-3 atom. In
such a case, the major N-alkylated compounds formed would be 2-methyl-4-nitroimidazole
derivatives.
2-Methyl-5-nitroimidazole (Tautomer I) 2-Methyl-4-nitroimidazole (Tautomer II)
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NN~N"-....N-:-N~"-....Ny"H + N:B- ~
80 CJ /)
Benzotriazole2.62 2.62 (Nl) 2.62 (N2)
2-Methyl-5-nitroimidazole2.79 2.79 (Nl) 2.79 (N3)
Scheme 2.12 Resonance structures of the anion that is formed by abstraction of a proton from the
amine nitrogenatomofbenzotriazole and 2-methyl-5-nitroimidazole
The site of N-alkylation in the various molecules was confirmed by l3e NMR spectral data
obtained from the major N-alkylated compounds formed, as well as by those obtained from by-
products. Due to the element of symmetry in benzotriazole 2.62 (anion N2), one would expect
that there would be only three aromatic l3e signals in the "c NMR spectra of all its alkylated
products. In practice, all the isolated benzotriazole derivatives synthesised in this work
exhibited six "c signals in the aromatic region of the spectra, suggesting that they had been
derived from 2.62 (Nl) in which all six the aromatic carbons are non-equivalent. Only one
benzotriazole alkylated by-product was isolated, and as its "c NMR spectrum had indeed only
three aromatic carbon signals, it was concluded that it had the structure 2-(2-hydroxyprop-l-
yl)benzotriazole 2.72 (see the preparation of compound 2.71 and the isolation of the by-product
2.72 in paragraph 2.3.2.2).
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A comparison of the chemical shift values of the carbon signals in the 13Cspectra of the N-
alkylated nitroimidazole compounds synthesised in this work and those in the spectra of
authentic 2-methyl-5-nitroimidazole and 2-methyl-4-nitroimidazole derivatives, confirmed the
earlier speculations on the preferred site of alkylation in this molecule. These data are shown in
Table 2.3.
TABLE 2.3 Comparison of 13CNMR data of a few N-alkylated nitroimidazole derivatives
synthesised in this study with those of *reference compounds
Compound
1-[(l-benzoyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.80
1-[(l-benzoyloxyprop-2-yloxy)methyl]-2-methyl-5-nitroimidazole 2.81
1-[(2-benzoyloxyprop-l-yloxy)methyl]-2-methyl-4-nitroimidazole 2.88
1-[(1,3-dibenzoyloxyprop-2-yloxy)methyl]-2-methyl-4-ni troimidazole 2.93
By-product of compound 2.93
* 1-(2-chloroethyl)-2-methyl-5-nitroimidazole
* 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole
*3-(2-methyl-4-nitroimidazol-I-yl)propionic acid
* 1-(2-cyanoethyl)-2-methyl-4-nitro-imidazole
l3CNMR chemical shift values of
heterocyclic ring carbon atoms
8 (ppm)
119.56,145.46,147.08
133.35, 138.36, 152.05
119.64,145.56,146.87
119.72,145.54,146.82
133.45, 138.27, 152.06
133.51,138.19,151.45
132.79,138.29,151.79
121.84,145.16,145.27
121.85,145.22,145.47
*Data obtained from the Aldrich Library of l3C and IH FTNMR spectra, Edition I, Volume 3 (1993).
The data in Table 2.3 confirm that the major products obtained in the N-alkylation of 2-methyl-
5-nitroimidazole in this work had formed as a result of N-alkylation at the N-3 atom, leading to
the formation of 2-methyl-4-nitroimidazole derivatives (e.g. 2.80, 2.88 and 2.93). The l3C
NMR chemical shift data of the by-products isolated in the synthesis of compounds 2.93 and
2.80 (compound 2.81), displayed in Table 2.3, are in good agreement with those of2-methyl-5-
nitroimidazole derivatives. As the main emphasis in this work was placed on the structures of
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the aliphatic prosthetic groups rather than those of the carrier molecules, no attempts were
made to isolate or prepare more of the 2-methyl-5-nitroimidazole derivatives.
Various reaction conditions are used for N-alkylation. For the condensation of2-nitroimidazole
with 2-benzoyloxyethoxymethyl chloride, Srivastava et al. (1991) used dimethylformamide as
solvent and triethylamine as base. For the condensation of the same substrate with 2-
bromoethyl-2-tetrahydropyranyl ether, Jerabek et al. (1986) used N,N-dimethylacetamide
(DMA) as solvent, sodium methoxide as base, and a reaction temperature of 90°C. Milder
reaction conditions were employed by Waterhouse et al. (1996) for the N-alkylation of 4-(4-
cyanophenoxymethyl)piperidine with propargyl bromide. The reaction was carried out at room
temperature, using dichloromethane as solvent and potassium carbonate as base. Acetonitrile is
also often used as solvent for N-alkylations (Chi et al., 1986; Shi et al., 1999; Yasunaga et al.,
1998). For the purpose of this work, the most suitable reaction conditions were selected,
depending on the type of alkylating agent used.
2.3.2.1 Preparation of N-alkylated intermediates for the synthesis of iodination precursors
containing a leaving group in a P-position with respect to an oxygen atom
As a rule-of-thumb, the terms "p-ester" and "p-hydroxy" refer to the position of the ester group
or the hydroxy group (P) relative to the ether oxygen atom in the prosthetic group. Precursors
2.65,2.69,2.83,2.85,2.90,2.95 and 2.97 all fall in the category mentioned in the heading. The
respective intermediates were prepared in a two-step procedure involving the N-alkylation of
the heterocyclic nitrogen compounds as the first step. For this, the specially prepared
chloromethyl ethers were used. The N-alkylation step was followed by hydrolysis of the
protecting ester function to obtain the target p-hydroxy intermediates. The reaction schemes in
Scheme 2.13 illustrate these N-alkylation reactions and give the p-esters that were formed in
the first step of these syntheses.
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N
N~ "NH
b
Benzotriazole R=H
R=CH3
2.63
2.67
2-Methyl-5-nitroimidazole
Rl = H; R2 = CH3 2.80
Rl = CH3; R2 = H 2.88
Rl = H; R2 = PhCO-O-CH2 2.93
Scheme 2.13 Synthesis of the N-alkylated benzotriazole and 2-methyl-4-nitroimidazole derivatives
These ~-esters were subsequently hydrolysed according to the reaction schemes in Scheme
2.14 to give the ~-hydroxy compounds 2.64, 2.68, 2.82, 2.89 and 2.94. These alcohols were the
intermediates for the synthesis of the precursors.
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room temp.
2.63; 2.67 + NH3(aq) methanol
R=H 2.64
R = CH3 2.68
methanol
2.80; 2.88; 2.93 + NH3(aq)
room temp.
Rl = H; R2 = CH3 2.82
Rl = CH3; R2 = H 2.89
Rl = H; R2 = Ph(CO)-O-CH2 2.94
Scheme 2.14 Synthesis of the N-alkylated benzotriazole and 2-methyl-4-nitroimidazole l3-hydroxy
compounds
The preparation of the various condensation products, as outlined in Scheme 2.13, as well as
their hydrolysis products, as outlined in Scheme 2.14, will now be discussed in greater detail.
2.3.2.1.1 Preparation of the condensation products 2.63, 2.67, 2.80, 2.88, 2.93
Because of the instability of the chloromethyl ethers (Guédin- Vuong & Nakatani, 1986), it was
decided to use the milder reaction conditions described by Waterhouse et al. (1996) for the
preparation of these condensation products. The amine and a three-molar excess of anhydrous
potassium carbonate were added to dichloromethane (or dried acetonitrile in the case of 2-
60
Stellenbosch University http://scholar.sun.ac.za
methyl-5-nitroimidazole), followed by the addition of a slight molar excess (based on the
mono/di-ester starting material content) of the chloromethyl ether in dichloromethane or
acetonitrile. The mixture was stirred at room temperature for a few hours until TLC (Methods
6,7 or 8) showed partial or total consumption of the amine. According to HPLC [Method 2(b)],
the condensation of benzotriazole and 2-chloromethoxyethyl benzoate 2.51 gave a major
product (64%) (l-[(2-benzoyloxyethoxy)methyl]benzotriazole 2.63), unreacted benzotriazole,
as well as unknown by-products. These by-products could possibly have been formed as a
result of alkylation of the benzotriazole anion N-2, but this was not verified. The isolated crude
product was purified, using column chromatography over silica gel, to give a fraction with a
purity of 94% in a yield of 24%, as well as a less pure fraction with a purity of 85% in a yield
of35%.
According to HPLC [Method 2(b)], the condensation ofbenzotriazole and the isomeric mixture
of 2-chloromethoxyprop-l-yl benzoate 2.56 and l-chloromethoxyprop-2-yl benzoate 2.57
(resulting from impure I-bromo-2-propanol 2.52 and therefore impure 2-hydroxyprop-I-yl
benzoate 2.54, as shown in Scheme 2.7) gave two major components with retention times
differing by approximately 0.5 min. in a ratio of 79:21. Together, they constituted
approximately 65% of all the constituents of the product. These two compounds were the
isomeric condensation products resulting from the isomeric mixture of 2.56 and 2.57. The
major condensation product, formed in a concentration of 79%, was 1-[(I-benzoyloxyprop-2-
yloxy)methyl]benzotriazole 2.67. Compound 2.67 and its isomer could not be completely
separated by means of column chromatography over silica gel. The major product (2.67) was
nevertheless purified to an isomeric purity of 76% by this method. Attempts to crystallise the
purified product 2.67 failed.
HPLC analysis of the product (2.67) formed in the alkylation of benzotriazole with pure 2-
chloromethoxyprop-I-yl benzoate 2.56, showed an isomeric purity of 97%. This high isomeric
purity of 2.67 was to be expected, and it reflects the 97% isomeric purity of 2-hydroxyprop-l-
yl benzoate 2.54, the starting material of the alkylating agent 2.56. 1-[(I-Benzoyloxyprop-2-
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yloxy)methyl]benzotriazole 2.67, prepared from pure 2.56, was crystallisable from methanol
after silica gel purification of the crude reaction product. The crystalline product had an overall
purity of 99%, without any isomeric product.
The synthesis of 1-[(1-benzoyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.80 was
carried out only using the isomeric mixture of 2-chloromethoxyprop-l-yl benzoate 2.56 and 1-
chloromethoxyprop-2-yl benzoate 2.57 as alkylating agent. This was done before the purer 2.56
became available. According to HPLC analysis (Method 5), the condensation of 2-methyl-5-
nitroimidazole and impure 2.56 resulted in a product with relatively low purity (approximately
37%). TLC (Method 9) of the crude product showed the presence of two components with very
similar Rf's. Column chromatography over silica gel, using ethyl acetate as mobile phase, gave
a first collected fraction enriched with respect to the less polar of these components. The HPLC
retention time of this fraction corresponded to that of the 37% peak shown in the
chromatogram of the crude reaction product. In contrast to the benzotriazole condensation
product 1-[(I-benzoyloxyprop-2-yloxy)methyl]benzotriazole 2.67 prepared from the impure
2.56, this semi-pure nitro imidazole product was crystallisable from methanol. Upon
crystallisation, a solid white product was obtained in a total yield of approximately 33%, and in
a purity of 98%. NMR and MS proved this product to be the condensation product 2.80. This
result shows that a purer alkylating agent is not necessarily needed to obtain a pure
nitroimidazole condensation product, unless a higher yield of product is required. A second
collected fraction, enriched with respect to the more polar component, could not be crystallised.
The chemical shift values of the heterocyclic ring carbons in the l3C NMR spectrum of the
compound present in this fraction were in good agreement with those of authentic 2-methyl-5-
nitroimidazole derivatives (see Table 2.3). This compound is therefore l-[(1-benzoyloxyprop-
2-yloxy)methyl]- 2-methyl-5-nitroimidazole 2.81.
The condensation product 1-[(2-benzoyloxyprop-l-yloxy)methyl]-2-methyl-4-nitroimidazole
2.88, prepared from 2-methyl-5-nitroimidazole 2.79 and l-chloromethoxyprop-2-yl benzoate
2.57, had an isomeric purity of only 74%, as shown by HPLC (Method 4). This was to be
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expected, as the isomeric purity of the monoester I-hydroxyprop-2-yl benzoate 2.55, the
starting material in the synthesis of 2.57, was only 70% (see Section 2.3.1.3). The crude
product was chromatographed over silica gel in order to remove most of the impurities and this
was followed by crystallisation of most of the contaminating isomer, 1-[(1-benzoyloxyprop-2-
yloxy)methyl]-2-methyl-4-nitroimidazole 2.80, from a methanol solution of the purified 2.88.
The mother liquor containing the enriched 2.88 was once again chromatographed over silica
gel to obtain 2.88 with an isomeric purity of 90%. The purified product was isolated in a yield
of31%.
As mentioned in Section 2.3.1.4, the synthesis of 1-[(1,3-dibenzoyloxyprop-2-yloxy)methyl]-2-
methyl-4-nitroimidazole 2.93 by condensation of the heterocyclic amine, 2-methyl-5-
nitroimidazole 2.79, with the alkylating agent 1,3-dibenzoyloxy-2-chloromethoxypropane 2.61,
was not as successful as the condensation with the other agents, 2-chloromethoxyethyl
benzoate 2.51, 2-chloromethoxyprop-l-yl benzoate 2.56 and l-chloromethoxyprop-2-yl
benzoate 2.57. This was blamed on the low and varying purity of 2.61, prepared from 1,3-
dibenzoyloxy-2-propanol 2.59. HPLC chromatograms (Method 5) always showed some
unreacted starting material, varying amounts of 1,3-dibenzoyloxy-2-propanol 2.59 (indicating
its poor conversion to chloromethyl ether 2.61), as well as two new peaks with slightly
different retention times with respect to each other. The ratio in which the desired product was
formed in relation to all the other constituents varied substantially from 6 to 33%, but the ratio
in which the two major constituents was formed was always in the order of 60:40. The identity
of the major product, which was the less polar component on TLC, was confirmed by IH and
13C NMR to be 1-[(1,3-dibenzoyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.93.
The chemical shift values of the heterocyclic ring carbons in the 13CNMR spectrum of the
minor; more polar fraction were in good agreement with those of authentic 2-methyl-5-
nitroimidazole derivatives (see Table 2.3), indicating it to be the 2-methyl-5-nitroimidazole
analogue of 2.93. Despite the highly impure reaction products, purification with silica gel
chromatography proved to be fairly successful. The reaction in which the major product
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constituted 33% of all the constituents by HPLC gave a yield of approximately 28% in a purity
of96%.
2.3.2.1.2 Preparation of the ~-hydroxy intermediates 2.64, 2.68, 2.82, 2.89, 2.94
The next step in the synthesis of the intermediates required for the synthesis of the precursors
was to convert the condensation products to the ~-hydroxy intermediates by alkaline
hydrolysis, as outlined in Scheme 2.14. Hydrolysis of the various condensation products was
carried out in methanolic ammonia according to the method used by Srivastava et al. (1991).
The hydrolysis products were extracted from the aqueous reaction mixtures with chloroform,
toluene or diethyl ether. Chloroform and ether proved to be the most efficient extraction
solvents. The hydrolysis of 1-[(2-benzoyloxyethoxy)methyl]benzotriazole 2.63 gave a product
that contained one major constituent, namely 1-[(2-hydroxyethoxy)methyl]benzotriazole 2.64
(HPLC, Method 2b). The chloroform extract of this product was not purified but used directly
for the synthesis of the corresponding tosylate precursor. The HPLC chromatogram (Method
2b) of 1-[(I-hydroxyprop-2-yloxy)methyl]benzotriazole 2.68, prepared from 76% isomerically
pure 1-[(I-benzoyloxyprop-2-yloxy)methyl]benzotriazole 2.67, also showed a single peak.
However, when changing the HPLC conditions (Method 6), resulting in an increase of the
retention time from 5 to 16 minutes, a more polar constituent with a slightly shorter retention
time appeared as a shoulder to the peak of the major constituent. The difference in retention
times was approximately 0.2 minutes and the ratio of the minor to the major peak was 20:80.
This shoulder was absent when compound 2.68 was prepared from 99% pure 2.67. These
results suggest that the shoulder can probably be ascribed to the presence of the other isomer in
the product. Compound 2.68, prepared from 99% pure 2.67, was chromatographed over silica
gel to give a main fraction in a yield of 91%.
As expected, the high purity of 1-[(1-benzoyloxyprop-2-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.80 resulted in an almost completely pure hydrolysis product 1-[(1-
hydroxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.82 (HPLC, Method 6). After
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purification, 2.82 was obtained in a yield of 93-97%. The yield of the hydrolysis product 1-[(2-
hydroxyprop-1-yloxy)methyl]-2-methyl-4-nitroimidazole 2.89 after silica gel chromatography
was 90%, and the 89% isomeric purity of 2.89 relates well to the 90% purity of its starting
material 1-[(2-benzoyloxyprop-I-yloxy)methyl]-2-methyl-4-nitroimidazole 2.88. The isomeric
purity of 2.89 was increased to 94% by crystallisation from ethyl acetate, but resulted in a
reduced overall yield of 55%.
For the conversion of the condensation product 1-[(1,3-dibenzoyloxyprop-2-yloxy)methyl]-2-
methyl-4-nitroimidazole 2.93 to a suitable precursor for labelling, two approaches were
possible. In the one approach, both ester groups in 2.93 could be hydrolysed, resulting in a
nucleoside analogue similar to compound 1.31. One of the hydroxyl groups in this analogue
could then be protected by selective acetylation, followed by the conversion of the other one to
a suitable leaving group according to the method of Wada et al. (2000). Another approach
would be to hydrolyse only one of the benzoyloxy groups of 2.93, resulting in a nucleoside
with one of the hydroxyl groups already protected, and thereby eliminating the need to protect
one of the hydroxyl groups again, as required in the first approach. The second approach was
selected for obvious reasons. The diester 2.93 was therefore partially hydrolysed in methanolic
ammonia to give the hydroxyester 1-[(1-benzoyloxy-3-hydroxyprop-2-yloxy)methyl]-2-
methyl-4-nitroimidazole 2.94. The reaction was carefully monitored by means of HPLC
(Method 5), which showed the formation of 2.94, as well as a small amount of the dihydroxy
compound, the formation of which could be suppressed by decreasing the ammonia content of
the reaction mixture to a molar ratio of approximately 48 mmoles NH3 per mmole 2.93. A
molar ratio of 190-370 mmoles NH3 per mmole ester was used in the hydrolyses of the other
condensation products. Quantitative and selective isolation of the hydroxyester 2.94 was
achieved by extracting the water-diluted reaction mixture with chloroform. All the polar
impurities, including the dihydroxy compound, remained in the aqueous phase. The crude
extract was chromatographed over silica gel, giving 96% pure 2.94 in a yield of 57%.
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2.3.2.2 Preparation of N-alkylated intermediates for the synthesis of precursors lacking a ~-
oxygen atom
The benzotriazole-derived precursors 1-(2-p-toluenesulphonyloxyprop-I-yl)benzotriazole 2.73
and 1-(2-methyl-3-p-toluenesulphonyloxyprop-l-yl)benzotriazoIe 2.77 fall in this category.
The rationale behind the selection of these compounds as precursors is explained in paragraph
2.3. The synthesis of their respective N-alkylated intermediates 1-(2-hydroxyprop-l-
yl)benzotriazole 2.71 and 1-(3-hydroxy-2-methylprop-l-yl)benzotriazole 2.76 was much more
straightforward than the synthesis of the intermediates required for the preparation of the
precursors containing a ~-oxygen atom. The N-alkylated intermediates 2.71 and 2.76 were
synthesised according to the method used by Yasunaga et al. (1998), as illustrated in Scheme
2.15.
reflux
~N
N~""'NH
o
acetonitrile
~
2.71
reflux
Benzotriazole
acetonitrile
~
+
2.76
Scheme 2.15 Synthesis of the N-alkylated benzotriazole intermediate compounds used for the
preparation of precursors lacking a ~-oxygen atom.
The alkylating agent used to prepare 1-(2-hydroxyprop-l-yl)benzotriazole 2.71 was the
isomerically purer l-bromo-2-propanol 2.52, prepared according to Scheme 2.10. The reaction
mixture was heated under reflux. HPLC analysis of the reaction mixture (Method 7) revealed
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the presence two products eluting about six minutes apart, in a ratio of 72:28. The more polar
compound, with the shorter retention time, was the major component. The two components
were separated by column chromatography over silica gel. The more polar component was
obtained in a 47% yield and in a purity of 97%. According to the data in Table 2.4, the l3C
NMR spectrum of this component had six signals in the aromatic region of the spectrum,
thereby confirming it to be 1-(2-hydroxyprop-l-yl)benzotriazole 2.71, the product of alkylation
at the N-I atom in the heterocyclic ring. The l3C NMR spectrum of the less polar component
only had three signals in its aromatic region which can be ascribed to the presence of three
pairs of equivalent aromatic carbons. This component was therefore assumed to be 2-(2-
hydroxyprop-l-yl)benzotriazole 2.72, resulting from alkylation at N-2 (see Scheme 2.12).
2.71 2.72
TABLE 2.4 Comparison of 13CNMR data of compounds 2.71 and 2.72
Compound l3CNMR chemical shift values of the aromatic ring carbons (ppm)
2.71 109.93, 119.45, 123.96, 127.34, 133.69, 145.35
2.72 118.02, 126.73, 144.35
The reaction conditions used for the synthesis of 1-(2-hydroxyprop-l-yl)benzotriazole 2.71
were also used successfully for the synthesis of 1-(3-hydroxy-2-methylprop-l-yl)benzotriazole
2.76, which was required as starting material for the preparation of 1-(2-methyl-3-p-
toluenesulphonyloxyprop-I-yl)benzotriazole 2.77. Benzotriazole was coupled to the
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bromohydrin (S)-(+)-3-bromo-2-methyl-l-propanol 2.75 as shown in Scheme 2.15. HPLC
analysis of the resulting product mixture (Method 7) again revealed the presence of two
products with retention times about nine minutes apart and in a ratio of 63:37. It was assumed
that the minor product was formed by alkylation at N-2, but this was not confirmed. The two
compounds were separated by means of silica gel chromatography to produce pure 1-(3-
hydroxy-2-methylprop-l-yl)benzotriazole 2.76 in 44% yield. It is interesting to note that the N-
alkylations with this reagent, as well as with I-bromo-2-propanol, both required elevated
reaction temperatures compared to the N-alkylations with the chloromethylethers 2-
chloromethoxyethyl benzoate 2.51 and 2-chloromethoxyprop-l-yl benzoate 2.56, which were
carried out at room temperature. The condensation reaction with the bromohydrin 3-bromo-2-
methyl-l-propanol at room temperature, for example, yielded only 7% product, 5% by-product
and 86% unreacted benzotriazole after 3.5 hours, illustrating the low reactivity of the
halohydrins as compared to the chloromethylethers.
2.3.3 Preparation of the Amine Precursors
The last step in the preparation of the precursors was the conversion of the hydroxyl group of
the N-alkylated intermediates to a tosylate or a triflate group. The tosylate group was generally
preferred as leaving group because of the superior stability of tosylate compounds as opposed
to triflates. The tosylates could therefore be stored for longer periods without significant
decomposition. The tosylates were generally prepared according to the method used by
Kiesewetter et al. (1986). The reactions were carried out in dichloromethane, with p-
toluenesulphonyl chloride (p-TsCI) as tosylating agent and triethylamine as base. The reaction
mixtures were heated under reflux until all or most of the starting material had been consumed
as monitored by TLC (Methods 7 or 8). In two cases, the tosylation reaction was carried out in
pyridine according to the method used by Argentini et al (1981). This method is useful for
small-scale reactions because the reaction is carried out without heating. However, due to the
more cumbersome work-up procedure, the Kiesewetter's method was generally preferred. As
explained earlier in paragraph 2.3, 2-methyl-4-nitro-l-[(2-trifluoromethanesulphonyloxyprop-
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l-yloxy)methyl]imidazole 2.90 was prepared as the triflate rather than the tosylate. Another
triflate, 2-methyl-4-nitro-l-[(I-trifluoromethanesulphonyloxyprop-2-yloxy)methyl]imidazole
2.85, was also prepared, in addition to its tosylate analogue 2-methyl-4-nitro-l-[(1-p-
toluenesulphonyloxyprop-2-yloxy)methyl]imidazole 2.83. The triflates were prepared
according to the method used by Jerabek et al. (1986). Crude tosylated products were purified
by column chromatography over silica gel in order to separate unreacted starting material, p-
TsCl and other by-products from the target compound. The triflates were not purified, as the
conversions appeared to have proceeded quantitatively (TLC). They were also not
characterized because of their instability in a solid form (Jerabek et al., 1986).
2.3.3.1 Preparation of iodination precursor 1-[(2-p-toluenesulphonyloxyethoxy)methyl]ben-
zotriazole 2.65
Starting from the ~-hydroxy intermediate 1-[(2-hydroxyethoxy)methyl]benzotriazole 2.64, the
compound was initially prepared according to the method used by Kiesewetter et al. (1986).
Column chromatography over silica gel assumedly gave the tosylate 2.65 in what was
calculated to be 34% yield. lts IH NMR spectrum, however, did not contain the characteristic
methyl and aromatic protons of the tosyl group. According to the data shown in Table 2.5, the
aliphatic region of the spectrum also showed certain similarities to those of the iodinated
product 1-[(2-iodoethoxy)methyl]benzotriazole 2.66b, prepared from an authentic precursor
2.65. Only the chemical shifts of the respective terminal methylene protons differed. This
suggested that the terminal methylene protons of the two compounds were attached to two
different atoms with different electronegativities. This evidence suggested that this fraction was
not the tosylate but the corresponding chlorinated product 1-[(2-
chloroethoxy)methyl]benzotriazole 2.66a. Mass spectra data supported this assumption by
clearly showing the two molecular ions of compound 2.66a, arising from the two stable
chlorine isotopes 35Cl and 37Cl [m/z 211(27%); 213 (8%)], in the correct isotopic abundance
ratio. In addition to this all, the reactivity of 2.66a towards radioiodide was also much lower
than would be expected for the tosylate (see Section 3.4.1). According to Kiesewetter et al.
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(1986), chlorination of the highly reactive tosylates is possible in the presence of chlorinated
solvents. Compound 2.66a was formed in a significant amount during the course of the
reaction. The tosylation reaction was repeated, using pyridine as solvent according to the
method used Argentini et al. (1981). Purification gave the target tosylate 2.65 in a yield of
62%. Radiosynthesis of 1-[(2-[123I]iodoethoxy)methyl]benzotriazole 2.66b was initially carried
out by using 1-[(2-chloroethoxy)methyl]benzotriazole 2.66a as the precursor, although 1-[(2-p-
toluenesulphonyloxyethoxy)methyl]benzotriazole 2.65 was also used later.
TABLE 2.5 Comparison of lH NMR (300 MHz) data of the aliphatic protons of 1-[(2-
chloroethoxy)methyl]benzotriazole 2.66a and 1-[(2-iodoethoxy)methyl]
benzotriazole 2.66b
Compound 2.66a Compound 2.66b
Protons 8 (ppm) J (Hz) Protons 8 (ppm) J (Hz
OCH2CH2Cl 3.55-3.82 (4H) m - CH2I 3.08-3.12 (2H) t 6.5
OCH2 3.71-3.75 (2H) t 6.5
NCH2 6.12 (2H) s - NCH2 6.03 (2H) s -
Ts-CH3 no signal
2.3.3.2 Preparation of iodination precursor 1-[(I-p-toluenesulphonyloxyprop-2-yloxy)-
methyl]benzotriazole 2.69
The tosylated benzotriazole precursor 2.69 was prepared from both the 80% and 100%
isomerically pure 1-[(1-hydroxyprop-2-yloxy)methyl]benzotriazole 2.68 (see Section
2.3.2.1.2). The reaction was carried out according to the dichloromethane/triethylamine method
used by Kiesewetter et al. (1986). The reaction mixtures were heated by refluxing either on a
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hot plate or with the reaction vessel immersed in an oil bath6 at 120DC. The reaction product
was purified by column chromatography over silica gel. A higher yield of the product (91%)
was obtained by heating the reaction mixture in an oil bath at 120DC, compared to a yield of
36% obtained when the reaction vessel was suspended above a hot plate. HPLC analysis
[Method 2(b)] showed that the purity of the tosylated benzotriazole 2.69 obtained from the
80% pure 1-[(I-hydroxyprop-2-yloxy)methyl]benzotriazole 2.68 was 93%, while the 100%
pure 2.68 gave 2.69 in a purity of 98%. Apparently the isomeric impurity [Ar-N-CH2-O-CH2-
CH(CH3)-OH] in the 80% pure 2.68 was not tosylated quantitatively, presumably because of
the steric hindrance resulting from the fact that its hydroxyl group is attached to a secondary
carbon. This implies that I-bromo-2-propanol does not need to be 100% pure in order to obtain
a relatively pure tosylate.
2.3.3.3 Preparation of iodination precursor 1-(2-p-toluenesulphonyloxyprop-l-yl)benzotriazole
2.73
Using the intermediate 1-(2-hydroxyprop-l-yl)benzotriazole 2.71 as the starting material, the
reaction was carried out in dichloromethane/triethylamine at an oil bath temperature" of 140-
160DC. A feature of this reaction was the formation of a by-product during prolonged heating
in an unsuccessful attempt to force the reaction to completion. After seven hours at 140-160DC,
the ratio of product:by-product was approximately 1:1 according to HPLC analysis [Method
2(b)]. The unidentified by-product was not isolated and characterized. Column chromatography
over silica gel gave a fraction with a purity of 92% in a yield of 37%. Crystallisation of this
material from ethyl acetate gave the target compound 2.73 in a purity of 97%. IH NMR
analysis confirmed the presence of the tosylate group in the product.
6 The temperature of the oil bath only indicates the surrounding temperature of the reaction mixture, and not the
temperature of the reaction mixture as such
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2.3.3.4 Preparation of iodination precursor 1-(2-methyl-3-p-toluenesulphonyloxyprop-l-yl)-
benzotriazole 2.77
The reaction was carried out in dichloromethane at an oil bath temperature of 140oe, using the
intermediate 1-(3-hydroxy-2-methylprop-l-yl)benzotriazole 2.76 as the starting material. The
crude product was' chromatographed twice over silica gel to give the target compound 2.77 in a
yield of 50% and a purity of 92%.
2.3.3.5 Preparation of iodination precursor 2-methyl-4-nitro-l-[( I-p-toluenesulphonyloxy-
prop-2-yloxy)methyl]imidazole 2.83
The reaction was carried out in dichloromethane for 4.5 hours at an oil bath temperature of
100oe, using the highly pure ~-hydroxy intermediate 1-[(I-hydroxyprop-2-yloxy)methyl]-2-
methyl-4-nitroimidazole 2.82 as the starting material. The conversion proceeded smoothly
(TLe, Method 10), giving a 96% pure target compound 2.83 in a yield of 91%, after
chromatography over silica gel. This yield corresponds well to that obtained in the synthesis of
the benzotriazole analogue 1-[(I-p- toluenesulphonyloxyprop- 2-yloxy)methyl]benzotriazole
2.69 at 1200e (see Section 2.3.3.2). This was to be expected as both compounds have identical
prosthetic groups and the reaction conditions were similar.
2.3.3.6 Preparation of iodination precursors 2-methyl-4-nitro-l-[(1-trifluoromethanesulpho-
nyloxyprop-2-yloxy)methyl]imidazole 2.85 and 2-methyl-4-nitro-l-[(2-trifluoro-
methanesulphonyloxyprop-l- yloxy)methyl ]imidazole _2.90
These two triflate precursors were prepared from the ~-hydroxy intermediates 1-[(1-
hydroxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.82 and 1-[(2-hydroxyprop-l-
yloxy)methyl]-2-methyl-4-nitroimidazole 2.89 respectively. They were prepared at the same
time in order to monitor their respective stabilities versus time. The triflates were prepared by
treating the ~-hydroxy compounds with trifluoromethanesulphonic (triflic) anhydride at -lOoe
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in a solution of dry acetonitrile. Extraction with dichloromethane from an aqueous mixture,
followed by evaporation to dryness, gave the products in quantitative yields. Triflate 2.85 was
obtained as a white solid and showed a single spot on TLC (Method 11). Triflate 2.90 was
obtained as an oil and showed a few minor impurities on the same TLC system. Both products
were stored as solutions in dichloromethane at -10°C. Triflate 2.85 appeared to be fairly stable
in a dichloromethane solution. No significant decomposition occurred over a period of
approximately three months, as judged by TLC. The triflate 2.90, however, decomposed almost
completely over the same period.
2.3.3.7 Preparation of iodination precursor I-[(I-benzoyloxy-3-trifluoromethanesulphonyl-
oxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.95
Iodination precursor 2.95 was prepared from I-[(I-benzoyloxy-3-hydroxyprop-2-
yloxy)methyl]-2-methyl-4-nitroimidazole 2.94 in a way similar to the preparation of the other
triflates 2.85 and 2.90. TLC showed an almost complete conversion of the starting material
2.94 to the target compound 2.95. However, after work-up of the reaction mixture according to
the procedure followed for the isolation of 2.85 and 2.90, HPLC analysis [Method 2(b)]
unexpectedly showed the almost complete decomposition of the triflate 2.95, with the
simultaneous reappearance of the starting material 2.94. It was not clear why the triflate 2.95
was unstable during aqueous work-up, whereas 2.85 and 2.90 stayed intact. It was subsequently
decided not to use the aqueous work-up procedure for 2.95, but to use this triflate in situ for
iodinations and radioiodinations.
2.3.3.8 Preparation of iodination precursor I-[(1-benzoyloxy-3-p-toluenesulphonyloxy-
prop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.97
Because of the instability of the triflate 2.95, as well as the low radiochemical yields obtained
using the triflate that had been prepared in situ, it was decided to also prepare its tosylated
analogue 2.97 from compound 2.94. This synthesis was done according to the method of Wada
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et al. (2000), in which the free hydroxyl group in the mono-acetyl ester of 1-[2-hydroxy-l-
(hydroxymethyl)ethoxy]methyl-2-nitroimidazole 1.31 was converted into a tosylate. This
method is essentially similar to that used by Argentini et al. (1981), in which pyridine is used
as solvent. TLC (Method 9) showed an almost complete conversion of the starting material
into the product. After removal of the pyridine and purification by column chromatography
over silica gel, the pure target tosylated iodination precursor 2.97 was obtained in a yield of
79%.
2.3.4 Preparation of the Iodinated Heterocyclic Amine Derivatives
In order to obtain "cold" iodinated compounds for characterisation purposes (NMR, MS),
portions of the precursors were converted into their respective iodinated analogues. In most
cases these iodo compounds were prepared from their respective tosylate precursors, except for
1-[(2-iodoprop-l-yloxy)methyl]-2-methyl-4-nitroimidazole 2.92 and 1-[(1-benzoyloxy-3-
iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.99, which were prepared from the
respective triflate precursors. In the case of the tosylates, the precursor was heated in an
acetone solution in the presence of a slight molar excess of sodium iodide. In the case of the
triflates, the crude triflate was reacted with sodium iodide at room temperature after replacing
the acetonitrile, in which the triflate had been formed, with acetone. The conversions were
complete within 15-20 minutes. Sodium triflate and traces of triflic acid were removed from
the crude reaction mixtures by extracting a dichloromethane or chloroform solution of the
crude product with aqueous sodium carbonate or bicarbonate solution and/or filtering it
through a column of aluminium oxide. Compound 2.99 was converted to 1-[(1-hydroxy-3-
iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.100 by means of alkaline hydrolysis
with sodium hydroxide. All the crude reaction products were chromatographed on silica gel to
give the purified iodinated compounds 1-[(2-iodoethoxy)methyl]benzotriazole 2.66b, 1-[(1-
iodoprop-2-yloxy)methyl]benzotriazole 2.70, 1-(2-iodoprop-l-yl)benzotriazole 2.74, 1-(3-iodo-
2-methylprop-l-yl)benzotriazole 2.78, 1-[(l-iodoprop-2-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.87, 1-[(2-iodoprop-l-yloxy)methyl]-2-methyl-4-nitroimidazole 2.92, 1-[(1-
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benzoyloxy-3-iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.99 and 1-[( 1-hydroxy-3-
iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.100.
~N'-...
N N~ CH(R)-CH 2-1
00
CH3
N~N'-...N~Io
R=H 2.66b
R = CH3 2.70
2.74 2.78
RI = CH3; R2 = H
RI = H; R2 = CH3
RI = PhCOO-CH2; R2 = H
RI = HO-CH2; R2 = H
2.87
2.92
2.99
2.100
The syntheses of the N-alkylated benzotriazole and 2-methyl-4-nitroimidazole derivatives, the
various iodination precursors and the iodinated compounds are summarized in Schemes 2.16
and2.17.
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N
N~ "NHo
Benzotriazole
,~~~~
CH3 8~~N 0 N~'J8""~~ o ~ (] oePhIJ II I;
2.63 2.67 2.71 2.76
+e +e +f +f
N eH3 8~0"Nl""N~ 8""~~ N~N"NJo ~oc o m, I;
2.64 2.73 2.772.68
+f +f + g CH3 +gNNl""n N CH3o o~o" 8""°" NyN"NJ A"~N?'N0' o '
2.65 2.69 2.74 2.78+ g +g
N 8~Z'1"" ~N No o~,
2.66b 2.70
a. 2-chloromethoxyethyl benzoate 2.51 b. 2-chloromethoxyprop-l-yl benzoate 2.56
c. I-bromo-2-propano12.52 d.3-bromo-2-methyl-l-propano12.75 e. NH3 (aq) f. p-TsCl g. NaI
Scheme 2.16 Synthesis ofbenzotriazole derivatives, iodination precursors and iodinated compounds
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2-methyl-5-nitroimidazole 2.79
R= OTs 2.83
R= OTf 2.85
+g
2-methyl-5-nitroimidazole
anion N-1
2-methyl-5-nitroimidazole
anion N-3
a. 2-chloromethoxyprop-l-yl benzoate 2.56 b. l-chloromethoxyprop-2-yl benzoate 2.57
c. 1,3-dibenzoyloxy-2-chloromethoxypropane 2.61 d. NH3 (ag) e. p-TsCI f. triflic anhydride g. Na!
h. NaOH
Scheme 2.17 Synthesis of 2-methyl-4-nitroimidazole derivatives, iodination precursors
and iodinated compounds
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CHAPTER3
RADIOLABELLING OF THE PRECURSORS WITH RADIOIODINE
3.1 GENERAL
In this study, two different radioisotopes of iodine, 1231and 131I, were used. While their physical
properties such as atomic mass, half-life and mode of decay differ, their chemical properties
are identical. The isotope with the shorter half-life, 1231 (t1/2= 13.2 hours), was used exclusively
in the radiosynthesis of the benzamide and heterocyclic amine compounds, while the isotope
with the longer half-life, 1311(t1/2= 8.02 days), was used in the radiosynthesis of the model
compounds during the pilot study. In the case of the radioiodinations carried out with 1231,
higher quantities of radioactivity were introduced into reaction mixtures to compensate for
decay. Both these sources of radioiodine are carrier-free, that is, they contained no stable
iodine. This implies that the radiolabelled products were also carrier-free, which means that
they did not contain any of their cold iodinated analogues and therefore had high specific
activities, as explained in Chapter 1. Furthermore, the radioiodinated species could generally be
separated easily from the precursors by chromatographic means, which generally resulted in
high effective specific activities.
Radioiodinations of the various tosylate and triflate precursors were generally done by iodide-
for-tosylate/triflate exchange, while the tributylstannyl precursor 4.28 was radioiodinated by
oxidative demetallation. Iodination with radioiodine or radioiodide was essentially similar to
that involving the stable isotope, except for the difference in stoichiometry of the reactions.
The ease with which the different radioiodinations proceeded, as well as the respective
radiochemical yields, differed substantially. No deliberate attempts were made to optimise
yields by systematic variation of the reaction parameters, as this was beyond the scope of this
work. The synthesis of the radioiodinated model compounds is only discussed in general,
whereas those of the benzamides and heterocyclic amines are discussed in greater detail.
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Radiochemical yields are quoted, and in some cases yields of similar products are compared,
for example when different types of precursors were used. The main object of this part of the
work was to obtain sufficient amounts of the radiolabelled compounds for stability studies.
Radioiodination reactions and stability studies were repeated at various stages of this
investigation to test the reproducibility of the stability data. Radiolabelling of the tosylate and
triflate precursors was generally carried out using the purest available precursor material.
Acetone or acetone/dioxane mixtures were used as solvents in the radioiodide-for-
tosylate/triflate exchange reactions. Radioiodide is generally supplied as a solution in aqueous
sodium hydroxide, which necessitated pre-drying of the solution, using a stream of nitrogen or
argon before addition of the precursor in order to ensure anhydrous reaction conditions.
Substitution reactions with the tosylates required heating of the reaction mixtures. Reaction
mixtures were analysed by means of radio-HPLC and/or radio- TLC to determine the progress
of a reaction, as well as to verify the authenticity of the major product. This was done by
comparing the retention times of the major peaks in the radio chromatograms with those in the
UV chromatograms of the corresponding cold iodinated reference compounds. A reversed
phase C-18 column, the outlet of which was connected to a sodium iodide radiodetector
coupled in series with a UV-detector, was used. Radiolabelling was always followed by
purification by means of column chromatography over silica gel, which resulted in the
separation of most of the unreacted radioiodide, as well as other radiochemical impurities, from
the target compound. In most cases, this also resulted in the complete or partial separation of
the labelled product from its lipophilic precursor, a requirement that was not essential for the
purpose of this work. Radiochemical yields are expressed as the decay-corrected amount of
activity obtained in a purified labelled form, as a percentage of the input activity in radioiodide
form. HPLC analyses did not give an accurate reflection of the radiochemical yields, because,
in some cases, substantial amounts of insoluble activity (up to 40% of the input activity)
remained behind in the reaction vessels after the transfer of the reaction mixtures to the silica
gel columns. It was not clear whether this residual activity was due to unreacted free
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radioiodide or to partially precipitated radiolabelled products. Purified products were dissolved
in human blood serum after removal of the organic solvent.
3.2 RADIOSYNTHESIS OF THE ~-IODOALKYLETHER MODEL COMPOUNDS
The tosylates and dry radioiodide were heated in an acetone or acetone/dioxane mixture at high
temperatures ranging from 120°C to 180°C. High temperatures were needed, presumably due
to the inhibiting effect towards nucleophilic substitution (SN) of an oxygen atom in a p-position
relative to the leaving group (Fleet, 1989). Reactions were monitored chromatographically.
Radiochemical yields (RCY) are displayed in Table 3.1.
TABLE 3.1 Radiochemical yields of 13II-labelled p-iodoalkylethers
Compound "Radiochemical Yield (%)
1-[131I]iodo- 2-phenoxyethane 2.4 78 ± 10 (n=II)
2-benzyloxy-I-[ 131I]iodoethane 2.7 79 ± 15 (n=3)
I-[1311]iodo-2-phenoxypropane 2.12 77 ± 6 (n=3)
2-[1311]iodo-I-phenoxy-propane 2.15 66 ± 7 (n=5)
I-[1311]iodo-2-phenoxy-butane 2.19 72 ± 16 (n=3)
1-[131I]iodo- 2-methoxy- 2-phenylethane 2.22 60 ± 19 (n=6)
• Average decay-corrected yield, based on purified output activity, expressed as a percentage of total input
activity
RCY s varied considerably, but were generally somewhat higher for the compounds containing
straight-chain aliphatic groups (C311]2.4 and [1311]2.7). Compound [1311]2.15 was probably
obtained in a lower Rey than compound [1311]2.12, because the SN reaction at a secondary
carbon atom proceeded at a slower rate (Fleet, 1989). The generally lower and more
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inconsistent RCYs obtained for [1311]2.22can most probably be ascribed to the higher steric
hindrance caused by the neighbouring phenyl group. Radio-TLC (Method 1) furthermore
revealed the formation of some radiochemical impurities during the radiosynthesis of
e311]2.22. These impurities, which were more polar than [1311]2.22,tended to diminish or
disappear completely on prolonged heating.
3.3 RADIOSYNTHESIS OF THE BENZAMIDE DERIVATIVES
These reactions, except for the synthesis of the iodoallyl product 2-(3-iodoprop-2-en-l-yloxy)-
3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.48, were all performed in acetone at reaction
temperatures of 150° to 170°C for periods of up to 20 minutes. The reaction progress was
monitored by means of radio-HPLC, generally using Method 1.
3.3.1 Radiosynthesis of 2-(2-[1231]iodoethoxy)-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide
2.42
Four experiments were conducted with the precursor 3-methoxy-N-(2-piperidin-I-ylethyl)-2-
[2-(p-toluenesulphonyloxy)ethoxy]benzamide 2.41. Radiochemical by-products were not
formed in significant amounts. The retention times of the major peaks in the
radiochromatograms were similar to those in the UV-chromatograms, confirming the
authenticity of the radioiodinated compound. The radiochemical yields, according to HPLC,
ranged from 72 to 94%, while the isolated yields after purification ranged from 65 to 83%. The
purified fractions were completely free from the precursor.
3.3.2 Radiosynthesis of 2-(1-[ 1231]iodoprop-2-yloxy)-3-methoxy-N-(2-piperidin-l-ylethyl)-
benzamide 2.44
Three experiments were conducted with the precursor 3-methoxy-N-(2-piperidin-l-ylethyl)-2-
•
[1-(p-toluenesulphonyloxy)prop-2-yloxy]benzamide 2.43. As in the previous case, the
81
Stellenbosch University http://scholar.sun.ac.za
reactions proceeded without the formation of significant amounts of radiochemical by-
products. Comparisons of radioactivity and UV signals from the chromatographic analysis of
[1231]2.44 and stable [1271]2.44 respectively, showed identical retention times. The isolated
radiochemical yields were generally lower than those of [1231]2.42, ranging from 57 to 67%.
The purified product showed no trace of the precursor.
3.3.3 Radiosynthesis of 2-(2-[ 1231]iodoprop-I-yloxy)-3-methoxy-N-(2-piperidin-I-ylethyl)-
benzamide 2.46
Three experiments were conducted with the precursor 3-methoxy-N-(2-piperidin-I-ylethyl)-2-
[2-(p-toluenesulphonyloxy)prop-I-yloxy]benzamide 2.45. In contrast to its isomer, [1231]2.44,
the formation of this product was accompanied by the formation of varying amounts of
radiochemical by-products. The HPLC purities ranged from 32 to 75%, while the total amount
of impurities ranged from 10 to 57%. These impurities were more polar than the main product,
and were unlikely to have arisen from impurities in the precursor 2.45, which appeared to be
fairly pure according to TLC (Methods 4 or 5). The formation of these impurities, which were
not identified, resulted in radiochemical yields of the product varying between 32 and 65%.
HPLC analysis, using a C-18 column and isoeratic elution with a mixture of 75% methanol and
25% water containing 0.1% triethylamine, gave a reasonable resolution of the two isomers
[1231]2.44 and [1231]2.46, with e231]2.44 having the slightly shorter retention time (more polar).
The radiochromatogram of [1231]2.46 had a small shoulder on the main peak, the retention time
of which corresponded to that of [1231]2.44. These retention times corresponded to those in the
UV chromatograms of the non-radioactive analogues. The integration of this shoulder was
obviously not very accurate, but (231]2.44 constituted less than 10% of [1231]2.46.
82
Stellenbosch University http://scholar.sun.ac.za
3.3.4 Radiosynthesis of 2-(3-[1231]iodoprop-2-en-l-yloxy)-3-methoxy-N-(2-piperidin-l-yl-
ethyl)benzamide 2.48
The reaction conditions required for the radio synthesis of [1231]2.48differed from those
employed in the radio synthesis of the preceding radio iodinated compounds 2.42, 2.44 and 2.46,
because of the different type of precursor, 3-methoxy-N-(2-piperidin-l-ylethyl)-2-[3-
(tributylstannyl)prop- 2-en-l- yloxy]benzamide 2.47, that was used. The labelling procedure was
based on the method used by Musachio and Lever (1992) for the oxidative
radioiododestannylation of N-alkylated spiperone analogues. Two experiments were
conducted. The tributylstannylated precursor was reacted with l231 at room temperature in the
presence of chloramine-Tas an oxidising agent. The work-up and purification procedure of the
radioiodinated compound [1231]2.48differed from Musachio and Lever's published method.
After quenching the reaction and neutralisation of the reaction mixture, the organic component
was extracted with dichloromethane and subsequently purified by chromatography over silica
gel, similarly to the purification of [1231]2.42,[1231]2.44and C231]2.46.The two experiments
gave an average overall radiochemical yield of 86% with radiochemical purities ranging from
94% to 99%. These figures illustrate the favourable properties of a tributyltin group as a
leaving group for radioiodination. The purified product contained no detectable trace of the
precursor. lts authenticity was confirmed by the corresponding retention times of the respective
radio- and UV-signals.
3.4 RADIOSYNTHESIS OF THE HETEROCYCLIC AMINES
Radioiodinations of the tosylate precursors of the heterocyclic amine derivatives were carried
out under reaction conditions similar to those used for the synthesis of the radioiodinated
benzamide compounds. Slightly different reaction temperatures, ranging between 130° and
150°C, were used. Reaction times were in the order of 10 to 15 minutes. Radioiodinations of
the triflate precursors were carried out at room temperature because of the high reactivity of the
triflates. The progress of the reactions was monitored by radio-HPLC, using Method 2(a) or
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2(b). It was found that substituting trifluoroacetic acid with triethylamine in the aqueous
mobile phase did not result in any significant changes in retention times or peak resolution.
3.4.1 Radiosynthesis of 1-[(2-e23I]iodoethoxy)methyl]benzotriazole 2.66b
This radioiodinated compound was prepared from both the chlorinated precursor 1-[(2-
chloroethoxy)methyl]benzotriazole 2.66a (see Section 2.3.3.1) and the tosylated precursor 1-
[(2-p-toluenesulphonyloxyethoxy)methyl]benzotriazole 2.65. The chlorinated precursor 2.66a
gave yields of 32% and 51% at reaction temperatures of 130° and 150°C respectively, as
determined by HPLC. At 150°C, a yield of 24% and a product purity of 93% were obtained
after purification. The tosylated precursor 2.65 gave an average HPLC yield of 78% at a
reaction temperature of either 130° or 150°C. In this case the temperature difference of 20°C
did not appear to result in a significantly different yield. Yields obtained after purification
varied between 48% and 70%, and purified fractions with an average radiochemical purity of
97% did not contain any detectable precursor. These figures confirmed the higher reactivity of
tosylates in comparison to halogenated precursors, because the tosylate is known to be a much
better leaving group. The radioiodinated products obtained from the two different precursors
had corresponding retention times and these retention times also corresponded to that of the
cold iodinated compound. The radioiodinations of both precursors were always accompanied
by the formation of some radiochemical by-products that were less polar than the main product.
The bulk of these impurities could be removed by means of column chromatography over silica
gel.
3.4.2 Radiosynthesis of 1-[(1-[123I]iodoprop-2-yloxy)methyl]benzotriazole 2.70
Four preparations were done with precursor 1-[(1-p-toluenesulphonyloxyprop-2-
yloxy)methyl]benzotriazole 2.69. The retention time of the main product corresponded to that
of the cold iodinated compound, thereby proving its authenticity. The yields and purities of the
product varied considerably throughout all the experiments. The HPLC radiochromatogram of
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a typical reaction mixture indicated the presence of a major impurity that appeared as a
shoulder with a slightly longer retention time than the major product. Some other less polar
mino~ impurities were also formed. On average e23I]2.70 represented 54% of all the
radioactive species appearing in the chromatograms, including the unreacted radioiodide. The
radiochemical purity appeared to deteriorate with the ageing of the precursor, despite its
storage at -lOaC. In one preparation, carried out approximately six months after the others,
using the same precursor and identical reaction conditions, the ratio of the product versus the
major impurity had changed from 84: 16 to 69:31. Another more polar impurity, previously
present only as a trace, now constituted 10% of the product. HPLC- [Method 2(a)] and TLC-
analysis (Method 7) of the precursor 2.69 did not indicate any detectable decomposition of the
precursor over time. Possible reasons for the increased formation of by-products were not
investigated. As before, the majority of the impurities could be removed by column
chromatography over silica gel. However, the major impurity could only be partially removed.
Recovered yields of the purest fractions, having radiochemical purities between 90% and 95%,
were in the order of23%. These fractions also did not show detectable traces of the precursor.
3.4.3 Radiosynthesis of 1-(2-[123I]iodoprop-l- yl)benzotriazole 2.74
The precursor 1-(2-p-toluenesulphonyloxyprop-l-yl)benzotriazole 2.73 was used as starting
material for the radiosynthesis of e23I]2.74. The radiochemical yield of this compound was
temperature dependent. At a reaction temperature that varied between 1300 and 135°C, the
recovered yield of the combined purified fractions was only in the order of 13-16%. At a
temperature of 150°C, the purest fraction was isolated in yields varying between 31% and 42%,
and its radiochemical purity varied between 95% and 98%. It showed no detectable trace of the
precursor. The retention time of the main product peak corresponded to that of the UV-signal
of the cold iodinated compound.
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3.4.4 Radiosynthesis of 1-(3-e231]iodo-2-methylprop-l-yl)benzotriazole 2.78
The precursor 1-(2-methyl-3-p-toluenesulphonyloxyprop-l-yl)benzotriazoIe 2.77 was used as
starting material for the radiosynthesis of [1231]2.78.The reactions were carried out at either
130°C or 150°C. The yield at BO°C, as determined by HPLC, was in the order of 60% after 10
minutes. At 150°C, a highest yield of about 85% was obtained after 10 minutes. This once
again demonstrated the temperature dependency of the substitution of tosylate with iodide. The
retention time of the main product corresponded to that of the cold iodinated compound. As
before, the good separation of the iodinated compound from its tosylated precursor resulted in a
purified product free from any trace of the precursor. The recovered radiochemical yield
obtained after the first reaction at BO°C was 38%, and the radiochemical purity of this fraction
was approximately 98%. The second reaction at 150°C gave the product in a yield of 49% to
65%, and a purity of 97-99%.
3.4.5 Radiosynthesis of 1-[(1-[1231]iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.87
The tosylate 2-methyl-4-nitro-l-[( I-p-toluenesulphonyloxyprop-2-yloxy)methyl]imidazole
2.83 and the triflate 2-methyl-4-nitro-l-[( I-trifluoromethanesulphonyloxyprop-2-
yloxy)methyl]imidazole 2.85 were both used as precursor for the radiosynthesis of [1231]2.87.
The tosylate was only used in two preparations. For comparison, one of these experiments was
conducted under the same conditions as were used in the experiment with the triflate as
precursor. The results of this comparison will be discussed in paragraph 3.4.5.3.
3.4.5.1 Synthesis from tosylate 2.83
The reaction with the tosylate 2.83 was carried out at 130°C and yielded a fairly pure product,
practically free from other radiochemical impurities. This could be attributed to the fact that
2.83 was obtained in a high purity because one of the intermediates in its preparation, the
condensation product 1-[(I-benzoyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.80,
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was crystallisable. The yield, as determined by HPLC, was 58% and the balance was made up
mainly by unreacted radioiodide. The retention time of the product peak corresponded to that
of the UV-signal of the cold iodinated compound. The recovered radiochemical yield after
purification was 47%, and the radiochemical purity was 95%. Unreacted radioiodide was the
major impurity. The purified product contained a trace of the tosylate precursor because the
two species could not be completely separated over silica gel. Various mobile phase
combinations were tried, and the best separation was obtained with a mixture of ethyl acetate,
hexane and chloroform (70: 15:15). Even this system did not give complete separation of the
tosylate and the iodinated product.
3.4.5.2 Synthesis from triflate 2.85
The radioiodination reactions were initially carried out using the triflate 2.85 that had been
purified by column chromatography over silica gel. The reaction was started at room
temperature, and the reaction temperature was later increased to 65°C. After 75 minutes at
room temperature, the yield, as determined by HPLC, was 42%. The reaction was not
accelerated by increasing the temperature. When the radioiodinations were carried out using
triflate 2.85 that had been purified by extraction with dichloromethane from an aqueous
medium, a yield of 91%, as determined by HPLC, was obtained after 45 minutes at room
temperature. A possible reason for this is that the silica gel-purified triflate probably still
contained trifluoromethanesulphonic acid (a by-product from the preparation of the triflate).
The acid could have inhibited the radioiodinations, while the extracted triflate was acid-free.
All further radioiodinations were carried out with the extracted triflate. "Cold" iodination of the
non-extracted triflate appeared to be more successful than radioiodination, as HPLC analysis of
the reaction mixture indicated complete conversion of the triflate to the iodinated compound.
The radioiodination reactions using the triflate 2.85 were generally carried out at room
temperature, using 1 - 5 mg triflate in 0.2 ml acetone. The reaction product was fairly pure, and
its HPLC retention time was similar to that obtained from the tosylate. Despite the high HPLC
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yields obtained, the recovered radiochemical yields, after purification, were somewhat
inconsistent. This was because of the high amount of residual activity that often remained in
the reaction vials after the transfer of the reaction mixtures to the silica gel column.
Radiochemical yields obtained under various reaction conditions are listed in Table 3.2.
TABLE 3.2 Radiochemical yields of 1-[(1-[123I]iodoprop-2-yloxy)methyl]-2-methyl-4-nitro-
imidazole 2.87 using 2-methyl-4-nitro-l-[ (l-trifluoromethanesulphonyloxyprop-
2-yloxy)methyl]imidazole 2.85 as precursor
Mass Age triflate Reaction Reaction Radiochemical yield Recovered
triflate temperature time (HPLC) radiochemical yield
(mg) (days) eC) (min.) (%) (%)
1.5 1 room 75 69 69
1.5 8 50°C 15 93 77
3.0 2 room 10 94 67
5.0 8 room 10 83 40
1.0 15 room 25 95 50
2.0 22 room 20 86 80
It appears that short-term ageing of the triflate 2.85, as well as its concentration in the reaction
mixture, did not significantly influence the radiochemical yields. HPLC yields were fairly
consistent, but recovered yields varied to some extent. The radiochemical purity of the fmal
product was always higher than 98%, but, as with the tosylates, the product contained a trace of
the triflate. The main feature of these results is that the triflate is a better precursor than the
tosylate for the radio synthesis of compounds of the type of [1231]2.87. Milder reaction
conditions can be used, and radiochemical yields are generally significantly higher. The only
disadvantage of the triflate route is the limited shelf life of the solid triflate which has to be
stored as a solution in an organic solvent such as dichloromethane. The tosylates, on the other
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hand, are very stable in solid form over several months when stored at -10°C. It was for this
reason that, in this study, tosylates were mostly preferred as precursors for radioiodinations.
3.4.5.3 Comparison of radioiodinations with 2-methyl-4-nitro-1-[(1-p-toluenesulphonyloxy-
prop- 2-yloxy)methyl]imidazole 2.83 and 2-methyl-4-nitro-l-[ (1-trifluoromethane-
sulphonyloxyprop-2-yloxy)methyl]imidazole 2.85
To illustrate the much higher reactivity of triflates, the tosylated precursor 2.83 and its triflate
analogue 2.85 were radio iodinated under identical reaction conditions. The precursor
concentration in acetone was 1.5 mg / 0.2 ml. Both reactions were initially carried out at 50°C.
The temperature of the tosylate reaction mixture was increased during the course of the
radioiodination. The radiochemical yields as determined by HPLC are shown in Table 3.3.
TABLE 3.3 Comparison of the radiochemical yield of 1-[(1-[123I]iodoprop-2-yloxy)methyl]-2-
methyl-4-nitroimidazole 2.87 from tosylate 2.83 and triflate 2.85 as precursors, as
determined by HPLC
Reaction temperature Reaction time Radiochemical yield of [1231]2.87 (%)
COC) (min.) From tosylate 2.83 From triflate 2.85
50 15 0.5 93
50 30 0.5 93
100 15 2.3 -
100 30 3.3 -
140 15 35 -
140 35 40 -
160 10 41 -
It is evident that the rate of radioiodination is strongly dependent on the temperature when the
tosylate is used as the precursor. In contrast, the radioiodination using the triflate proceeds at a
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high rate at a relatively low temperature. For commercial purposes, where high yields and short
reaction times are required, the triflate would be the preferred precursor.
3.4.6 Radiosynthesis of 1-[(2-C231]iodoprop-l-yloxy)methyl]-2-methyl-4-nitroimidazole 2.92
According to Fleet (1989), nucleophilic substitution at a secondary carbon in carbohydrates
requires the use of a triflate, rather than a mesylate or a tosylate as leaving group since the
oxygen atom in the carbohydrate ring, situated in a P-position with respect to the leaving
group, dramatically slows down SN reactions. The radio synthesis of [1231]2.92 also requires a
nucleophilic substitution of a leaving group at a secondary carbon, which is in a {3-position
relative to an oxygen atom. It was therefore decided to prepare this compound by using only
the triflate precursor 2-methyl-4-nitro-l-[(2-trifluoromethanesulphonyloxyprop-l-
yloxy)methyl]imidazole 2.90. All the labelling reactions were carried out at room temperature,
with the precursor concentration varying between 1 and 9 mg / 0.2 ml acetone. Radiochemical
yields (Rf.Ys) and purities are listed in Table 3.4.
TABLE 3.4 Radiochemical yields and purities of 1-[(2-[123I]iodoprop-l-yloxy)methyl]-2-
methyl-4-nitroimidazole 2.92 from the triflate precursor 2.90 as starting
material
Mass triflate Age triflate Reaction HPLC yield Recovered RCY Radiochemical purity of
time the final product
(mg) (days) (min) (%) (%) (%)
3.0 1 50 46 30 91
9.0 1 45 45 29 91
5.0 8 53 43 20 84
1.0 15 40 42 20 84
1.0 22 20 26 10 77
The results in Table 3.4 reflect the much lower radiochemical yield of [1231]2.92obtained from
the triflate precursor 2.90, in comparison to the yield of [1231]2.87 obtained from the triflate
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precursor 2.85 shown in Table 3.2. This was mainly because of the formation of an unknown
volatile radiochemical impurity during the labelling reaction between 2.90 and radioiodide. The
removal of this impurity, by concentrating the reaction mixtures to dryness before the product
was purified by column chromatography over silica gel, resulted in activity losses ranging from
14% to 41%. By omitting the concentration step, it was possible to isolate the impurity in a
radiochemical yield of 37 to 52%. Radio-HPLC analysis of such an isolated fraction showed
the presence of three components [(Method 2 (b)]. The first component had the same retention
time as the radioiodide, but it is unlikely that it could have been the iodide because iodide is not
volatile. It is possible that it could have been molecular iodine, which is volatile. This,
however, would imply that the original radioiodide had been partially oxidised during the
labelling reaction, to give volatile radioiodine that did not take part in a nucleophilic
substitution reaction. On the other hand, the complete absence of oxidising agents in the
reaction mixture, as well as the apparent absence of conditions that could promote any form of
oxidation, makes this assumption questionable. The second component appeared approximately
halfway between the first component and the product [1231]2.92in the chromatogram. The third
component was a trace of the target compound C231]2.92. The relative proportions of the three
components were approximately 51:40:7, respectively. Evaporation to dryness of this fraction
resulted in an approximate 85% loss of its radioactivity. Radio-HPLC analysis of the dried
residue indicated the partial disappearance of the first two components, with a concurrent
enrichment in [1231]2.92.This confirmed that the product was not volatile. No further attempt
was made to identify the first and the second component of the isolated fraction.
The radiochemical yields of 1-[(2-[1231]iodoprop-l-yloxy)methyl]-2-methyl-4-nitroimidazole
2.92 did not appear to be related to the concentration of the precursor. However, despite the
shorter reaction time employed in the reaction listed as the last entry in Table 3.4, there seemed
to be a general trend of decreasing yield, as well as decreasing radiochemical purity of
[1231]2.92,with ageing of the triflate precursor 2.90. This is in agreement with the observed
decomposition of the precursor 2.90 over time (see paragraph 2.3.3.6), and is in contrast to the
consistent yields of [1231]2.87obtained despite ageing of the triflate 2.85, as shown in Table
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3.2. These results illustrate the disadvantage of using a triflate as precursor in which the triflate
group is bound to a secondary carbon atom.
The average isomeric purity of the purified product [1231]2.92 was not as high as that of its
structural isomer [1231]2.87. This was mainly because of the presence of a trace of C231]2.87
that was always present in [1231]2.92.A possible reason is that the triflate 2.90, the precursor for
C231]2.92, contained a trace of its isomer, the triflate 2.85, the precursor for C231]2.87. The
authenticity of these two radioiodinated isomers was confirmed by the corresponding retention
times of their respective cold iodinated analogues in an HPLC chromatogram.
3.4.7 Radiosynthesis of 1-[(1-benzoyloxy-3-C231]iodoprop-2-yloxy)methyl]-2-methyl-4-
nitro imidazole 2.99 and its conversion to 1-[(I-hydroxy-3-[1231]iodoprop-2-
yloxy)methyl]-2-methyl-4-nitroimidazole 2.100
3.4.7.1 Attempted radiosynthesis of C231]2.99 from the triflate 1-[(I-benzoyloxy-3-
trifluoromethanesulphonyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.95
as precursor
Because of the unsuccessful isolation of the pure triflate 2.95 in the synthesis of this precursor
(see Section 2.3.3.7), attempts were made to carry out the radioiodinations using the crude
reaction mixtures after their dissolution in acetone. Radiochemical yields as determined by
HPLC, however, were very low (less than 10%). This is reminiscent of the modest yields of 1-
[(I-[1231]iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.87 obtained from the
insufficiently purified 2-methyl-4-nitro-l- [(1-trifluoromethanesulphonyloxyprop- 2-
yloxy)methyl]imidazole 2.85 (see paragraph 3.4.5.2). Attempts to synthesise C231]2.99 from
the triflate precursor were therefore abandoned.
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3.4.7.2 Radiosynthesis of [1231]2.99 from the tosylate 1-[(I-benzoyloxy-3-p-
toluenesulphonyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.97 as
precursor
The radio synthesis of C231]2.99 from the tosylate precursor 2.97 proved to be fairly successful.
Reaction conditions were similar to those used for all the other radioiodide-for-tosylate
exchange reactions. A reaction temperature of 150°C and a reaction time of 30 minutes resulted
in a high HPLC yield (94%). The retention time of the product corresponded to that of the cold
iodinated compound 1-[(I-benzoyloxy-3-iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole
2.99. Alkaline hydrolysis of C231]2.99 gave a compound having a retention time corresponding
to that of the cold iodinated compound 1-[(I-hydroxy-3-iodoprop-2-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.100. The hydrolysis was effectively carried out with sodium hydroxide in
aqueous ethanol at room temperature for 30 minutes. In most cases radio-HPLC analysis of the
hydrolysis mixture indicated almost complete conversion of C231]2.99 to [1231]2.100 after 10
minutes. This step also led to some de-iodination, as well as the formation of a slightly less
polar radiochemical impurity (3%). Wada et al. (2000) made use of a cation-exchange resin to
neutralise the hydrolysis mixture before evaporating it to dryness. In the present investigation,
this neutralisation step was initially omitted, resulting in substantial de-iodination of [1231]2.100
(increase of the free radioiodide content from 8% to 78%). This did not happen when the
hydrolysis mixture was pre-treated with a cation exchange resin. The neutralisation step was
followed by the usual purification over silica gel, using ethyl acetate as mobile phase.
Recovered yields ranged from 48% to 62% of the initial activity input. The radiochemical
purity of the purified product was approximately 96%, with the previously mentioned less
polar compound as the major radiochemical impurity.
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CHAPTER4
EVALUATION OF THE RADIOCHEMICAL STABILITY OF THE LABELLED
COMPOUNDS
As mentioned in the statement of objectives, only in vitro stability tests were carried out on the
various labelled compounds with the aim to observe stability trends. The release of free
radioiodide from the labelled compound over time was the criterion by which its stability was
assessed. It was not planned to monitor the stability over short, regular time intervals, but
rather to determine it over a short-term (3 to 5 hours) and a long-term (21 to 24 hours) period.
Human blood serum was used as the test medium. The serum had been separated from the
blood cells by means of centrifugation of a freshly drawn blood sample in a tube containing an
anti-coagulating agent, and stored in sterile vials at 4°C. The labelled compound, after its
chromatographic purification over silica gel, was evaporated to dryness with a stream of
nitrogen, and the dried residue dissolved in a small amount of the serum by means of a strong
vortex action. Additional fresh serum was added and a small aliquot of the solution was taken
to represent the sample at time zero. The rest of the serum solution was then incubated in an
incubator oven or water bath set at 37°C. Aliquots were taken at the indicated time intervals.
4.1 EVALUATION OF THE RADIOCHEMICAL STABILITY OF THE
RADIOIODINATED COMPOUNDS PREPARED IN THE PILOT STUDY
The stability results of the radioiodinated analogues of the iodinated compounds 2.4, 2.7, 2.12,
2.15, 2.19, 2.22, 2.26 and 2.30 are presented in Figure 4.1. To verify the accuracy of some of
the data, TLC and HPLC were both utilised in a few experiments to determine the amount of
released radioiodide. No other breakdown products were observed. The results in Fig. 4.1
represent the average of the data, obtained from both TLC and HPLC, from two or more
experiments. No significant differences were observed between the data obtained from these
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two methods. Except for compounds 2.26 and 2.30, which were regarded as approximately
crude references, the combined data obtained by the two methods supplied sufficiently
reproducible data per compound. The results obtained at three hours reflect the short-term
radiochemical stability, while those obtained at 21 hours reflect the long-term stability of the
radioiodinated compounds .
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Figure 4.1. Release of radioiodide from the 131I-labelled {J-iodoalkylether derivatives l-iodo-2-
phenoxyethane 2.4, I-benzyloxy-2-iodoethane 2.7, l-iodo-Z-phenoxypropane 2.12, 2-
iodo-l-phenoxypropane 2.15, l-iodo-2-phenoxy-butane 2.19, l-iodo-2-methoxy-2-
phenylethane 2.22, l-iodo-3-phenoxypropane 2.26 and l-iodo-2-phenylethane 2.30
versus incubation time in human blood serum at 37 oe.
The significantly higher degree of de-iodination exhibited by the compounds lacking a ~-
oxygen atom, l-iodo-3-phenoxypropane 2.26 and l-iodo-2-phenylethane 2.30, in comparison
with the ~-iodoethers l-iodo-2-phenoxyethane 2.4, I-benzyloxy-2-iodoethane 2.7, l-iodo-2-
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phenoxypropane 2.12, 2-iodo-l-phenoxy-propane 2.15, l-iodo-2-phenoxy-butane 2.19 and 1-
iodo-2-methoxy-2-phenylethane 2.22, confirms the stabilising effect of a ~-oxygen atom in an
iodoalkoxy unit. It is clear that compounds 2.4, 2.7, 2.12, 2.15, 2.19 and 2.22 are all reasonably
stable during the first three hours of incubation, while those containing a branched structure in
the aliphatic chain (2.12, 2.15, 2.19 and 2.22) show even slightly superior stability. After 21
hours the straight chain compounds 2.4 and 2.7 show higher degrees of de-iodination than
compounds 2.12, 2.15, 2.19 and 2.22. This increased stability of compounds 2.12, 2.15, 2.19
and 2.22 is most probably caused by the steric effect of the branched structure of the aliphatic
chain. The position of the branched structure (alpha or beta with respect to the ether oxygen as
displayed in compounds 2.12 and 2.15, respectively) does not appear to exert a significant
influence on the stabilising effect. The influence of the size of the group is somewhat
ambiguous. l-Iodo-2-phenoxy-butane 2.19, having an a-ethyl group, displays a slightly higher
degree of de-iodination after 21 hours than l-iodo-2-phenoxypropane 2.12, having an a-methyl
group, suggesting that the more space-filling group causes more instability. On the basis of this
argument, it would be expected that l-iodo-2-methoxy-2-phenylethane 2.22, having a bigger a-
phenyl group, would be less stable than 2.12, which contains a smaller a-methyl group.
However, 2.22 displays a similar degree of stability to that of 2.12. A possible explanation for
this ambiguity is given in the following paragraph.
Another feature of the stability results is the significantly higher degree of de-iodination after
21 hours displayed by the benzylic ether I-benzyloxy-2-iodoethane 2.7 as opposed to that of
the phenolic ether l-iodo-2-phenoxyethane 2.4. This can possibly be explained in terms of the
mechanism by which dehalogenation of haloalkanes occur. According to Anders and Pohl
(1985), the in vivo metabolism of these compounds generally involves a preferred
hydroxylation at the halogen-bearing carbon atom, followed by an elimination of the halide
ion. Electron-donating groups in such a molecule would stabilise a carbenium ion intermediate
in the metabolic hydroxylation process by means of a resonance effect, while electron removal
by an inductive mechanism destabilises such intermediates (French et al., 1991). The ~-
heteroatom is too distant to have a positive resonance effect, but can provide a deactivating
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inductive effect, thereby resulting in diminished de-halogenation (French et al., 1991). When
an electron-withdrawing group such as a phenyl group is present in the vicinity of the halogen-
bearing carbon, it can assist the ~-heteroatom in exerting a -I effect, resulting in increased
stability of the carbon-halogen bond. This effect should be diminished with an increase in the
distance between the phenyl group and the halogen-bearing carbon. Assuming that the in vivo
dehalogenation process as proposed by Anders and Pohl is also, to some extent, applicable to
ex vivo processes, the following arguments can be presented. In the benzylic ether 2.7 the
phenyl group is one atom further removed from the halogen-bearing carbon, as opposed to the
one in the phenolic ether 2.4. The carbenium intermediate in 2.7 will therefore experience a
diminished net inductive effect and therefore less destabilisation compared to 2.4.
Consequently, compound 2.7 will be more prone to dehalogenation in comparison to 2.4. These
arguments might also explain the higher than expected degree of stability shown by l-iodo-2-
methoxy-2-phenylethane 2.22, in which the phenyl group is attached to the carbon adjacent to
the halogen-bearing carbon, resulting in a higher net inductive effect, more destabilisation of
the carbenium ion intermediate, and therefore less de-iodination. It is assumed that this effect
outweighs the negative influence of the space-filling property of the phenyl group on the
radiochemical stability of 2.22.
4.2 EVALUATION OF THE RADIOCHEMICAL STABILITY OF THE
RADIOIODINATED BENZAMIDE DERIVATIVES
The results of the evaluation of the stability of the radio iodinated analogues of compounds
2.42, 2.44, 2.46 and 2.48 are presented in Figure 4.2. The release of free radioiodide was
determined by means of HPLC analysis only. No other breakdown products were observed. All
the data supplied represent the averages from the results of two to four experiments per
compound.
The stability trends of the compounds displayed in Figure 4.2 are in agreement with those
given in Figure 4.1. The straight-chain ,B-iodoethoxymoiety in 2-(2-iodoethoxy)-3-methoxy-N-
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(2-piperidin-l-ylethyl)benzamide 2.42 de-iodinates at a faster rate than the branched chain
moieties in 2-( l-iodoprop-2-yloxy)-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.44 and 2-
(2-iodoprop-l-yloxy)-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.46, confirming the
stabilising effect of a branched structure in such a unit. Apparently there is no significant
difference between the stabilities of the isomers 2.44 and 2.46, in agreement with the stability
trends displayed by l-iodo-2-phenoxypropane 2.12 and 2-iodo-l-phenoxypropane 2.15 in
Figure 4.1. Another significant feature is that, over the long term (21 to 24 hours), the extent of
de-iodination (-50%) of the straight-chain moiety in the benzamide 2.42 (Figure 4.2) is
significantly higher than that of the same moiety in the model compound l-iodo-2-
phenoxyethane 2.4 (Figure 4.1) (-14%). The reason for this phenomenon is not clear, but the
higher instability of 2.42 could perhaps be related to the presence of the nearby amide and/or
methoxy groups on the aromatic ring. If this assumption is correct, it illustrates the influence of
the chemical environment on the stability of these moieties. The superior long-term stability
displayed by the iodovinyl moiety in 2-(3-iodoprop-2-en-l-yloxy)-3-methoxy-N-(2-piperidin-
l-ylethyl)benzamide 2.48 is to be expected. However, the medium-term stability of 2.44 and
2.46 compares well with that of 2.48.
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Figure 4.2. Release of radioiodide from the 1231-labelled benzamide derivatives 2-(2-iodoethoxy)-3-
methoxy-N-(2-piperidin-I-ylethyl)benzamide 2.42, 2-(I-iodoprop-2-yloxy)-3-methoxy-N-
(2-piperidin-l-ylethyl)benzamide 2.44, 2-(2-iodoprop-l-yloxy)-3-methoxy-N-(2-piperidin-
l-ylethyl)benzamide 2.46 and 2-(3-iodoprop-2-en-l-yloxy)-3-methoxy-N-(2-piperidin-l-
ylethyl)benzamide 2.48 versus incubation time in human blood serum at 370C.
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4.3 EVALUATION OF THE RADIOCHEMICAL STABILITY OF
THE RADIOIODINATED HETEROCYCLIC AMINE DERIVATIVES
The stability evaluation results of the radioiodinated analogues of compounds 2.66b, 2.70,
2.74, 2.78, the reference compound 1-(3-iodo-2-propen-l-yl)benzotriazole, 2.87, 2.92 and
2.100 are presented in Figures 4.3 to 4.5. The release of free radioiodide was determined only
by means of HPLC analysis. No other breakdown products were observed. All data were
obtained as averages from the results of two to five experiments per compound. The data for
the 1231-labelled 1-(3-iodo-2-propen-l-yl)benzotriazole, displayed in Figure 4.3, were obtained
from another source (Visser, 2002).
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Figure 4.3 Release of radioiodide from the 123I-Iabelled benzotriazole derivatives 1-[(2-
iodoethoxy)methyl]benzotriazole 2.66b, 1-[(I-iodoprop-2-yloxy)methyl]benzotriazole
2.70, 1-(2-iodoprop-l-yl)benzotriazole 2.74, 1-(3-iodo-2-methylprop-l-yl)benzotriazole
2.78 and 1-(3-iodo-2-propen-l-yl)benzotriazole versus incubation time in human blood
serum at 37°C.
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The radiochemical stability trends of the ~-iodoalkylether compounds displayed in Figure 4.3
are, once again, in agreement with those in Figures 4.1 and 4.2. The straight-chain (3-
iodoethoxy moiety in [1231]2.66bde-iodinates at a faster rate than the branched chain moiety in
[1231]2.70,especially over the long term. A comparison of the rates of de-iodination between
the straight chain moieties [1231]2.66b (Fig. 4.3) and 2-(2-iodoethoxy)-3-methoxy-N-(2-
piperidin-l-ylethyl)benzamide 2.42 (Fig. 4.2) shows a lesser degree of de-iodination of the
former than the latter. This difference in long-term stability is not as significant as that between
2.42 and l-iodo-2-phenoxyethane 2.4 (Fig. 4.1), but could probably also be ascribed to the
influence of the chemical environment. The significantly higher de-iodination rates exhibited
by the (3-oxygen-Iackingmoieties in [1231]2.74and [1231]2.78,in comparison with that shown by
[1231]2.70,are also in agreement with the stability trend shown by 1-[1311]iodo-2-phenylethane
2.30 (Fig. 4.1). Apparently the branched structure on its own does not contribute significantly
to the increased stability shown by a moiety of the type shown in 2.70, but rather the
combination of the branched structure and a (3-oxygen. Compound 2.74, in which the iodine
atom is attached to a secondary carbon atom, also appears to de-iodinate at a slightly slower
rate than 2.78, in which the iodine atom is attached to a primary carbon atom. This difference,
however, is not really significant, implying that the position of the iodine atom with respect to
the branched methyl group does not have a significant influence on stability. This is also in
agreement with the small differences in stability observed between the (3-oxygen-containing 2-
(l-iodoprop-2-yloxy)-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.44 and 2-(2-iodoprop-
l-yloxy)-3-methoxy-N-(2-piperidin-l-yleth:yl)benzamide 2.46, as well as between l-iodo-2-
phenoxypropane 2.12 and 2-iodo-l-phenoxy-propane 2.15. The apparent higher degree of de-
iodination shown by the imidazole derivative 1-[(2-[1231]iodoprop-l-yloxy)methyl]-2-methyl-4-
nitro imidazole 2.92 in comparison to that of 1-[(1-C231]iodoprop-2-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.87 in Figure 4.4 can be ascribed to the higher amount of free radioiodide
present in 2.92 at time zero. The graphs in Figure 4.5 show that the rates of de-iodination of
these two compounds are quite similar.
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Figure 4.4 Release of radio iodide from the 1231-labelled2-methyl-4-nitroimidazole derivatives l-[(l-iodoprop-
2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.87, 1-[(2-iodoprop-1-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.92 and 1-[(1-hydroxy-3-[1231]iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole
2.100 versus incubation time in human blood serum at 37°C.
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Figure 4.5 Comparative release of radioiodide from the 1231-labelled2-methyl-4-nitroimidazole derivatives 1-
[(l-iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.87 and 1-[(2-iodoprop-l-
yloxy)methyl]-2-methyl-4-nitroimidazole 2.92 versus incubation time in human blood serum at 370c.
The bar graphs III Figure 4.3 show that the stability of 1-[(1-iodoprop-2-
yloxy)methyl]benzotriazole 2.70 compares favourably with that of 1-(3-iodo-2-propen-l-
yl)benzotriazole, even over the long term. This is in contrast to the poorer long-term stability
shown by the identical ,6-iodoethoxy moiety in the benzamide 2.44, in comparison with that of
101
Stellenbosch University http://scholar.sun.ac.za
the iodovinyl moiety in the benzamide 2-(3-iodoprop-2-en-l-yloxy)-3-methoxy-N-(2-piperidin-
l-ylethyl)benzamide 2.48 (see Fig. 4.2). This difference in stability could probably again be
ascribed to the influence of the chemical environment.
Finally, the de-iodination rates of the nitroimidazole derivatives 1-[(I-iodoprop-2-
yloxy)methyl]-2-methyl-4-nitroimidazole 2.87 and 1-[(l-hydroxy- 3-iodoprop- 2-yloxy)methyl]-
2-methyl-4-nitroimidazole 2.100 shown in Figure 4.4 are quite similar, suggesting that
substituting a methyl group with a hydroxymethyl group as the side chain in a ,B-iodoethoxy
moiety does not have a significant influence on the stability of such a moiety. It further
suggests that a radioiodinated analogue of the radiofluorinated 1-[(I-fluoro-3-hydroxyprop-2-
yloxy)methyl]-2-nitroimidazole 1.32 could also be developed as a radiopharmaceutical.
Furthermore, the radioiodinated analogues of the nitroimidazoles 2.87 and 2.100 could be
considered as possible infection- or inflammation-seeking agents, as their chemical structures
bear resemblance to that of the established infection- or inflammation- seeking agent
omidazole 1.13 (see paragraph 1.2.2). They could also be utilised for imaging hypoxic tissues
(Wada et al., 2000).
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CHAPTERS
SUMMARY AND FINAL CONCLUSIONS
The radiochemical stability of radiopharmaceuticals is a very important consideration in the
radiopharmaceutical field. The retention of the incorporated radionuclide by its organic carrier
is vital with regard to the correct diagnosis of diseases, as well as the elimination of
unnecessary irradiation of healthy organs. This is especially applicable to radioiodinated
radiopharmaceuticals, as the carbon-iodine bond is the weakest in the carbon-halogen series.
Traditionally, radioiodine is incorporated into organic structures such as phenyl rings and vinyl
prosthetic units that give a certain degree of stability to the bond. However, for reasons already
mentioned, the need also exists for alternative structural units for the incorporation of
radioiodine. The main objective of this study was to investigate the trends in radiochemical
stability of various radioiodinated organic compounds, with particular emphasis on those
compounds containing so-called iodinated prosthetic groups. The ~-iodoethoxyl moiety was
selected as the prosthetic group for investigation because it is a relatively novel prosthetic
group in radiopharmaceutical chemistry.
The study was started by conducting a systematic investigation into the in vitro radiochemical
stability of model compounds containing radioiodinated ~-iodoethoxyl units and derivatives
thereof, as well as the stability of reference compounds lacking a ~-oxygen atom. Tosylated
precursors suitable for labelling were synthesised, and their radioiodinated analogues were
obtained in modest to fair radiochemical yields. Throughout this study, no deliberate attempts
were made to optimise either chemical or radiochemical yields, as this was considered to be
beyond the scope of this work. Stability evaluation was carried out ex vivo, under semi-
physiological conditions. The results confirmed that aliphatic radioiodinated units are much
less prone to de-iodination when they contain an oxygen atom in a ~-position relative to the
iodine atom. This investigation also showed for the first time that the introduction of a side
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chain, in the form of a small unit such as a methyl group, into such a moiety further improves
its stability, especially the long-term stability.
The study was extended to the investigation of the stability behaviour of a few selected
prosthetic units incorporated into carrier molecules, such as phenolic benzamides and
heterocyclic amines. Some of these carrier molecules were structurally similar to established
radiopharmaceutical compounds. The synthesis of the tosylated precursors of the
radioiodinated benzamides and heterocyclic amines were slightly more complex than the
synthesis of the model compounds. The radiochemical evaluation of these radioiodinated
compounds showed similar de-iodination trends to those shown by the radioiodinated model
compounds. Furthermore, there were indications that the chemical environment of the ~-
iodoethoxyl units might influence their stability. The radiochemical stability of the stabilised ~-
iodoethoxyl units, especially those present in the heterocyclic amines, compares favourably
with that of the "gold standard" iodovinyl units.
This work has shown that there is a promising future in utilising the ~-iodoethoxyl unit in
radiopharmaceutical chemistry, provided that the unit is stabilised as shown in this
investigation. The evaluation of the radiochemical stability of these units in vivo is considered
to be the following important step in the development of such compounds, because very little is
known about their stability against metabolic processes in the body. Other aspects such as more
practical radiolabelling methods should also be investigated.
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CHAPTER6
EXPERIMENTAL
6.1 GENERAL
Unless stated otherwise, all reagents and solvents were of analytical grade and were purchased
from Aldrich Chemicals. These solvents and chemicals were used without distillation or further
purification. Dichloromethane, acetonitrile and acetone were dried over 4Á molecular sieves.
[13II]iodine was obtained from Amersham Buchler (Germany). [123I]iodine was produced at
iThemba LABS, Faure, South Africa by the 127I(p,5n)l23Xe ~ l23Iroute and recovered as a no-
carrier-added product in 0.01 M NaOH solution. The solutions containing [123I]iodine were
concentrated approximately 3 to 4 fold in order to increase the radioactivity concentration,
which ranged between 240 mCi (8.88 GBq) and 400 mCi (14.8 GBq) per milliliter at the time
of labelling. For the pilot study work, HPLC, using isoeratic elution, was carried out using a
Knauer or Waters Model 510 pump. Reversed phase columns (Multo Sorb RP18, LichroCart
RP18 and Synergi Cl2) were used. For the work on the benzamides and heterocyclic amines,
gradient elution was carried out using a Perkin Elmer Series 200 LC Binary Pump equipped
with a Rheodyne Model 7125 injector, and a Phenomenex Luna 511 CI8 (250 x 4.6 mm)
reversed-phase column. All gradient elutions were linear. HPLC pumps were connected to a
UV detector (254nm) coupled in series with a radiation flow detector with a NaI(TI) crystal and
the necessary electronic devices (ORTEC). Data were recorded and processed on a Hewlett
Packard Series 3394 integrator. GC-MS analysis of bromopropanol preparations was done on a
Carlo Erba QMD-1000 instrument, using a GC column (40 m) of fused silica coated with PS-
089 (5% phenyl). The purity analysis of bromopropanol preparations was carried out on a
Hewlett Packard Series 6890 gas chromatograph. A DB 1701 capillary column (50 m x 0.32
mm) was used. The identities of the individual bromopropanol isomers were verified by
comparison of their respective retention times with those of a commercial isomer mixture with
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known composition. Analytical thin layer chromatography (TLC) was performed using silica
gel UV254 pre-coated aluminium-supported plates. Developed plates were inspected under a
Model UVGL-58 Mineralight'ÏLamp (UV-254/366 nm) at 254 nm. All silica gel column
chromatography purification procedures were done by means of descending chromatography
on packed columns (inside diameter = 10 mm). The silica gel (particle size 0.063 - 0.2 mm)
was purchased from Fluka. Collected fractions were developed on TLC alongside an aliquot of
the crude reaction mixture. The most intense spot in the TLC chromatogram of the reaction
mixture was regarded as the main product. Reaction mixtures and fractions obtained from
preparative column chromatography were concentrated or evaporated to dryness under reduced
pressure on a rotary evaporator (Buchi). Radioactivity measurements were done in a
radionuclide assay calibrator (Vinten). Autoradiography (inspection of radio-TLC plates) was
performed on an InstantImager System (Packard). Melting points were determined on an
Electrothermal digital melting point apparatus and are uncorrected. For the compounds
synthesized in the pilot study, proton nuclear magnetic resonance (lH NMR) spectra were
recorded on a Bruker 200 MHz instrument. No l3C NMR data were recorded for these
compounds. IH and l3C NMR spectra of the benzamides and heterocyclic amines were
recorded on either a 300MHz Varian VXR spectrometer equipped with a Varian magnet (7.0
T) or a 600MHz Varian Unity Inova spectrometer equipped with an Oxford magnet (14.09 T).
Standard pulse sequences were used to obtain IH and l3C NMR spectra. Unless stated
otherwise, all spectra were recorded using CDCl3 as solvent and tetramethylsilane (TMS) as
the internal reference. l3CNMR spectra were processed by using the chemical shift value of the
centre of the three peak multiplet of chloroform-d (77.0 ppm) as internal reference. Mass
spectra were recorded on an AMD 604 double focussing mass spectrometer. Mass spectra were
not recorded for compounds prepared in the pilot study. Stability experiments were carried out
in a water-jacketed incubator oven (Forma Scientific, Ohio, U.S.A.).
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6.2 CHROMATOGRAPHIC METHODS
6.2.1 HPLC: Binary gradient elution
In all of these methods, a Luna 5J.!Cl8 (250 x 4.6 mm) reversed phase column was used.
All gradient elutions were linear.
Method 1
A = 0.1% Aqueous triethylamine, B = Acetonitrile
STEP TIME FLOW RATE MOBILE PHASE COMPOSITION
1. 5 min. lml/min. 40%A 60%B
2. 10min. lml/min. 20%A 80%B
3. 5 min. lml/min. 0% A 100%B
4. 5 min. lml/min. 0% A 100%B
Method 2
(a) A = 0.1% Aqueous triethylamine, B = Acetonitrile
(b) A = 0.1% Aqueous trifluoroacetic acid, B = Acetonitrile
STEP TIME FLOW RATE MOBILE PHASE COMPOSITION
1. 3 min. lml/min. 70%A 30%B
2. 5 min. lml/min. 50%A 50%B
3. 5 min. lml/min. 40%A 60%B
4. 5 min. lml/min. O%A 100%B
5. 15min. lml/min. O%A 100%B
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STEP
1.
2.
STEP
1.
2.
3.
STEP
1.
2.
3.
Method 3
(a) A = 0.1% Aqueous trifluoroacetic acid, B = Acetonitrile
(b) A = O.OIM Phosphate buffer (pH 2), B = Acetonitrile
TIME
15 min.
5 min.
FLOW RATE
lmllmin.
lml/min.
Method 4
MOBILE PHASE COMPOSITION
70%A 30%B
O%A 100 %B
A = 0.1% Aqueous trifluoroacetic acid, B = Acetonitrile
TIME
15 min.
5 min.
5 min.
FLOW RATE
lmllmin.
lml/min.
Irnl/min.
Method 5
MOBILE PHASE COMPOSITION
60%A 40%B
O%A 100%B
O%A 100%B
A = 0.1% Aqueous trifluoroacetic acid, B = Acetonitrile
TIME
15 min.
5 min.
5 min.
FLOW RATE
lrnl/min.
lml/min.
lmllmin.
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50%A 50%B
O%A 100%B
O%A 100%B
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Method 6
A = 0.1% Aqueous trifluoroacetic acid, B = Acetonitrile
STEP TIME
1. 5 min.
2. 5 min.
3. 5 min.
4. 5 min.
FLOW RATE
lml/min.
lml/min.
lml/min.
lml/min.
MOBILE PHASE COMPOSITION
90%A 10%B
70%A 30%B
50%A 50 %B
O%A 100%B
Method 7
A = 0.1% Aqueous trifluoroacetic acid, B =Acetonitrile
STEP
1.
2.
3.
TIME
15 min.
3 min.
5 min.
FLOW RATE
lml/min.
lml/min.
lml/min.
MOBILE PHASE COMPOSITION
80%A 20%B
O%A 100%B
O%A 100 %B
6.2.2 HPLC: Isoeratic elution
Method 8
Stationary phase: Multosorb Cl8 (300 x 4.6 mm) reversed phase
Mobile phase: Acetonitrile/water = 55:45
Flow rate: 1ml/min
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Method 9
Stationary phase: C12 (150 x 4.6 mm) reversed phase
Mobile phase: Acetonitrile/water = 63:37
Flow rate: 1ml/min
6.2.3 TLC: Method number and mobile phase
Method 1:Hexane:chloroform = 70:30 (v/v)
Method 2: Hexane:acetone = 90:10 (v/v)
Method 3: Hexane:acetone = 80:20 (v/v)
Method 4: Diisopropylether:methanol:25% aqueous ammonia = 80:20: 1 (v/v/v)
Method 5: Diisopropylether:isopropanol:25% aqueous ammonia = 85: 15:0.5 (v/v/v)
Method 6: Petroleum ether:ethyl acetate = 1:1 (v/v)
Method 7: Petroleum ether:ethyl acetate = 2: 1 (v/v)
Method 8: Petroleum ether:ethyl acetate = 3: 1 (v/v)
Method 9: Ethyl acetate
Method 10: Ethyl acetate:petroleum ether = 3:1 (v/v)
Method Il: Ethyl acetate:methanol = 20: 1 (v/v)
Method 12: Hexane:ethanol = 65:35
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6.2.4 Gas Chromatography
Method 1
Starting temperature: 40°C
Hold time: Omin.
Oven Ramp: 4°C / min.
Final temperature: 250°C
Hold time: 15min.
Inlet temperature: 200°C
Carrier gas: Helium
Detector type: FID
Detector temperature: 275°C
Retention times: I-Bromo-2-propanol = 16.5 min.
2-Bromo-l-propanol = 17.8 min.
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6.3 COLD SYNTHESES
6.3.1 Synthesis of p-Iodoalkylether Derivatives and Reference Compounds
In this section the yields of the iodinated compounds obtained in the last step of the synthesis
were in most cases not recorded because of the small amounts of products that were recovered.
2-Phenoxyethyl p-toluenesulphonate (2.3)
A mixture of p-bromophenetole 2.1 (0.9 g, 4.5 mmol) and HMPT containing 15% water (25
ml) was heated in an oil bath at 130°C for 6 h, cooled to room temperature, diluted with water
(70 ml) and extracted with diethylether (3 x 40 ml). The combined ether extracts were washed
with water (2 x 25 ml), dried over anhydrous sodium sulphate, and the drying agent filtered off.
Concentration of the filtrate under reduced pressure at 35°C gave the crude product, 2-
phenoxyethanol 2.2 (0.44g), as an oil, which was not further purified. A portion of 2.2 (0.2 g)
was mixed with a solution of p-toluenesulphonyl chloride (tosyl chloride) (0.31 g, 1.6 mmol) in
dry pyridine (2 ml) and the mixture was refrigerated overnight at 4°C. The reaction mixture
was subsequently poured into water (20 ml) and extracted with CHCl3 (2 x 15 ml). The
combined chloroform extract was washed with 0.1N H2S04 (2 x 15 ml) and water (2 x 15 ml),
dried over anhydrous sodium sulphate, and the drying agent filtered off. Concentration of the
filtrate under reduced pressure at 95°-100°C gave 2-phenoxyethyl p-toluenesulphonate 2.3
(0.33 g, 55%). TLC (Method 1) showed a single spot. The product was therefore used without
further purification. 'u NMR (200 MHz) 8: 2.49 (s, 3H), 4.18 (t, 2H), 4.41 (t, 2H), 6.8-7.9 (m,
9H, aromatic protons).
l-Iodo-2-phenoxyethane (2.4)
Sodium iodide (41 mg, 0.27 mmol) was added to a solution of 2-phenoxyethyl p-
toluenesulphonate 2.3 (70 mg, 0.24 mmol) in acetone (1 ml) and the mixture was refluxed and
stirred on a hot plate for approximately 1 hour. The precipitate that had formed was filtered off
and the filtrate evaporated to dryness under reduced pressure to give l-iodo-2-phenoxyethane
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2.4 (55 mg, 92%). IH NMR (200 MHz) 8: 3.47 (t, J = 6.5 Hz, 2H), 4.3 (t, J = 6.9 Hz, 2H),
6.93-7.38 (m, 5H, aromatic protons).
2-Benzyloxyethyl p-toluenesulphonate (2.6)
This compound was prepared from commercially available 2-benzyloxyethanol 2.5 (0.3 g, 2.0
mmol) according to the procedure described for the preparation of 2-phenoxyethyl p-
toluenesulphonate 2.3. Column chromatography over silica gel, using chloroform as mobile
phase, gave pure 2-benzyloxyethyl p-toluenesulphonate 2.6 (0.27 g, 45%). IH NMR (200
MHz) 8: 2.47 (s, 3H), 3.72 (t, 2H), 4.23 (t, 2H), 4.52 (s, 2H), 7.3-7.9 (m, 9H, aromatic protons).
I-Benzyloxy-2-iodoethane (2.7)
This compound was prepared from 2-benzyloxyethyl p-toluenesulphonate 2.6 according to the
procedure described for the preparation of 1-iodo-2-phenoxyethane 2.4, except for heating the
reaction mixture in an oil bath at 120°C. The mixture was chromatographed over silica gel with
hexane/chloroform = 90110 to give 1-benzyloxy-2-iodoethane 2.7. IH NMR (200 MHz) 8: 3.33
(t, 2H), 3.76 (t, 2H), 4.63 (s, 2H), 7.3-7.4 (m, 5H, aromatic protons).
2-Phenoxy-l-propanol (2.10)
Potassium phenoxide 2.8 was prepared by heating a mixture of KOH (3 g, 53.5 mmol), phenol
(5 g, 53.1 mmol) and ethanol (55 ml) at 70°C until the solid material was completely dissolved,
followed by concentration to complete dryness under reduced pressure at 70°C. Potassium
phenoxide 2.8 (1 g, 7.6 mmol) was stirred with acetonitrile (30 ml) in the presence of a small
quantity of 18-Crown-6 (228 mg, 0.9 mmol) at 35°C. The resulting solution was stirred for 30
min. at room temperature. Ethyl 2-bromopropionate (2g, 11.1 mmol) was added to the solution
of the phenoxide and the reaction mixture was stirred at 30°-35°C for approximately 2.5 hours,
after which TLC (Method 2) indicated the complete consumption of the phenoxide. The
potassium bromide that had been formed in the reaction was filtered off, and the filtrate was
concentrated under reduced pressure at 60°C. Diethyl ether (40 ml) was added to the residue,
the resulting precipitate was filtered off and the filtrate was extracted with water (15ml). The
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supernatant ether layer, containing the organic product, was dried over anhydrous sodium
sulphate, the drying agent was filtered off, and the filtrate was concentrated under reduced
pressure at 100°C to complete dryness to give 1.5 g crude ethyl-2-phenoxypropionate 2.9. A
solution of 2.9 (1 g, 5.15 mmol) in diethylether (3 ml) was added dropwise to a stirred and
chilled (5°C) suspension of lithiumaluminiumhydride (LAR) (0.4 g, 10.53 mmol) in freshly
distilled tetrahydrofuran (THF) (10 ml). The reaction mixture was subsequently refluxed for 3h
after which TLC (Method 2) showed some unreacted starting material. The addition of more
LAH (0.4 g) and refluxing the reaction mixture for a further hour resulted in the complete
conversion of 2.9 to the product. The excess LAH was decomposed by slow addition of O.IN
NaOH (10 ml) to the cooled and stirred reaction mixture, after which dichloromethane (50 ml)
and water (70 ml) were added and the mixture vigorously stirred. The resulting emulsion was
filtered through celite. The organic layer was separated, dried over anhydrous sodium sulphate,
the drying agent was filtered off, and the filtrate was concentrated to dryness under reduced
pressure at 60°C to give 2-phenoxy-l-propanol 2.10 (0.54 g, 69%). IH NMR (200 MHz) 8:
1.31 (d, J = 6.2 Hz, 3H), 2.37 (s, lH), 3.75 (m, 2H), 4.54 (m, IH), 7.0 (m, 3H, aromatic
protons), 7.33 (m, 2H, aromatic protons).
2-Phenoxyprop-l-yl p-toluenesulphonate (2.11)
This compound was prepared from 2-phenoxy-I-propanol 2.10 (0.3 g, 2.0 mmol) according to
the procedure described for the preparation of 2-phenoxyethyl p-toluenesulphonate 2.3 to give
unpurified 2-phenoxyprop-l-ylp-toluenesulphonate 2.11 (0.58 g 96%). IH NMR (200 MHz) 8:
1.34 (d, J= 6.3 Hz, 3H), 2.48 (s, 3H), 4.16 (m, 2H), 4.59 (m, IH), 6.83-7.82 (m, 9H, aromatic
protons).
l-Iodo-2-phenoxypropane (2.12)
This compound was prepared from 2-phenoxyprop-l-yl p-toluenesulphonate 2.11 according to
the procedure described for the preparation of I-benzyloxy-2-iodoethane 2.7, except for using
dioxane/acetone (l: 1) as solvent, to give I-iodo-2-phenoxypropane 2.12. IH NMR (200 MHz)
8: 1.52 (d, J= 6.1 Hz, 3H), 3.38 (m, 2H), 4.44 (m, IH), 6.93-7.38 (m, 5H, aromatic protons).
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l-Phenoxyprop-I-yl p-toluenesulphonate (2.14)
This compound was prepared from commercially available 1-phenoxypropan-2-o1 2.13 (0.5 g,
3.3 mmol) according to the procedure described for the preparation of 2-phenoxyethyl p-
toluene sulphonate 2.3. The crude product was crystallised from methanol to give pure
crystalline 1-phenoxyprop-2-yl p-toluenesulphonate 2.14 (0.56 g, 56%), m.p. 100-101°C, IH
NMR (200 MHz) 0: 1.47 (d, J= 6.5 Hz, 3H), 2.48 (s, 3H), 4.0 (m, 2H), 4.92 (m, 1H), 6.71-7.87
(m, 9H, aromatic protons).
Z-Iodo-l=phenoxypropane (2.15)
This compound was prepared from 1-phenoxyprop-2-yl p-toluenesulphonate 2.14 according to
the procedure described for the preparation of 1-iodo-2-phenoxyethane 2.4. The reaction
mixture was heated and stirred on a hot plate for 4 hours, and the product was
chromatographed as described for the purification of l-benzyloxy-z-iodoethane 2.7 to give 2-
iodo-l-phenoxypropane 2.15. IH NMR (200 MHz) 0: 2.04 (d, J = 6.9 Hz, 3H), 4.09 (m, 1H),
4.35 (m, 2H), 6.93-7.38 (m, 5H, aromatic protons).
2-Phenoxy-l-butanol (2.17)
A solution of 2-phenoxybutyric acid (1 g, 5.6 mmol) in diethylether (3 ml) was added dropwise
to a stirred and cooled (ice bath) suspension of LAH (0.64 g, 16.9 mmol) in dry THF (16 ml).
The reaction mixture was subsequently refluxed for 1.5 hours after which TLC (Method 3)
showed complete consumption of the starting material. The reaction mixture was worked up as
described for the preparation of2-phenoxy-l-propanoI2.10. The organic extract was dried over
anhydrous sodium sulphate, the drying agent was filtered off, and the filtrate was concentrated
to dryness under reduced pressure at 45°C to give 2-phenoxy-l-butanoI2.17 (0.88 g, 96%). IH
NMR (200 MHz) 0: 1.0 (t, J= 7.5 Hz, 3H), 1.75 (m, 2H), 1.98 (m, 1H), 3.83 (m, 2H), 4.34 (m,
1H), 6.90-7.36 (m, 5H, aromatic protons).
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2-Phenoxybut-l-yl p-toluenesulphonate (2.18)
This compound was prepared from 2-phenoxy-1-butanol 2.17 (0.2 g, 1.2 mmol) according to
the procedure described for the preparation of 2-phenoxyethyl p-toluenesulphonate 2.3. The
crude product was purified by column chromatography over silica gel, using chloroform as
mobile phase, to give pure 2-phenoxybut-1-yl p-toluenesulphonate 2.18 (0.23 g, 59%). JH
NMR (200 MHz) 8: 0.98 (t, J = 7.4 Hz, 3H), 1.75 (m, 2H), 2.47 (s, 3H), 4.15 (m, 2H), 4.37 (m,
1H), 6.81-7.81 (m, 9H, aromatic protons).
l-Iodo-2-phenoxybutane (2.19)
This compound was prepared from 2-phenoxybut-l-yl p-toluenesulphonate 2.18 according to
the procedure described for the preparation of 1-benzyloxy- 2-iodoethane 2.7, using
acetone/dioxane (3: 1) as solvent. The reaction mixture was heated for 3.5 hours in an oil bath
at 120°C, and the product was purified by column chromatography over silica gel, using
hexane/chloroform (70/30) as mobile phase, to give l-iodo-2-phenoxybutane 2.19. JH NMR
(200 MHz) 8: 1.06 (t, J = 7.4 Hz, 3H), 1.91 (m, 2H), 3.39 (m, 2H), 4.17 (m, 1H), 6.94-7.38 (m,
5H, aromatic protons).
2-Methoxy-2-phenylethyl p-toluenesulphonate (2.21)
This compound was prepared from commercially available 2-methoxy-2-phenylethanol 2.20
(1.0 g, 6.6 mmol) according to the procedure described for the preparation of 2-phenoxyethyl
p-toluenesulphonate 2.3. The crude product was crystallised from hexane/ethanol (3: 1) to give
pure, crystalline 2-methoxy-2-phenylethyl p-toluenesulphonate 2.21 (1.7 g, 85%). No melting
point data was obtained for this compound. JH NMR (200 MHz) 8: 2.50 (s, 3H), 3.27 (s, 3H),
4.12 (m, 2H), 4.45 (m, 1H), 7.25-7.44 (m, 7H, aromatic protons), 7.76-7.85 (m, 2H, aromatic
protons).
l-Iodo-2-methoxy-2-phenylethane (2.22)
This compound was prepared from 2.21 according to the procedure described for the
preparation of l-iodo-2-phenoxyethane 2.4, except for heating the reaction mixture in an oil
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bath at 180°C. The crude product was purified by column chromatography over silica gel,
using hexane/chloroform (90: 10) as mobile phase, to give 1-iodo-2-methoxy-2-phenylethane
2.22. IH NMR (200 MHz) 8: 3.33-3.42 (m, 5H), 4.34 (m, 1H), 7.32-7.46 (m, 5H, aromatic
protons).
3-Phenoxyprop-l-yl p-toluenesulphonate (2.25)
The precursor for the tosylate 2.25, 3-phenoxy-1-propanol 2.24, was prepared from 1-bromo-3-
phenoxypropane 2.23 (0.5 g, 2.3 mmol) according to the procedure described for the
preparation of 2-phenoxyethanol 2.2 from ~-bromophenetole 2.1. The target tosylate 2.25 was
prepared from crude 2.24 (0.3 g, 1.9 mmol) according to the procedure described for the
preparation of 2-phenoxyethyl p-toluenesulphonate 2.3 from 2-phenoxyethanol 2.2 to give
crude 3-phenoxyprop-1-ylp-toluenesulphonate 2.25 (0.26 g, 43%).
l-Iodo-3-phenoxypropane (2.26)
Crude 3-phenoxyprop-1-yl p-toluenesulphonate 2.25 (0.1 g, 0.3 mmol) was refluxed with
sodium iodide (73 mg, 0.49 mmol) in acetone/dioxane (3:1) (2 ml) in an oil bath at 120 °C for 3
hours. The reaction mixture was evaporated to dryness under a stream of argon and the residue
chromatographed over silica gel with hexane/CllCl, (9: 1) to give pure 1-iodo-3-
phenoxypropane 2.26. IH NMR (200 MHz) 8: 2.32 (m, 2H), 3.4 (t, J = 8 Hz, 2H), 4.1 (t, J = 8
Hz, 2H), 6.9-7.4 (m, 5H, aromatic protons).
2-Phenylethyl p-toluenesulphonate (2.29)
The precursor for the tosylate 2.29, 2-phenylethyl alcohol 2.28, was prepared from 1-bromo-2-
phenylethane 2.27 (0.5 g, 2.7 mmol) according to the procedure described for the preparation
of 2-phenoxyethanol 2.2 from ~-bromophenetole 2.1. The target tosylate 2.29 was prepared
from crude 2.28 (0.2 g, 1.6 mmol) according to the procedure described for the preparation of
2-phenoxyethyl p-toluenesulphonate 2.3 from 2-phenoxyethanol 2.2 to give crude 2-
phenylethyl p-toluenesulphonate 2.29 (0.39 g, 86%).
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l-Iodo-2-phenylethane (2.30)
Crude 2-phenylethyl p-toluenesulphonate 2.29 (0.1 g, 0.36 mmol) was refluxed with sodium
iodide (80 mg, 0.53 mmol) in acetone/dioxane (1: 1) (2 ml) in an oil bath at 120°C for 1.5
hours. The reaction mixture was evaporated to dryness under a stream of argon and the residue
chromatographed over silica gel with hexane/CllCl, (9: 1) to give pure l-iodo-2-phenylethane
2.30. 'n NMR (200 MHz) 8: 3.2 (t, J = 8 Hz, 2H), 3.4 (t, J = 8 Hz, 2H), 7.2-7.4 (m, 5H,
aromatic protons).
6.3.2 Synthesis of the Benzamide Derivatives
2-Hydroxy-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide (2.33)
Thionyl chloride (0.75 ml, 10.3 mmol) and a few drops of dimethylformamide (20 J.lI)were
added to a solution of 3-methoxysalicylic acid 2.31 (0.5 g, 2.97 mmol) in chloroform (5 ml).
The mixture was refluxed for 30 min., after which some additional thionyl chloride (0.5 ml)
and dimethylformamide (50 ul) were added. Heating was continued for another 30 min., after
which the solvent and excess thionyl chloride were distilled off on a water bath at 80°C under
reduced pressure. The residue was dissolved in chloroform (2.5 ml) and added to a solution of
1-(2-aminoethyl)piperidine (0.42 g, 3.3 mmol) in chloroform (1.0 ml). Triethylamine (1.9 ml)
was added to this mixture, which was stirred overnight at room temperature, diluted with
chloroform (10 ml) and washed successively with 2% sodium hydrogen carbonate (10 ml) and
water (10 ml). The solution of the organic product in chloroform was dried over anhydrous
MgS04, the drying agent filtered off, and the filtrate evaporated to dryness at 800e under
reduced pressure. The resulting crude residue was purified by column chromatography over
silica gel, using diisopropyl ether/methanol/aqueous ammonia (80:20: 1) as mobile phase to
give 2-hydroxy-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.33 as a light brown oil (315
mg, 38%). 'rr NMR (300 MHz) 8: 1.43-1.51 (m, 2H, piperidine CH2), 1.58-1.66 (m, 4H,
piperidine CH2), 2.48-2.51 (m, 4H, piperidine CH2), 2.58-2.62 (t, J = 6.0 Hz, 2H, NCH2), 3.52-
3.57 (m, 2H, CONHCH2), 3.9 (s, 3H, OCH3), 6.79-6.84 (t, J = 8.1 Hz, IH, aromatic proton),
6.97-7.01(d, J = 7.9 Hz, IH, aromatic proton), 7.10-7.l3 (d, J = 8.2 Hz, IH, aromatic proton),
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7.70 (bs, 1H, NH). l3C NMR (75 MHz) 8: 24.27 (piperidine CH2), 25.97 (piperidine CH2),
35.99 (CONHCH2CH2), 54.40 (piperidine NCH2), 56.25 (CONHCH2CH2), 56.91 (OCH3),
115.02 (aromatic C), 115.33 (aromatic C), 117.91 (aromatic C), 118.37 (aromatic C), 149.62
(aromatic C), 152.16 (aromatic C-OH), 170.30 (C=O). MS (EI) m/z (%) 278 M+(5), 151 (6),
111 (12),98 (100),41 (6),28 (5).
3-Methoxy- N-(2-piperidin-l-ylethyl)- 2-[2 -(p-toluenesulphonyloxy )ethoxy Jbenzamide (2.41)
A mixture of ethylene glycol 2.34 (dried by distillation over anhydrous sodium sulphate) (810
mg, 13.0 mmol) and p-toluenesulphonyl chloride (5.7 g, 30 mmol) was dissolved in dry
dichloromethane (30 ml). Triethylamine (4.5 ml) was added to the mixture, the mixture was
heated under reflux for 6 hours, cooled, the triethylammonium chloride filtered off, and the
filter cake washed with dichloromethane. The combined filtrate and washings was evaporated
to dryness under reduced pressure. The residue was chromatographed over silica gel (20 g),
using chloroform/hexane (70:30), followed by chloroform as mobile phases to give a pure
fraction of the coupling reagent ethylene di-p-toluenesulphonate (TET) 2.35. A 20% aqueous
solution of tetrabutylammonium hydroxide (0.5 ml, 0.38 mmol) was added to a solution of 2-
hydroxy-3-methoxy-N-(2-piperidin-1-ylethyl)benzamide 2.33 (80 mg, 0.29 mmol) in
acetonitrile (15 ml). The solution was concentrated to dryness under reduced pressure at 50°-
55°C. The residue was re-dissolved in acetonitrile (8 ml) and the solution was again
concentrated to dryness as before. This step was repeated twice, using dry acetonitrile, and a
final temperature of 65°-70°C to ensure complete dryness of the tetrabutylammonium
phenoxide. The dried material was dissolved in dry acetonitrile (3 ml) and treated with a
solution ofTET 2.35 (1.0 g, 2.7 mmol) in dry acetonitrile (6 ml). The mixture was refluxed for
approximately 1.5 hours until TLC (Method 4) indicated total consumption of the benzamide
2.33. The reaction mixture was concentrated to dryness, after which the residue was re-
dissolved in chloroform (lO ml), the chloroform solution washed once with water (5 ml), dried
over anhydrous sodium sulphate, and the drying agent filtered off. The filtrate was
concentrated to dryness, re-dissolved in acetonitrile (3 ml) under gentle heating, and the
solution was cooled overnight at -10°C to allow as much as possible of the excess TET to
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crystallise. The crystals were filtered off, washed with small portions of chilled acetonitrile,
and the combined filtrate and washings were concentrated to dryness. The residue was
chromatographed over silica gel (4 g) with chloroform as mobile phase to remove the
remainder of the TET as well as other impurities. The required product was eluted with
diisopropyl ether/methanol/triethylamine (80:20:2) to give crude 2.41 (219 mg). Further
column chromatography over silica gel and elution with diisopropyl ether/methanol/aqueous
ammoma (85: 15:0.5) gave pure 3-methoxy-N-(2-piperidin-l-ylethyl)-2-[2-(p-
toluenesulphonyloxy)ethoxy]benzamide 2.41 (78 mg, 57%). IH NMR (300 MHz) 8: 1.41-1.45
(m, 2H, piperidine CH2), 1.51-1.59 (m, 4H, piperidine CH2), 2.41-2.45 (s, m, 3H, 4H, Ts-CH3
and piperidine CH2 overlapping), 2.51-2.55 (t, J = 6.4 Hz, 2H, NCH2), 3.54-3.60 (m, 2H,
CONHCH2), 3.86 (s, 3H, OCH3), 4.29- 4.40 (m, AA'BB' spin system, 4H, OCH2CH2), 7.02-
7.05 (dd, 3Jvic = 8.2 Hz, IH, phenyl H), 7.14-7.20 (t, J = 8.0 Hz, IH, phenyl H), 7.36-7.38,
7.81-7.84 (m, AA'BB' spin system, 2H, 2H, Ts aromatic H), 7.67-7.70 (dd, 3Jvic = 8.0 Hz, IH,
phenyl H), 8.04 (bs, IH, NH). I3C NMR (75 MHz) 8: 21.74 (Ts-CH3), 24.52 (piperidine CH2),
26.08 (piperidine CH2), 36.88 (CONHCH2CH2), 54.57 (piperidine NCH2), 56.27
(CONHCH2CH2), 57.69 (OCH3), 68.77 (CH20Ts), 70.94 (OCH2), 115.49 (phenyl C), 123.35
(phenyl C), 125.02 (phenyl C), 128.05 (phenyl C), 128.40 (Ts aromatic C), 130.36 (Ts
aromatic C), 133.31 (Ts aromatic C), 145.51 (Ts aromatic C), 145.78 (phenyl C), 152.73
(phenyl C), 165.42 (C=O). MS (EI) m/z (%) 476 M+(0.1),366 (1), 276 (2),291 (27),235 (23),
177 (22), 149 (13), 98 (100), 57 (87), 28 (92).
2-(2-Iodoethoxy)-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide (2.42)
The starting compound 3-methoxy-N-(2-piperidin-l-ylethyl)-2-[2-(p-toluenesulphonyloxy)-
ethoxy]benzamide 2.41 (20 mg, 0.042 mmol) was dissolved in acetone (0.5 ml) containing
sodium iodide (8 mg, 0.053 mmol) and the mixture was heated at reflux temperature in a sealed
vial (5 ml) on a hot plate for approximately I hour. The reaction mixture was subsequently
chromatographed over silica gel (3 g) and the required product was eluted with diisopropyl
ether/methanol/aqueous ammonia (80:20:0.2) to give pure 2-(2-iodoethoxy)-3-methoxy-N-(2-
piperidin-l-ylethyl)benzamide 2.42 (14 mg, 77%). IH NMR (300 MHz) 8: 1.46-1.54 (m, 2H,
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piperidine CH2), 1.63-1.70 (m, 4H, piperidine CH2), 2.52-2.55 (m, 4H, piperidine CH2), 2.63-
2.67 (t, J = 6.2 Hz, 2H, NCH2), 3.48-3.53 (t, J = 7.3 Hz, 2H, CH21), 3.63-3.70 (m, 2H,
CONHCH2), 3.91 (s, 3H, OCH3), 4.34-4.39 (t, J = 7.3 Hz, 2H, ArOCH2), 7.06-7.09 (dd, 3Jvic =
8.2 Hz, 1H, aromatic H), 7.17-7.22 (t, J= 8.1 Hz, 1H, aromatic H), 7.70-7.73 (dd, 'i: = 8.0
Hz, 4J = 1.6 Hz, 1H, aromatic H), 8.23 (bs, 1H, NH). l3C NMR (75 MHz) 8: 1.80 (CH21), 24.20
(piperidine CH2), 25.75 (piperidine CH2), 36.68 (CONHCH2CH2), 54.66 (piperidine NCH2),
56.34 (CONHCH2CH2), 57.72 (OCH3), 74.24 (OCH2), 115.59 (aromatic C), 123.25 (aromatic
C), 125.01 (aromatic C), 127.80 (aromatic C), 145.94 (aromatic C), 152.76 (aromatic C),
165.76 (C=O). MS (EI) m/z (%) 432 M+ (0.2), 322 (2), 276 (0.8), 220 (0.8), 193 (1), 150 (4),
111 (24),98 (100), 55 (3),41 (2).
3-Methoxy-N -(2 -piperidin-l-ylethyl)-2 -[l-(p-toluenesulphonyloxy )prop- 2-yloxyJbenzamide
(2.43) and 3-methoxy-N -(2-piperidin-l-ylethyl)-2-[2-(p-toluenesulphonyloxy )prop-l-
yloxyJbenzamide (2.45)
Triethylamine (8.0 ml) was added to a mixture of propane-1 ,2-diol (2.0 g, 26.3 mmol) and p-
toluenesulphonyl chloride (11.0 g, 57.7 mmol) in dry dichloromethane (60 ml), and the
solution was refluxed in an oil bath at a temperature varying between 80°-120°C for a total of 9
hours. The reaction mixture was cooled, filtered, and the filter cake washed with a small
portion of dichloromethane. The combined filtrate and washing was evaporated to dryness
under reduced pressure and the residue chromatographed over silica gel (30 g), using
chloroformlhexane (50:50) as mobile phase, to give a pure fraction of the coupling reagent
propylene 1,2-di-p-toluenesulphonate (TPT) 2.37. A 20% aqueous solution of
tetrabutylammonium hydroxide (0.5 ml, 0.38 mmol) was added to a solution of 2-hydroxy-3-
methoxy-N-(2-piperidin-1-ylethyl)benzamide 2.33 (75 mg, 0.27 mmol) in acetonitrile (14 ml).
The solution was concentrated to dryness under reduced pressure at 40-50°C. The residue was
dried by repeated dissolution in acetonitrile (7 ml) and concentration to dryness, after which the
residue was dissolved in dry acetonitrile (3 ml) and treated with a solution of TPT 2.37 (1.0 g,
2.6 mmol) in dry acetonitrile (4.5 ml). The reaction mixture was heated under reflux for 30
min. until TLC (Method 4 or 5) indicated total consumption of the benzamide 2.33. The
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reaction mixture was concentrated to dryness, and the residue was chromatographed over silica
gel (6 g). Chloroform was used as mobile phase to remove apolar impurities, followed by
diisopropyl ether/methanol/aqueous ammonia [85:15:0.5] (75 ml) and [75:25:0.2] (25 ml) to
isolate the mixture of isomers. The crude isolated material was subjected to further
chromatography over fresh silica gel (6g), using diisopropyl ether/isopropanol/aqueous
ammonia [85:15:0.5] (125 ml), followed by diisopropyl ether/methanol/aqueous ammonia
[85:15:0.5] (25 ml) as mobile phases. Four main fractions were collected. The first fraction
consisted mainly of 3-methoxy-N-(2-piperidin-1-ylethyl)-2-[1-(p-toluenesulphonyloxy)prop-2-
yloxy]benzamide 2.43 (25 mg, 19%). lH NMR (600MHz) 8: 1.31 (d, J = 6.4 Hz, 3H, CHCH3),
1.42-1.46 (m, 2H, piperidine CH2), 1.54-1.57 (m, 4H, piperidine CH2), 2.42-2.45 (s, m, 3H,
4H, Ts-CH3 and piperidine CH2 overlapping), 2.50-2.52 (t, J = 6.1 Hz, 2H, NCH2), 3.49-3.59
(m, 2H, CONHCH2), 3.84 (s, 3H, OCH3), 4.16 (AB spin system, Jgem = 10.5 Hz, Jvic = 4.4 Hz,
1H, CH20Ts), 4.27 (AB spin system, Jgem = 10.5 Hz, Jvic = 5.2 Hz, 1H, CH20Ts), 4.70-4.73
(m, 1H, OCHCH3), 7.0 (dd, 'i:= 8.2 Hz, 1H, phenyl H), 7.11-7.14 (t, J= 7.9 Hz, 1H, phenyl
H), 7.32-7.34,7.75-7.77 (m, AA'BB' spin system, 4H, Ts aromatic H), 7.64-7.66 (dd, 3Jvic = 7.9
Hz, 1H, phenyl H), 7.93 (bs, 1H, NH). J3C NMR (150 MHz) 8: 16.89 (CHCH3, 21.91 (Ts-
CH3), 24.67 (piperidine CH2), 26.09 (piperidine CH2), 36.88 (CONHCH2CH2), 54.67
(piperidine NCH2), 56.29 (CONHCH2CH2), 57.80 (OCH3), 72.05 (CH20Ts), 76.53 (CH-O),
115.25 (phenyl C), 123.19 (phenyl C), 124.49 (phenyl C), 128.17 (phenyl C), 128.59 (Ts
aromatic C), 130.11 (Ts aromatic C), 133.17 (Ts aromatic C), 144.29 (Ts aromatic C), 145.14
(phenyl C), 152.43 (phenyl C), 165.43 (C=O). MS (EI) m/z (%) 490 M+ (0.1), 380 (1), 363
(0.5), 318 (0.5), 276 (3), 220 (1), 151 (3), 111 (13), 98 (100), 70 (4), 41 (3). The second
fraction consisted of a mixture of isomers enriched in 2.43 (32 mg, 24%); the third fraction
consisted of a mixture of isomers enriched in 2.45 (20 mg, 15%); the fourth fraction consisted
mainly of 3-methoxy-N-(2-piperidin-1-ylethyl)-2-[2-(p-toluenesulphonyloxy)prop-1-
yloxy]benzamide 2.45 (18 mg, 14%). lH NMR (600MHz) 8: 1.43 (d, m, J = 6.6 Hz, 3H, 2H,
CHCH3 and piperidine CH2 overlapping), 1.56-1.60 (m, 4H, piperidine CH2), 2.42 (s, 3H, Ts-
CH3), 2.45 (m, 4H, piperidine CH2), 2.54-2.56 (t, 6.3 Hz, 2H, NCH2), 3.49-3.63 (m, 2H,
CONHCH2), 3.84 (s, 3H, OCH3), 3.95 (dd, Jgem = 10.5 Hz, Jvic = 4.0 Hz, 1H, CHCH20), 4.18
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(dd, Jgem = 10.5 Hz, Jvic = 5.7 Hz, IH, CHCH20), 4.98-5.03 (m, IH, CHOTs), 7.0 (dd, 3Jvic =
8.1 Hz, IH, phenyl H), 7.12-7.15 (t, J = 8.0 Hz, IH, phenyl H), 7.30-7.31, 7.80-7.82 (m,
AA'BB' spin system, 2H, 2H, Ts aromatic H), 7.62-7.64 (dd, 'i:= 7.9 Hz, IH, phenyl H), 7.87
(bs, IH, NH). l3C NMR (150 MHz) 8: 17.75 (CHCH3), 21.88 (Ts-CH3), 24.63 (piperidine
CH2), 26.13 (piperidine CH2), 37.05 (CONHCH2CH2), 54.68 (piperidine NCH2), 56.31
(CONHCH2CH2), 57.84 (OCH3), 75.14 (CH-OTs), 77.85 (OCH2), 115.34 (phenyl C), 123.10
(phenyl C), 124.73 (phenyl C), 127.78 (phenyl C), 128.06 (Ts aromatic C), 130.01 (Ts
aromatic C), 134.43 (Ts aromatic C), 144.99 (Ts aromatic C), 145.80 (phenyl C), 152.38
(phenyl C), 165.30 (C=O). MS (EI) m/z (%) 490 M+(0.2), 380 (3), 361 (2),295 (7), 291 (35),
251 (9), 177 (17), 137 (11), 111 (32), 98 (100), 55 (4),41 (7).
2-(1-Iodoprop-2-yloxy)-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide (2.44).
This compound was prepared from 3-methoxy-N-(2-piperidin-l-ylethyl)-2-[I-(p-
toluenesulphonyloxy)prop-2-yloxy]benzamide 2.43 (17 mg, 0.035 mmol) according to the
procedure used for the preparation of 2-(2-iodoethoxy)-3-methoxy-N-(2-piperidin-l-
ylethyl)benzamide 2.42. Chromatographic purification of the product gave 8 mg (52%) of the
target compound 2-( l-iodoprop-2-yloxy)-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.44.
IH NMR (600MHz) 8: 1.45-1.49 (d, m, J = 6.2 Hz, CHCH3 and piperidine CH2 overlapping,
3H, 2H), 1.59-1.63 (m, piperidine CH], 4H), 2.44 (m, piperidine CH2, 4H), 2.54-2.56 (t, J = 6.0
Hz, NCH], 2H), 3.44-3.47 (AB spin system, CH21, Jgem = 9.9 Hz, Jvic = 7.6 Hz, IH), 3.49-3.51
(AB spin system, CH21, Jgem = 9.9 Hz, Jvic = 4.4 Hz, IH), 3.53-3.66 (m, CONHCH2, 2H), 3.9
(s, OCH3, 3H), 4.52-4.55 (m, OCHCH3, IH), 7.03 (dd, 3Jvic = 8.2 Hz, phenylH, IH), 7.14-7.17
(t, J = 8.0 Hz, phenyl H, IH), 7.69 (dd, 3Jvic = 7.8 Hz, phenyl H, IH), 8.03 (bs, NH, IH). l3C
NMR (150 MHz) 8: 9.69 (CH21), 19.99 (OCHCH3), 24.41 (piperidine CH2), 25.88 (piperidine
CH2), 36.70 (CONHCH2CH2), 54.55 (piperidine NCH2), 56.08 (CONHCH2CH2), 57.82
(OCH3), 78.59 (OCHCH3), 115.03 (phenyl C), 122.93 (phenyl C), 124.28 (phenyl C), 128.46
(phenyl C), 144.15 (phenyl C), 152.30 (phenyl C), 165.33 (C=O). MS (EI) m/z (%) 336 (1),
278 (1),259 (0.5), 179 (2), 142 (5), 111 (20),98 (89), 55 (9), 18 (100).
123
Stellenbosch University http://scholar.sun.ac.za
2-(2-Iodoprop-l-yloxy )-3-methoxy-N -(2-piperidin-l-ylethyl)benzamide (2.46).
This compound was prepared from 3-methoxy-N-(2-piperidin-1-ylethyl)-2-[2-(p-
toluenesulphonyloxy)prop-1-yloxy]benzamide 2.45 (14 mg, 0.028 mmol) according to the
procedure used for the preparation of 2-(2-iodoethoxy)-3-methoxy-N-(2-piperidin-1-
ylethyl)benzamide 2.42. Chromatographic purification of the product gave 8 mg (63%) of the
target compound 2-(2-iodoprop-1-yloxy)-3-methoxy-N-(2-piperidin-1-ylethyl)benzamide 2.46.
JHNMR (600MHz) 8: 1.45-1.47 (m, piperidine CH2, 2H), 1.58-1.61 (m, piperidine CHb 4H),
2.02 (d, J = 6.7Hz, I-CHCH3, 3H), 2.45 (m, piperidine CHb 4H), 2.57 (br t, NCH2, 2H), 3.59-
3.62 (m, CONHCHb 2H), 3.88 (s, OCH3, 3H), 4.12 (dd, OCH2CH, Jgem = 10.3 Hz, Jvic = 7.5
Hz, 1H), 4.26 (dd, OCH2CH, Jgem = 10.3 Hz, Jvic = 5.9 Hz, 1H), 4.47-4.53 (m, ICHCH3, 1H),
7.02 (dd, 3Jvic = 8.1 Hz, phenyl H, 1H), 7.13-7.15 (t, J = 8.0 Hz, phenyl H, 1H), 7.64 (dd, 3Jvic =
8.0 Hz, phenyl H, 1H), 8.0 (bs, NH, 1H). l3C NMR (150 MHz) 8: 23.54 (CH-I), 24.62
(piperidine CH2), 25.11 (ICHCH3), 26.13 (piperidine CH2), 37.04 (CONHCH2CH2), 54.80
(piperidine NCH2), 56.37 (CONHCH2CH2), 58.01 (OCH3), 80.28 (OCH2), 115.35 (phenyl C),
123.10 (phenyl C), 124.78 (phenyl C), 127.87 (phenyl C), 145.90 (phenyl C), 152.48 (phenyl
C), 165.48 (C=O). MS (EI) m/z (%) 336 (0.5), 278 (1.0), 254 (1.0), 193 (0.5), 151 (3), III
(23),98 (100), 55 (6), 18 (18).
(E)-3-(Tributylstannyl)prop-2-en-l-yl p-toluenesulphonate (TBS-PROP- TOS) (2.40)
This compound was synthesized from propargyl alcohol 2.38 in a two-step procedure
consisting of the addition of tributyltin hydride to the alkynyl group, followed by the tosylation
of the hydroxyl group with p-toluenesulphonyl chloride (p-TsCI) according to the protocol of
Musachio and Lever (1992). Thus, a mixture of propargyl alcohol 2.38 (0.4 g, 7.1 mmol), tri-
butyltin hydride (2.7 g, 9.3 mmol) and a catalytic amount of2,2'-azobisisobutyronitrile (15 mg)
was heated in an oil bath (80°C) for 2.5 hours. The product mixture was chromatographed over
silica gel (15 g), using hexane/ethyl acetate (92:8) as mobile phase. The fraction enriched in the
target compound, (E)-3-(tributylstannyl)prop-2-en-l-01 2.39a (the more polar component on
TLC), was subjected to further chromatographic purification over silica gel (20 g), using
hexane/ethyl acetate (92:8), followed by (96:4) as mobile phases. The purified product 2.39a
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(366 mg, 1.1 mmol) was reacted with p- TsCI (266 mg, 1.4 mmol) and potassium
trimethylsilanolate (650 mg, 5.1 mmol) in diethyl ether at -20°C for approximately 2 hours.
After work-up, the crude product was chromatographed three times over silica gel (6 g) with
mixtures of hexane/ethyl acetate (95:5, 85:15, and finally 98:2) to give TBS-PROP-TOS 2.40
as a colourless oil (187 mg, 35%). The IH NMR data are given in Table 2.1.
3-Methoxy-N-(2-piperidin-l-ylethyl)- 2-[3-(tributylstannyl)prop- 2-en-l-yloxy Jbenzarnide (2.47)
A 20% aqueous solution of tetrabutylammonium hydroxide (0.2 ml, 0.16 mmol) was added to a
solution of 2-hydroxy-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.33 (30 mg, 0.11
mmol) in acetonitrile (3 ml). The solution was concentrated to dryness under reduced pressure
at 40-50°C. To ensure complete removal of any residual water, the residue was dissolved in dry
acetonitrile (3 ml), the solution concentrated to dryness, and this procedure was repeated twice
more. The dried residue was dissolved in dry acetonitrile (1.2 ml) and treated with a solution of
TBS-PROP-TOS 2.40 (76 mg, 0.15 mmol) in dry acetonitrile (1.0 ml). This reaction mixture
was heated and stirred in an oil bath at a temperature of 100-11O°Cuntil TLC analysis (Method
4) indicated total consumption of the starting compound 2.33. The reaction mixture was
subsequently concentrated with a stream of nitrogen, the residue was diluted with ethyl acetate,
and chromatographed over silica gel (4 g) with hexane/ethyl acetate (90: 10) and finally with
diisopropyl ether/methanol/aqueous ammonia (80:20:0.5) to give pure 3-methoxy-N-(2-
piperidin-l-ylethyl)-2-[3-(tributylstannyl)prop-2-en-l-yloxy]benzamide 2.47 (55 mg, 84%). IH
NMR (300 MHz) 8: 0.85-0.93 (m, n-Bu protons, 15H), 1.23-1.36 (m, Bu protons, 6H), 1.41-
1.50 (m, Bu protons and piperidine CH2 overlapping, 8H), 1.56-1.63 (m, piperidine CH2, 4H),
2.43-2.47 (m, piperidine CH2, 4H), 2.53-2.57 (t, J = 6.4 Hz, NCH2, 2H), 3.55-3.61 (m,
CONHCH2, 2H), 3.9 (s, OCH3, 3H), 4.62-4.65 (dd, ArOCH2, 3Jvic = 7.0 Hz, 4J= 2.7 Hz, 2H),
6.24-6.28 (m, CH=CH overlapping, 2H), 7.03-7.06 (dd, 3Jvic = 8.2 Hz, phenyl H, IH), 7.13-
7.18 (t, J= 8.0 Hz, phenyl H, lH), 7.72-7.75 (dd, 'i;= 8.0 Hz, phenyl H, lH), 8.39 (bs, NH,
IH). l3C NMR (75 MHz) 8: 9.18 (Bu3-C), 13.43 (Bu3-C), 24.18 (piperidine CH2), 25.75
(piperidine CH2), 27.07 (Bu3-C), 28.83 (Bu3-C), 36.61 (CONHCH2CH2), 54.33 (piperidine
NCH2), 55.89 (CONHCH2CH2), 57.47 (OCH3), 77.42 (OCH2), 114.99 (phenyl C), 122.93
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(phenyl C), 124.20 (phenyl C), 127.74 (phenyl C), 134.25 (CH=CH-Sn), 142.95 (CH=CH),
146.27 (phenyl C), 152.84 (phenyl C), 165.46 (C=O). MS (EI) m/z (%) 607 M+(0.2),551 (19),
498 (3), 397 (10), 378 (2),268 (2), 177 (5), 155 (64),98 (100), 41 (5).
2-(3-Iodoprop-2-en-l-yloxy )-3-methoxy- N-(2-piperidin-l-ylethyl)benzamide (2.48)
A solution of 12(9 mg, 0.04 mmol) in dichloromethane (0.57 ml) was added to a solution of 3-
methoxy-N-(2-piperidin-l-ylethyl)-2-[3-(tributylstannyl)prop-2-en-l-yloxy ]benzamide 2.47
(20 mg, 0.03 mmol) in dichloromethane (0.1 ml). The reaction mixture was stirred at room
temperature for 1 hour, after which the reaction was quenched by the addition ofNa2S20s (12.8
mg, 0.06 mmol) in water (1.5 ml). The aqueous phase was made alkaline with IN NaOH (0.1
ml), additional dichloromethane (1 ml) was added to the product, and the layers were
separated. The aqueous phase was extracted twice with dichloromethane (0.5 ml), the
combined extracts were dried over anhydrous MgS04, the drying agent filtered off, and the
filtrate concentrated with a stream of nitrogen. The crude residue was chromatographed over
silica gel (4 g) with diisopropyl ether/methanol/aqueous ammonia (90: 10:1) to give pure 2-(3-
iodoprop-2-en-l-yloxy)-3-methoxy-N-(2-piperidin-l-ylethyl)benzamide 2.48 (10.7 mg, 73%).
'n NMR (300 MHz) 8: 1.44-1.50 (m, piperidine CHb 2H), 1.57-1.64 (m, piperidine CHb 4H),
2.44-2.47 (m, piperidine CHb 4H), 2.53-2.57 (t, J = 6.2 Hz, NCH2, 2H), 3.56-3.62 (m,
CONHCH2, 2H), 3.9 (s, OCH3, 3H), 4.47-4.53 (dd, ArOCHb 3Jvic = 6.4 Hz, 4J = 1.3 Hz, 2H),
6.52-6.58 (dt, 3Jvic = 14.6 Hz, 4J= 1.4 Hz, CH=Cm, IH), 6.83-6.93 (dt, 'i:= 14.6 Hz, 4J= 6.4
Hz, CH=CHI, IH), 7.05-7.08 (dd, 3Jvic = 8.2 Hz, phenyl H, IH), 7.17-7.22 (t, J = 8.1 Hz,
phenyl H, IH), 7.69-7.72 (dd, 'i:= 7.9 Hz, phenyl H, IH), 8.2 (bs, NH, IH). l3CNMR (150
MHz) 8: 24.49 (piperidine CH2), 26.06 (piperidine CH2), 36.79 (CONHCH2CH2), 54.49
(piperidine NCH2), 56.19 (CONHCH2CH2), 57.44 (OCH3), 75.33 (OCH2), 80.94 (CH=CH-I),
115.01 (phenyl C), 122.88 (phenyl C), 124.72 (phenyl C), 127.89 (phenyl C), 141.13 (CH=CH-
I), 145.53 (phenyl C), 152.52 (phenyl C), 165.12 (C=O). MS (EI) m/z (%) 444 M+ (0.3), 334
(2), 194 (1), 167 (5), 111 (34),98 (100), 55 (3),42 (2).
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6.3.3 Synthesis of the Heterocyclic Amine Derivatives
6.3.3.1 Synthesis of the alkylating agents and the benzotriazole derivatives
2-Hydroxyethyl benzoate (2.50)
Ethylene glycol was dried by distillation over anhydrous sodium sulphate. Concentrated
sulphuric acid (0.5 ml) and molecular sieves (3Á, 5 g) were added to a mixture of benzoic acid
2.49 (13.0 g, 0.1 mole) and dry ethylene glycol 2.34 (19.6 g, 0.3 mole). The mixture was
suspended in an oil bath (170o-185°C) and refluxed for 3 hours, diluted with water (100 ml),
and repeatedly extracted with chloroform (50 ml). The resulting emulsion was filtered through
a pad of filter aid, and the organic phase was separated from the supernatant water layer. The
combined chloroform extracts were washed with water (50 ml) and sodium hydrogen carbonate
(6%, 40 ml), dried over anhydrous MgS04, the drying agent was filtered off, and the filtrate
evaporated to dryness to give 2-hydroxyethyl benzoate 2.50 as an oily product that solidified
into a soft wax upon cooling (12.8 g, 72%). IH NMR (300 MHz) 8: 2.76 (bs, OH, 1H), 3.95-
3.98 (t, J = 4.7 Hz, CH20H, 2H), 4.46-4.49 (t, J = 4.6 Hz, C02CH2, 2H), 7.44-7.50 (m, H-3, H-
5 phenyl, 2H), 7.57- 7.63 [t (with fine structure), H-4 phenyl, 1H], 8.08-8.12 (m, H-2, H-6
phenyl, 2H). l3C NMR (75 MHz) 8: 61.25 (CH20H), 66.56 (COCH2), 128.53 (phenyl C),
129.81 (phenyl C), 129.99 (phenyl C), 133.31 (phenyl C), 167.23 (C=O). MS (EI) m/z (%) 148
(M+- H20)(0.5), 135 (2),123 (43),105 (100), 77 (52), 51 (17), 18 (7).
2-Chloromethoxyethyl benzoate (2.51) [Guédin-Vuong and Nakatani (1986)]
A mixture of para formaldehyde (165 mg, 5.5 mmol) and dichloromethane (3 ml) was placed in
a 10 ml conical flask together with a magnetic stirrer bar, and cooled to -15°C by means of a
liquid nitrogen-ethanol mixture. A stream of hydrogen chloride (generated by the addition of
concentrated H2S04 to a mixture of ammonium chloride and 32% HCI) was bubbled through a
concentrated H2S04 trap, and passed through the vigorously stirred mixture until a clear
solution was formed. The flow of hydrogen chloride was maintained, the solution was kept at
-15 to -10°C and was treated dropwise with a solution of 2-hydroxyethyl benzoate 2.50 (0.8 g,
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4.8 mmol) in dichloromethane (1.5 ml). After completion of the addition of the benzoate
solution, the reaction mixture was stirred for another 5 minutes at -10 to -12°C, after which the
introduction of hydrogen chloride was stopped and the residual hydrogen chloride driven from
the reaction mixture using a brisk flow of nitrogen. After two minutes, the cold reaction
mixture was poured into a chilled suspension of anhydrous potassium carbonate (8 g) in
dichloromethane (20 ml). The mixture was stirred for 10-15 minutes, the potassium carbonate
filtered off, and the solvent evaporated from the filtrate at 20°C under reduced pressure to give
a light yellow oil (0.95 g, 93%). This crude product was immediately refrigerated at -10°C and
was used as soon as possible.
1-[(2-Benzoyloxyethoxy)methyl] benzotriazole (2.63)
A solution of freshly prepared 2-chloromethoxyethyl benzoate 2.51 (526 mg, 2.4 mmol) in
dichloromethane (8 ml) was added to a mixture of benzotriazole 2.62 (232 mg, 1.9 mmol) and
anhydrous potassium carbonate (820 mg, 5.9 mmol) in dichloromethane (15 ml). The mixture
was stirred at room temperature for 6 hours, after which the potassium carbonate was filtered
off and the filtrate evaporated at 50°C under reduced pressure. The crude product was
chromatographed over silica gel (7 g), using petroleum ether/ethyl acetate (4: 1) as mobile
phase. Two fractions of the target compound 2.63 of 140 mg (24%) and 207 mg (35%) were
isolated in purities of 94% and 85% respectively. IH NMR (600 MHz) 8: 3.85 (t, J = 4.6 Hz,
OCH2, 2H), 4.41 (t, J= 4.6 Hz, CH20CO, 2H), 6.09 (s, NCH20, 2H), 7.37-7.41 (m, H-3, H-5
phenyl, H benzotriazole overlapping, 3H), 7.47-7.49 (t, J = 7.6 Hz, H-4 phenyl, IH), 7.53-7.55
(t, J= 7.4 Hz, Hbenzotriazole, IH), 7.68 (d, J= 8.3 Hz, Hbenzotriazole, IH), 7.87 (d, J= 7.6
Hz, H-2, H-6 phenyl, 2H), 8.08 (d, J = 8.3 Hz, H benzotriazole, IH). l3CNMR (150 MHz) 8:
63.13 (CH2CH2), 67.05 (CH2CH2), 77.12 (NCH2), 109.87 (C benzotriazole), 120.07 (C
benzotriazole), 124.44 (C benzotriazole), 128.03 (C benzotriazole), 128.29 (phenyl C), 129.57
(phenyl C), 129.66 (phenyl C), 132.63 (C benzotriazole), 133.01 (phenyl C), 146.47 (C
benzotriazole), 166.27 (C=O). MS (EI) m/z (%) 298 [M+Ht (1), 209 (3), 197 (3), 181 (6), 167
(6), 149 (70), 105 (100), 77 (43), 51 (8).
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1-[(2-Hydroxyethoxy)methyIJ benzotriazole (2.64)
Concentrated (25%) ammoma (25 ml) was added to a solution of 1-[(2-
benzoyloxyethoxy)methyl]benzotriazole 2.63 (306 mg, 1.0 mmol) in methanol (25 ml). The
mixture was stirred for a few hours at room temperature until TLC (Method 6) indicated a total
conversion of 2.63 to the hydroxyethoxymethylbenzotriazole 2.64. The reaction mixture was
concentrated under reduced pressure at 40-50°C to a volume of 20 ml, the remaining aqueous
suspension was extracted twice with chloroform (2 x 20 ml), and the chloroform distilled off
under reduced pressure to give a crude extract. This extract was dissolved in toluene (20 ml)
and the toluene solution washed with water (2 x lOmI), dried over anhydrous MgS04, the
drying agent filtered off and the filtrate evaporated to dryness to give an oil. This product was
chromatographed over silica gel (4 g) with ethyl acetate/petroleum ether (2: 1) to give pure 1-
[(2-hydroxyethoxy)methyl]benzotriazole 2.64 (19 mg, 10%). More of the target compound
2.64 was recovered from the combined water layers by extraction with chloroform (lOmI),
followed by the normal work-up procedures to give 2.64 as a crude oily product (171 mg,
86%). IH NMR (600 MHz) 8: 3.64-3.70 (m, AA'BB' spin system, OCH2CH20H, 4H), 6.07 (s,
NCH20, 2H), 7.41-7.44 (t, J = 7.9 Hz, H benzotriazole, 1H), 7.54-7.56 (t, J = 7.6 Hz, H
benzotriazole, 1H), 7.68-7.70 (d, J= 8.3 Hz, Hbenzotriazole, 1H), 8.08-8.10 (d, J= 8.5 Hz, H
benzotriazole, 1H). l3C NMR (150 MHz) 8: 61.42 (CH20H), 70.72 (OCH2CH2), 77.25 (NCH2),
109.73 (C-benzotriazole), 120.13 (C-benzotriazole), 124.52 (C-benzotriazole), 128.16 (C-
benzotriazole), 132.74 (C-benzotriazole), 146.37 (C-benzotriazole). MS (EI) m/z (%) 193 M+
(21),163 (34),132 (33),120 (34),105 (45), 91 (47),77 (100),51 (27),45 (68),29 (8).
1-[(2-p- Toluenesulphonyloxyethoxy)methylJ benzotriazole (2.65)
p-Toluenesulphonyl chloride (40 mg, 0.21 mmol) was added to a solution of crude 1-[(2-
hydroxyethoxy)methyl]benzotriazole (2.64) (24 mg, approximately 0.12 mmol) in dry pyridine
(0.25 ml). The reaction mixture was refrigerated overnight at 5°C, after which it was diluted
with water (2 ml) and extracted three times with CHCl3 (3 x 0.5 ml). The combined chloroform
extracts were washed with O.lN H2S04 (I ml) and water (1 ml) and dried over anhydrous
MgS04. The drying agent was filtered off and the filtrate evaporated to dryness with a stream
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of nitrogen. The crude extract was chromatographed over silica gel (3 g), using the following
mobile phases: petroleum ether/ethyl acetate (3:1), (2:1) and (1:1). A pure fraction of 1-[(2-p-
toluenesulphonyloxyethoxy)methyl]benzotriazole 2.65 was collected (27 mg, 62%). IH NMR
(300 MHz) 8: 2.45 (s, Ts-CH3, 3H), 3.68-3.71 (m, X2 component of A2X2 spin system,
CH20CH2> 2H), 4.12-4.15 (m, A2 component of A2X2 spin system, CH20Ts, 2H), 6.0 (s,
NCH20, 2H), 7.33-7.36, 7.74-7.78 (m, AA'BB' spin system, Ts aromatic H, 4H), 7.44-7.49
(ddd, 'i:= 8.4 Hz, Hbenzotriazole, IH), 7.56- 7.61 (ddd, 3Jvic = 8.3 Hz, Hbenzotriazole, IH),
7.66-7.70 (d, with fine structure, H benzotriazole, IH), 8.11-8.15 (d, with fine structure, H
benzotriazole, IH). l3C NMR (75 MHz) 8: 21.48 (Ts-CH3), 66.71 (CH20Ts), 68.19
(OCH2CH2), 76.98 (NCH2), 109.89 (C-benzotriazole), 120.26 (C-benzotriazole), 124.70 (C-
benzotriazole), 128.08 (Ts aromatic C), 128.37 (C-benzotriazole), 130.04 (Ts aromatic C),
132.84 (Ts aromatic C), 133.05 (C-benzotriazole), 145.22 (Ts aromatic C), 146.67 (C-
benzotriazole). HRMS: m/z M+ = 347.0939, calc. for C16H1704N3S= 347.0939. MS (EI) m/z
(%) 347 M+(33), 228 (9), 192 (26), 156 (9), 155 (100), 120 (29), 91 (80),65 (10).
1-[(2-lodoethoxy)methylJ benzotriazole (2.66b)
A mixture of 1-[(2-p-toluenesulphonyloxyethoxy)methyl]benzotriazole 2.65 (20 mg, 0.06
mmol), sodium iodide (15 mg, 0.1 mmol) and acetone (0.5 ml), together with a magnetic stirrer
bar, were sealed in a 5 ml glass vial with a cap. The mixture was heated and stirred on a hot
plate at reflux temperature for 40 minutes. The reaction product was concentrated with a stream
of nitrogen and chromatographed over silica gel (3 g) with petroleum ether/ethyl acetate (2: 1)
to give pure 1-[(2-iodoethoxy)methyl]benzotriazole 2.66b (14 mg, 80%). IH NMR (300 MHz)
8: 3.08-3.12 (t, J = 6.5 Hz, CH21, 2H), 3.71-3.75 (t, J = 6.5 Hz, OCH2CH2 , 2H), 6.03 (s, NCH2>
2H), 7.37-7.43 (ddd, 3Jvic = 8.4 Hz, H benzotriazole, 1 H), 7.50-7.56 (ddd, 3Jvic = 8.4 Hz, H
benzotriazole, 1 H), 7.67-7.71 (d, with fine structure, H benzotriazole, IH), 8.05-8.09 (d, with
fine structure, H benzotriazole, IH). l3C NMR (75 MHz) 8: 1.06 (CH21), 69.73 (OCH2CH2),
76.72 (NCH2), 110.01 (C-benzotriazole), 120.26 (C-benzotriazole), 124.68 (C-benzotriazole),
128.30 (C-benzotriazole), 132.87 (C-benzotriazole), 146.70 (C-benzotriazole). HRMS: m/z M+
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= 302.9874, calc. for C9HIOON31 = 302.9868. MS (EI) m/z (%) 303 M+ (37),275 (11),245 (9),
231 (16), 176 (44),155 (100),132 (18),120 (19), 77 (42), 65 (12),18 (12).
Z-Hydroxyprop-l=yl benzoate (2.54) from 70% I-bromo-2-propanoI2.52
A solution of sodium hydroxide (20%, 5 ml) was added to a suspension of benzoic acid (3 g) in
ethanol (5 ml), the mixture was heated until the solid material dissolved, and the solution was
evaporated to near dryness under reduced pressure at 70°C. To ensure complete removal of
residual water, the residue was dissolved in absolute ethanol (30 ml), and the solution was
again concentrated to dryness under reduced pressure. This procedure was repeated once more.
The sodium benzoate was finally dried under vacuum at 100°C. A mixture of sodium benzoate
(1.58 g, 11 mmol) and I-bromo-2-propanol 2.52 (1.56 g, 11.2 mmol) in dimethylformamide
(DMF) (40 ml) was stirred in an oil bath at 120-130°C until the solid material was dissolved.
The resulting solution was further heated for approximately 1 hour at 130°C, after which
another portion of I-bromo-2-propanol (0.77 g, 5.5 mmol) was added to the solution. Heating
was continued at BO-140°C for 40 minutes, after which the DMF was distilled off at 100°C
under reduced pressure. The residue was suspended in CHCl3 (30 ml), and the mixture was
successively washed with water (15 ml), sodium hydrogen carbonate (6%, 15 ml) and finally
with water (15 ml). The chloroform solution was dried over anhydrous MgS04, the drying
agent was filtered off, and the filtrate evaporated to dryness at 80°C under reduced pressure to
give a crude product that was chromatographed over silica gel (8 g). Mixtures of petroleum
ether/ethyl acetate (5: 1 and 2: 1) were used as mobile phases. Pure fractions were combined to
give 2-hydroxyprop-l-yl benzoate 2.54 (1.35 g, 68%) in a 65% isomeric purity [HPLC Method
3(a)]. [Characterization was only done on the purer 2-hydroxyprop-l-yl benzoate 2.54, the
synthesis of which is described later].
l-Bromo-Z-propanol (2.52) ["isomer-free"]
Method 1: A solution of 2,2,6,6-tetramethylpiperidine (2.83 g, 20 mmol) in dry THF (10 ml)
was added dropwise to a freshly prepared solution of ethylmagnesium bromide (20 mmol) in
dry THF (50 ml) under a slow stream of nitrogen. The mixture was heated under reflux for 4
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hours. A solution of propylene oxide (20 mmol) in dry THF (10ml) was added dropwise to the
reaction mixture cooled at -5°C in an ice/salt bath. The solution was stirred at O°Cfor 2 hours,
and then at room temperature for 18-20 hours. A saturated solution of ammonium chloride (30
ml) was then carefully added under cooling. Two layers were formed. The THF was distilled
off at room temperature under reduced pressure, and the resulting aqueous solution was
extracted three times with diethyl ether (3 x 25 ml). The ethereal extract was washed with
saturated NH4Cl and NaCI solutions and dried overnight over anhydrous sodium sulphate. The
drying agent was filtered off and the solvent evaporated under reduced pressure. To avoid
isomerization the residue was distilled at an air-bath temperature of 50°C in a Kugelrohr
apparatus at a vacuum of 1x10-3 Torr and cooling of the distilled fractions with dry ice. A
nearly colourless liquid was obtained (1.15 g, 41%). GC-MS m/z (%) 138 M+ (0.5), 140 M+
(0.5), 125 (10), 123 (10),95 (3),93 (3),45 (100),43 (20).
Method 2: An analogous preparation, usmg diisopropylamine instead of 2,2,6,6-
tetramethylpiperidine, was also carried out. Starting with diisopropylamine (12.6 g, 125 mmol),
I-bromo-2-propanol 2.52 was obtained as a colourless liquid (7.5 g, 43%) in an isomeric purity
of99.7 % (GC Method 1).
2-Hydroxyprop-l-yl benzoate (2.54) from 99.7% isomerically pure I-bromo-2-propanoI2.52
A mixture of sodium benzoate (3.0 g, 20.8 mmol) and I-bromo-2-propanol 2.52 (3.5 g, 25
mmol) in HMPA (30 ml) was stirred in an oil bath at 60°C for 2 hours. The reaction mixture
was poured into an HCl solution (5%, 60 ml) and the mixture was extracted three times with
diethyl ether (3 x 45 ml). The combined ethereal extracts were washed twice with water (2 x 25
ml), dried over anhydrous MgS04, the drying agent filtered off, and the filtrate evaporated to
dryness under reduced pressure to give a crude product (3.5 g). This product was
chromatographed over silica gel (20 g) as before. The fractions containing the product were
combined, evaporated to dryness, dissolved in chloroform (20 ml), washed with NaHC03
solution (6%, 10 ml) to remove traces of benzoic acid, and finally with water (10 ml). After
drying over anhydrous MgS04, followed by filtration of the drying agent and removal of the
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solvent under reduced pressure at 70-80°C, 2-hydroxyprop-l-yl benzoate 2.54 (2.18 g, 58%)
was obtained in a 97% isomeric purity [HPLC Method 3(a)]. IH NMR (600 MHz) 8: 1.28-1.30
(d, J = 6.3 Hz, CHCH3, 3H), 2.40 (bs, OH, IH), 4.17-4.22 (m, CHOH, -COrCHH overlap,
2H), 4.33-4.35 (dd, Jgem = 10.7 Hz, Jvic = 2.9 Hz, -COrCHH, IH), 7.43-7.45 (t, with fine
structure, H-3, H-5 phenyl, 2H), 7.55-7.58 (t, with fine structure, H-4 phenyl, IH), 8.05-8.06
(d, with fine structure, H-2, H-6 phenyl, 2H). l3C NMR (150 MHz) 8: 19.27 (CHCH3), 66.18
(CHOH), 70.04 (C02CH2), 128.38 (phenyl C), 129.61 (phenyl C), 129.84 [phenyl C (ipso)],
133.13 (phenyl C), 166.65 (C=O). MS (EI) m/z (%) 180 M+ (0.5), 136 (21), 123 (10), 105
(100),92 (14), 77 (45),51 (15),45 (7).
2-Chloromethoxyprop-l-yl benzoate (2.56) from 65% isomerically pure 2-hydroxyprop-l-yl
benzoate 2.54
2-Chloromethoxyprop-l-yl benzoate 2.56 was prepared from 2-hydroxyprop-l-yl benzoate
2.54 (1.0 g, 5.55 mmol) and paraformaldehyde (0.19 g, 6.33 mmol) according to the procedure
used for the preparation of 2-chloromethoxyethyl benzoate 2.51. The target compound 2.56
was obtained as a light-yellow crude oil (1.26 g, 100%).
2-Chloromethoxyprop-l-yl benzoate (2.56) from 97% isomerically pure 2-hydroxyprop-l- yl
benzoate 2.54
2-Chloromethoxyprop-l-yl benzoate 2.56 was prepared from 2-hydroxyprop-l-yl benzoate
2.54 (1.0 g, 5.55 mmol) and paraformaldehyde (0.19 g, 6.33 mmol) according to the procedure
used for the preparation of2-chloromethoxyethyl benzoate 2.51. The dichloromethane solution,
containing the target compound 2.56, was concentrated under reduced pressure at room
temperature to a volume of 17 ml. The approximate solid content of this solution (1.2 g, 100%)
was determined by evaporating a small portion to dryness and calculating the total mass by
means of extrapolation. The solution was immediately refrigerated at -10°C.
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1-[(1-Benzoyloxyprop-2-yloxy)methyl]benzotriazole (2.67) from isomerically Impure 2-
chloromethoxyprop-l-yl benzoate 2.56
This compound was prepared from benzotriazole (200 mg, 1.7 mmol), anhydrous potassium
carbonate (0.7 g) and freshly prepared isomerically impure 2-chloromethoxyprop-1-yl benzoate
2.56 (503 mg, 2.2 mmol) according to the procedure used for the preparation of 1-[(2-
benzoyloxyethoxy)methyl]benzotriazole (2.63). The reaction product was chromatographed
over silica gel (8 g) using petroleum ether/ethyl acetate mixtures (10:1, 5:1,2:1) as mobile
phases. Fractions containing the product were combined and evaporated to dryness to give 1-
[(1-benzoyloxyprop-2-yloxy)methyl]benzotriazole 2.67 as an oil (413 mg, 79%) in an isomeric
purity of 76% [HPLC Method 2(b)]. [Characterization was only done on the purer 1-[(1-
benzoyloxyprop-2-yloxy)methyl]benzotriazole 2.67, the synthesis of which is described
below].
1-[(1 -Benzoyloxyprop-2-yloxy)methyl} benzotriazole (2.67) from isomerically pure 2-
chloromethoxyprop-1-yl benzoate 2.56
This compound was prepared from benzotriazole (300 mg, 2.52 mmol), anhydrous potassium
carbonate (1.05 g) and freshly prepared 2-chloromethoxyprop-1-yl benzoate 2.56 (700 mg, 3.1
mmol) according to the procedure used for the preparation of 1-[(2-
benzoyloxyethoxy)methyl]benzotriazole (2.63). Chromatography was carried out over silica
gel (25 g), using petroleum ether/ethyl acetate mixtures (6:1, 2:1, and 1:1) as mobile phases.
The combined fractions containing the product gave a crude white solid (683 mg, 87% pure).
Crystallisation of this material (615 mg) from methanol (3 ml) gave the pure target compound
2.67 (389 mg, 55%), in a purity of 99% [HPLC Method 2(b)], m.p. 68-68.5°C, IH NMR (600
MHz) 8: 1.20-1.21 (d, J= 6.3 Hz, OCHCH3, 3H), 4.02-4.07 (m, OCHCH3, 1H), 4.22-4.27 (m,
CH20CO, 2H), 6.11 (s, NCH20, 2H), 7.33-7.36 (m, H-3, H-5 phenyl, H benzotriazole
overlapping, 3H), 7.41-7.44 (t, J = 8.0 Hz, H-4 phenyl, 1H), 7.50-7.53 (t, J = 7.4 Hz, H
benzotriazole, 1H), 7.65-7.67 (d, J = 8.3 Hz, H benzotriazole, 1H), 7.75-7.77 (d, with fine
structure, H-2, H-6 phenyl, 2H), 8.03-8.05 (d, J= 8.3 Hz, Hbenzotriazole, 1H). 13C NMR (150
MHz) 8: 16.38 (CHCH3), 67.18 (CH20CO), 72.11 (CHCH3), 75.37 (NCH2), 109.91 (C
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benzotriazole), 119.94 (C benzotriazole), 124.33 (C benzotriazole), 127.90 (C benzotriazole),
128.26 (phenyl C), 129.44 (phenyl C), 129.56 (phenyl C), 132.62 (C benzotriazole), 132.89
(phenyl C), 146.40 (C benzotriazole), 166.07 (C=O). MS (EI) m/z (%) 311 M+ (0.5), 195 (3),
180 (3),163 (26),132 (14),105 (100), 77 (47), 51 (11), 18 (6).
1-[(J-Hydroxyprop-2-yloxy)methyl]benzotriazole (2.68) from 76% pure 1-[(1-benzoyloxyprop-
2-yloxy)methyl ]benzotriazole 2.67
An aqueous solution of ammonia (25%, 30 ml) was added to a solution of 1-[(1-
benzoyloxyprop-2-yloxy)methyl]benzotriazole 2.67 (378 mg, 1.2 mmol) in methanol (30 ml).
The reaction mixture was stirred overnight at room temperature, after which it was
concentrated at 50°C under reduced pressure to a volume of approximately 20 ml. The mixture
was extracted twice both with toluene (2 x 20 ml) and CRCl3 (2 x 20 ml). Each extract was
dried separately over anhydrous MgS04, the drying agent was filtered off, and the filtrates
concentrated to dryness under reduced pressure at 50°C. Crude 1-[(1-hydroxyprop-2-
yloxy)methyl]benzotriazole 2.68 was obtained from both the toluene (64 mg, 25%) and the
chloroform (198 mg, 78%) extracts, both in an isomeric purity of 80% (RPLC, Method 6).
[Characterization was only done on the purer 1-[(1-hydroxyprop-2-yloxy)methyl]benzotriazole
2.68, the synthesis of which is described below].
1-[(J-Hydroxyprop-2-yloxy)methyl}benzotriazole (2.68) from 99% pure 1-[(1-benzoyloxyprop-
2-yloxy)methyl]benzotriazole 2.67
Concentrated ammonia solution (25%, 28 ml) was added to a solution of 99% pure 1-[(1-
benzoyloxyprop-2-yloxy)methyl]benzotriazole 2.67 (353 mg, 1.1 mmol) in methanol (28 ml)
and the mixture was stirred overnight at room temperature, after which the reaction mixture
was concentrated under reduced pressure at 50°C to a volume of approximately 30 ml. The
mixture was extracted twice with diethyl ether (2 x 30 ml), and once with CRCl3 (30 ml). All
the extracts were combined, dried over anhydrous MgS04, the drying agent was filtered off,
and the filtrate concentrated to dryness to give 264 mg of crude material. This material was
chromatographed over silica gel (8 g) using initially petroleum ether/ethyl acetate (2: 1) as the
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mobile phase. The first fraction (35 ml) was discarded, and elution was continued with
petroleum ether/ethyl acetate (1:1). The second fraction (40 ml) was discarded, and the product
was collected in the subsequent fraction (30 ml). This fraction was evaporated to dryness under
reduced pressure at 80-90°C to give 1-[(1-hydroxyprop-2-yloxy)methyl]benzotriazole 2.68
(214 mg, 91%) in a purity of 96% (HPLC, Method 6). IH NMR (600 MHz) 8: 1.06 (d, J = 6.3
Hz, OCHCH3, 3H), 2.04 (bs, OH, IH), 3.46-3.49 (dd, Jgem = 11.9 Hz, .i; = 6.7 Hz, CH20H),
IH), 3.52-3.55 (dd, Jgem = 11.9 Hz, Jyic = 3.4 Hz, CH20H J IH), 3.76-3.81 (m, OCHCH3, IH),
6.10, 6.13 (AB spin system, 2Jgem = 11.5 Hz, NCH2, 2H), 7.40-7.43 (t, with fine structure, H
benzotriazole, IH), 7.53-7.55 (t, with fine structure, Hbenzotriazole, IH), 7.69-7.71 (d, J = 8.3
Hz, H benzotriazole, IH), 8.07-8.09 (d, J = 8.3 Hz, H benzotriazole, IH). 13CNMR (150
MHz) 8: 15.86 (CHCH3), 66.13 (CH20H), 75.41 (NCH2), 75.57 (CHCH3), 109.72 (C
benzotriazole), 120.06 (C benzotriazole), 124.42 (C benzotriazole), 128.03 (C benzotriazole),
132.70 (C benzotriazole), 146.32 (C benzotriazole). MS (EI) m/z (%) 207 M+(3), 177 (39), 133
(66),120 (27),104 (37), 91 (46),77 (100), 59 (28),51 (21),31 (24),29 (4).
l-[(1-p- Toluenesulphonyloxyprop-2-yloxy) methyl] benzotriazole (2.69) from 80% pure 1-[(1-
hydroxyprop- 2-yloxy)methyl ]benzotriazole 2.68
Triethylamine (0.1 ml) and p-toluenesulphonyl chloride (126 mg, 0.7 mmol) were added to a
solution of the crude CHCh extract of 1-[(1-hydroxyprop-2-yloxy)methyl]benzotriazole 2.68
(130 mg, approximately 0.6 mmol) in dry dichloromethane (6 ml). The mixture was refluxed
and stirred on a hot plate for 6 hours, after which TLC (Methods 6 or 7) showed the presence
of the unreacted starting compound 2.68. Additional p- TsCI (20 mg, 0.1 mmol) was added to
the reaction mixture and the mixture was further refluxed for several hours, after which
unreacted 2.68 was still present. The reaction mixture was evaporated to dryness to give a
crude product that was chromatographed over silica gel (8 g), using petroleum ether/ethyl
acetate (10:1, 5:1, 3:1), and finally CHCl3 as mobile phases. Only the fraction eluted with
CHCl3 contained 1-[(1-p-toluenesulphonyloxyprop-2-yloxy)methyl]benzotriazole 2.69 (83 mg,
36%) in an isomeric purity of 98% [HPLC Method 2(b)]. IH NMR (300 MHz) 8: 0.94 (d, J =
6.2 Hz, OCHCH3, 3H), 2.39 (s, Ts-CH3, 3H), 3.79-3.88 (m, OCHCR3 and CH20Ts overlap,
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3H), 5.96 (s, NCH20, 2H), 7.26-7.29, 7.65-7.68 (m, AA'BB' spin system, Ts aromatic H, 4H),
7.36-7.41 (ddd, 'i: = 8.3 Hz, H benzotriazole, 1H), 7.47-7.53 (ddd, 3Jvic = 8.3 Hz, H
benzotriazole, 1H), 7.60-7.64 (d, with fine structure, H benzotriazole, 1H), 8.03-8.07 (d, with
fine structure, H benzotriazole, 1H). l3C NMR (75 MHz) 0: 16.05 (CHCH3), 21.45 (Ts-CH3),
71.92 (CH20Ts), 71.98 (CHCH3), 75.65 (NCH2), 110.01 (C benzotriazole), 120.16 (C
benzotriazole), 124.60 (C benzotriazole), 127.99 (Ts aromatic C), 128.24 (C benzotriazole),
130.02 (Ts aromatic C), 132.83 (Ts aromatic C), 132.93 (C benzotriazole), 145.17 (Ts aromatic
C), 146.61 (C benzotriazole). HRMS: m/z M+ = 361.1117, calc. for C17H1904N3S = 361.1096.
MS (EI) m/z (%) 361 M+ (59), 242 (16),206 (45), 189 (14), 155 (98), 132 (81), 91 (100),65
(12).
1-[(1-p-Toluenesulphonyloxyprop-2-yloxy)methyl}benzotriazole (2.69) from 96% pure 1-[(1-
hydroxyprop-2-yloxy)methyl]benzotriazole 2.68
A mixture of 1-[(1-hydroxyprop-2-yloxy)methyl]benzotriazole 2.68 (100 mg, 0.5 mmol), p-
toluenesulphonyl chloride (126 mg, 0.7 mmol) and triethylamine (0.1 ml) in dry
dichloromethane (5 ml) was refluxed and stirred in an oil bath at 120°C for 6 hours. Additional
p- TsCI (68 mg, 0.3 mmol) was added to the reaction mixture and reflux was continued for a
further 3 hours. The reaction mixture was evaporated to dryness under reduced pressure at
50°C and chromatographed over silica gel (8 g), using initially petroleum ether/ethyl acetate
(5:1) as mobile phase. The first fraction (55 ml) was discarded, and elution was continued with
petroleum ether/ethyl acetate (1:1). The second fraction (15 ml) was discarded, and the product
was collected in the subsequent fraction (15 ml). This fraction was evaporated to dryness under
reduced pressure at 80-90°C to grve 1-[(1-p-toluenesulphonyloxyprop-2-
yloxy)methyl]benzotriazole 2.69 (153 mg, 91%) in a 98% purity [HPLC Method 2(b)]. IH
NMR (600 MHz) 0: 1.0 (d, J = 6.1 Hz, OCHCH3, 3H), 2.45 (s, Ts-CH3, 3H), 3.86-3.89 (m,
OCHCH3, 1H), 3.91-3.94 (m, CH20Ts, 2H), 6.0 (s, NCH20, 2H), 7.30-7.32, 7.68-7.70 (m,
AA'BB' spin system, Ts aromatic H, 4H), 7.40-7.43 (t, with fine structure, H benzotriazole,
1H), 7.52-7.54 (t, with fine structure, H benzotriazole, 1H), 7.64-7.65 (d, J = 8.3 Hz, H
benzotriazole, IH), 8.07-8.08 (d, J = 8.3 Hz, H benzotriazole, 1H). l3C NMR (150 MHz) 0:
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16.25 (CHCH3), 21.63 (Ts-CH3), 71.93 (CH20Ts), 71.98 (CHCH3), 75.64 (NCH2), 109.88 (C
benzotriazole), 120.0 (C benzotriazole), 124.42 (C benzotriazole), 127.81 (Ts aromatic C),
128.06 (C benzotriazole), 129.84 (Ts aromatic C), 132.63 (Ts aromatic C), 132.70 (C
benzotriazole), 144.93 (Ts aromatic C), 146.37 (C benzotriazole). MS (EI) m/z (%) 361 M+
(33),242 (8), 206 (19), 173 (6), 155 (92), 132 (42), 120 (30), 104 (24), 91 (100),77 (43), 65
(16),39 (5).
1-[(l-Iodoprop- 2-yloxy )methylJ benzotriazole (2.70)
A mixture of 98% pure 1-[(I-p-toluenesulphonyloxyprop-2-yloxy)methyl]benzotriazoIe 2.69
(48 mg, 0.13 mmol) and sodium iodide (23 mg, 0.15 mmol) in acetone (1 ml) was heated and
stirred in a sealed vial (5 ml) in an oil bath at 100-130°C for 1.5 hours. After evaporation of the
solvent with a stream of nitrogen, the reaction product was chromatographed over silica gel (5
g) with petroleum ether/ethyl acetate (3:1) to give 1-[(I-iodoprop-2-
yloxy)methyl]benzotriazole 2.70 as an oil (36 mg, 86%) in a 99% purity [HPLC Method 2(b)].
IH NMR (600 MHz) 8: 1.2 (d, J= 6.1 Hz, OCHCH3, 3H), 3.11-3.14 (dd, Jgem = 10.6 Hz, Jyic =
5.5 Hz, csm, IH), 3.17-3.20 (dd, Jgem = 10.6 Hz, Jyic = 4.8 Hz, CHHl, IH), 3.59-3.63 (m,
OCHCH3, IH), 6.07 (s, NCH), 2H), 7.41-7.44 (t, with fine structure, H benzotriazole), IH),
7.54-7.57 (t, with fine structure, H benzotriazole, IH), 7.72-7.74 (d, J = 8.3 Hz, H
benzotriazole, IH), 8.08-8.10 (d, J = 8.3 Hz, H benzotriazole, IH). 13CNMR (150 MHz) 8:
10.23 (CH21), 20.29 (CHCH3), 73.20 (NCH2), 75.15 (CHCH3), 110.07 (C benzotriazole),
120.02 (C benzotriazole), 124.45 (C benzotriazole), 128.02 (C benzotriazole), 132.74 (C
benzotriazole), 146.41 (C benzotriazole). MS (EI) m/z (%) 317 M+ (45), 289 (10), 259 (22),
231 (31), 190 (61),169 (100),132 (52),119 (47), 77 (67), 41 (65),27 (5).
1-(2-Hydroxyprop-1-yl)benzotriazole (2.71)
A mixture ofbenzotriazole (200 mg, 1.7 mmol), anhydrous K2C03 (720 mg, 5.2 mmol) and 1-
bromo-2-propanol (99.7% isomeric purity) (413 mg, 2.5 mmol) in acetonitrile (20 ml) was
refluxed and stirred on a hot plate for 5.5 hours. Additional I-bromo-2-propanol (383 mg, 2.3
mmol) was added to the reaction mixture, and the mixture was refluxed for another 5.5 hours.
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The reaction mixture was filtered and the filtrate evaporated to dryness at 85°C under reduced
pressure. The crude product was chromatographed over silica gel (lOg), using initially
petroleum ether/ethyl acetate (3: 1) as the mobile phase. The first fraction (33 ml) was
discarded, and elution was continued with petroleum ether/ethyl acetate (1: 1). The second
fraction (25 ml) was discarded, and elution was continued with ethyl acetate. The first 20 ml
(fraction 3) contained impurities, while the subsequent fractions 4 and 5 (5 ml each) contained
the product (most intense spot on TLC). Fraction 4 was re-chromatographed on silica gel (5 g),
using petroleum ether/ethyl acetate (1: 1) as the mobile phase. The first 30 ml was discarded
and the subsequent product-containing fraction (30 ml) was combined with fraction 5 obtained
from the first column purification procedure. Evaporation to dryness gave 1-(2-hydroxyprop-1-
yl)benzotriazole 2.71 as an oily substance which later solidified into a solid wax (141 mg,
47%). IH NMR (600 MHz) 8: 1.34-1.35 (d, J = 6.1 Hz, CHCH3, 3H), 3.38 (s, OH, 1H), 4.45-
4.53 (CH-OH, NCHH overlap, 2H), 4.62-4.64 (AB spin system, dd, Jgem = 13.5 Hz, Jyic = 2.8
Hz, NCHH, 1H), 7.27-7.30 (t, with fine structure, H benzotriazole, 1H), 7.44-7.47 (t, with fine
structure, H benzotriazole, 1H), 7.59-7.61 (d, with fme structure, H benzotriazole, 1H), 7.84-
7.85 (d, with fine structure, H benzotriazole, 1H). 13CNMR (150 MHz) 8: 20.62 (CHCH3),
55.16 (NCH2), 66.97 (CHCH3), 109.93 (C benzotriazole), 119.45 (C benzotriazole), 123.96 (C
benzotriazole), 127.34 (C benzotriazole), 133.69 (C benzotriazole), 145.35 (C benzotriazole).
MS (EI) m/z (%) 177 M+ (35), 132 (41), 104 (77), 91 (25), 77 (100),51 (26),45 (37), 18 (12).
A small amount of the less polar product 2-(2-hydroxyprop-1-yl)benzotriazole 2.72 was also
isolated (85 mg). 13CNMR 8: 19.91 (CHCH3), 62.78 (NCH2), 66.62 (CHCH3), 118.02 (C
benzotriazole), 126.73 (C benzotriazole), 144.35 (C benzotriazole).
1-(2-p- Toluenesulphonyloxyprop-I-yl)benzotriazole (2.73)
A mixture of 1-(2-hydroxyprop-I-y1)benzotriazole 2.71 (85 mg, 0.48 mmoi), triethylamine (0.1
ml) and p-toluenesulphonyl chloride (123 mg, 0.65 mmol) in dry dichloromethane (2 ml) was
refluxed and stirred in an oil bath at 140°C for 4 hours. The reaction mixture was reduced in
volume with a stream of nitrogen to approximately 1 ml, additional triethylamine (0.1 ml) was
added to the mixture and heating was continued at 150°-160°C for 2 hours. Additional p-
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toluenesulphonyl chloride (50 mg) was added to the reaction mixture and heating was
continued for another 1 hour at 140°C. The reaction mixture was chromatographed over silica
gel (8 g), using CHCI3, followed by a gradient of petroleum ether/ethyl acetate (3:1, 2:1 and
1:1) as mobile phases. Fractions containing a product having the same R, value as the main
component in the crude reaction mixture were combined and evaporated to dryness to give a
white crystalline solid (59 mg, 37%). Crystallisation from ethyl acetate gave 1-(2-p-
toluenesulphonyloxyprop-l-yl)benzotriazole 2.73 (41 mg, 26%) in a purity of 97% [HPLC
Method 2(b)], m.p. 151.5-152°C, IH NMR (600 MHz) 8: 1.49 (d, J = 6.3 Hz, CHCH3, 3H),
2.34 (s, Ts-CH3, 3H), 4.67-4.71 (AB spin system, dd, Jgem = 15.0 Hz, Jyic = 7.5 Hz, NCHH,
IH), 4.74-4.77 (AB spin system, dd, Jgem = 15.0 Hz, i.; = 3.7 Hz, NCHH, IH), 4.98-5.03 (m,
CHOTs, IH), 6.98-7.0, 7.31-7.32 (m, AA'BB' spin system, Ts aromatic H, 4H), 7.33-7.36 (t,
with fine structure, H benzotriazole, IH), 7.44-7.47 (t, with fine structure, H benzotriazole,
IH), 7.50-7.52 (d, with fine structure, Hbenzotriazole, IH), 7.93-7.95 (d, with fine structure, H
benzotriazole, IH). 13C NMR (150 MHz) 8: 18.94 (CHCH3), 21.58 (Ts-CH3), 52.21 (NCH2),
77.50 (CHOTs), 109.69 (C benzotriazole), 119.76 (C benzotriazole), 123.86 (C benzotriazole),
126.97 (Ts aromatic C), 127.69 (C benzotriazole), 129.52 (Ts aromatic C), 132.37 (Ts aromatic
C), 133.31 (C benzotriazole), 144.69 (Ts aromatic C), 145.62 (C benzotriazole). HRMS: m/z
M+ = 331.0978, calc. for C16H1703N3S = 331.0991. MS (EI) m/z (%) 331 M+ (38), 223 (13),
194 (15), 155 (100), 132 (56), 104 (13), 91 (45) 65 (6).
1-(2-Iodoprop-l-yl)benzotriazole (2.74)
A mixture of 1-(2-p-toluenesulphonyloxyprop-1-yl)benzotriazole 2.73 (25 mg, 0.075 mmol)
and sodium iodide (17 mg, 0.113 mmol) in acetone (0.8 ml) was heated with stirring in a sealed
vial in an oil bath at 120-125°C for 2.5 hours. After evaporation of the solvent, the reaction
mixture was chromatographed over silica gel (8 g) using petroleum ether/ethyl acetate (3: 1) as
mobile phase, to give 1-(2-iodoprop-l-yl)benzotriazole 2.74 as a off-white semi-solid (17.5
mg, 81%) in a purity of 99% [HPLC Method 2(b)]. IH NMR (300 MHz) 8: 1.89-1.92 (d, J =
6.9 Hz, CHCH3, 3H), 4.61-4.73 (m, CHI, IH), 4.91 (AB spin system, dd, Jgem = 14.6 Hz, i.; =
8.2 Hz, NCHH, IH), 5.06 (AB spin system, dd, Jgem = 14.6 Hz, Jyic = 6.6 Hz, NCHH, IH),
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7.41-7.47 (t, with fine structure, H benzotriazole, 1H), 7.54-7.60 (t, with fine structure, H
benzotriazole, 1H), 7.61-7.64 (d, with fine structure, H benzotriazole, 1H), 8.12-8.15 (d, with
fme structure, H benzotriazole, 1H). l3C NMR (75 MHz) 8: 20.10 (I-CHCH3), 25.55(CHCH3),
57.20 (NCH2), 109.35 (C benzotriazole), 120.35 (C benzotriazole), 124.26 (C benzotriazole),
127.88 (C benzotriazole), 133.22 (C benzotriazole), 145.93 (C benzotriazole). MS (EI) m/z (%)
287 M+ (100),258 (10), 230 (78), 203 (20), 160 (18), 132 (63), 104 (18), 77 (44),41 (37),27
(6).
1-(3-Hydroxy-2-methylprop-l-yl)benzotriazole (2.76)
A mixture of benzotriazole (100 mg, 0.84 mmol), anhydrous K2C03 (360 mg) and (S)-(+)-3-
bromo-2-methyl-1-propanol (97%, 192 mg, 1.25 mmol) in acetonitrile (10 ml) was refluxed
and stirred on a hot plate for 1 hour. The reaction mixture was filtered and the filtrate
evaporated to dryness. Column chromatography over silica gel (5 g), using petroleum
ether/ethyl acetate (1: 1) as mobile phase, gave two fractions, of which the more polar fraction
(lower Rfon TLC) yielded 1-(3-hydroxy-2-methylprop-1-yl)benzotriazole 2.76 (70 mg, 44%).
IH NMR (300 MHz) 8: 1.01 (d, J = 7.0 Hz, CHCH3, 3H), 2.38-2.49 (m, CH2CH, OH
overlapping, 2H), 3.47-3.63 (m, CH20H, 2H), 4.60-4.67 (AB spin system, dd, Jgem = 14.2 Hz,
i.; = 6.5 Hz, NCHH, 1H), 4.75-4.82 (AB spin system, dd, Jgem = 14.2 Hz, Jyic = 6.7 Hz,
NCHH, 1H), 7.38-7.44 (t, with fine structure, H benzotriazole, 1H), 7.50-7.56 (t, with fine
structure, H benzotriazole, 1H), 7.63-7.66 (d, with fine structure, H benzotriazole, 1H), 8.08-
8.12 (d, with fme structure, H benzotriazole, 1H). l3C NMR (75 MHz) 8: 14.45 (CHCH3),
36.43 (CHCH3), 50.09 (NCH2), 64.29 (CH20H), 109.65 (C benzotriazole), 120.02 (C
benzotriazole), 124.06 (C benzotriazole), 127.52 (C benzotriazole), 133.72 (C benzotriazole),
145.91 (C benzotriazole). MS (EI) m/z (%) 191 M+ (51), 161 (8), 132 (51), 119 (19), 91 (100),
77 (95), 55 (25), 31 (38), 27 (13).
1-(2-Methyl-3-p-toluenesulphonyloxyprop-l-yl)benzotriazole (2.77)
This compound was prepared from 1-(3-hydroxy-2-methylprop-1-yl)benzotriazole 2.76 (55
mg, 0.29 mmol) and p-toluenesulphonyl chloride (85 mg, 0.45 mmol) according to the
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procedure used for the preparation of 1-(2-p-toluenesulphonyloxyprop-1-yl)benzotriazole 2.73.
Column chromatography over silica gel (7 g) and elution with CHCI3, followed by petroleum
ether/ethyl acetate (1:1), gave an impure product. A second purification over silica gel (6 g),
using petroleum ether/ethyl acetate (2: 1) as mobile phase, gave pure 1-(2-methyl-3-p-
toluenesulphonyloxyprop-1-yl)benzotriazole 2.77 (49 mg, 50%). IH NMR (300 MHz) 8: 1.02
(d,J= 6.9 Hz, CHCH3, 3H), 2.45 (s, Ts-CH3, 3H), 2.63-2.73 (m, CH2CH, 1H), 3.95 (d,J= 5.4
Hz, CH20Ts, 2H), 4.49-4.56 (AB spin system, dd, Jgem = 14.2 Hz, Jvic = 7.0 Hz, NCHH, 1H),
4.63-4.71 (AB spin system, dd, Jgem = 14.2 Hz, Jvic = 6.7 Hz, NCHH, 1H), 7.33-7.36, 7.76-7.78
(m, AA'BB' spin system, Ts aromatic H, 4H), 7.39-7.45 (m, H benzotriazole, 1H), 7.53-7.55
(m, Hbenzotriazole, 2H), 8.08-8.10 (d, with fine structure, Hbenzotriazole, 1H). l3CNMR (75
MHz) 8: 14.28 (CHCH3), 21.44 (Ts-CH3), 34.01 (CHCH3), 49.57 (NCH2), 71.44 (CH20Ts),
109.32 (C benzotriazole), 120.15 (C benzotriazole), 124.11 (C benzotriazole), 127.72 (C
benzotriazole), 128.01 (Ts aromatic C), 130.09 (Ts aromatic C), 132.61 (Ts aromatic C),
133.50 (C benzotriazole), 145.29 (Ts aromatic C), 145.95 (C benzotriazole). MS (EI) m/z (%)
345 M+ (12), 221 (6), 190 (14), 172 (13), 144 (23), 120 (27), 91 (100), 77 (63), 65 (26), 18
(32).
1-(3-Iodo-2-methylprop-l-yl)benzotriazole (2.78)
This compound was prepared from 1-(2-methyl-3-p-toluenesulphonyloxyprop-1-
yl)benzotriazole 2.77 (17 mg, 0.05 mmol) and sodium iodide (10 mg, 0.07 mmol) according to
the procedure used for the preparation of 1-(2-iodoprop-1-yl)benzotriazole 2.74. Column
chromatography over silica gel gave 1-(3-iodo-2-methylprop-1-yl)benzotriazole 2.78 (12 mg,
82%). IH NMR (600 MHz) 8: 1.09 (d, J = 6.8 Hz, CHCH3, 3H), 2.31-2.36 (m, CH2CH, 1H),
3.15 (AB spin system, dd, Jgem = 10.3 Hz, Jvic = 4.9 Hz, CHHI, 1H), 3.23 (AB spin system, dd,
Jgem = 10.3 Hz, Jvic = 5.4 Hz, CHHI, 1H), 4.51 (AB spin system, dd, Jgem = 14.0 Hz, Jvic = 6.7
Hz, NCHH, 1H), 4.65 (AB spin system, dd, Jgem = 14.2 Hz, Jvic = 7.1 Hz, NCHH, 1H), 7.37-
7.40 (t, J = 7.5 Hz, H benzotriazole, 1H), 7.50-7.53 (t, J = 7.6 Hz, H benzotriazole, 1H), 7.62
(d, J= 8.3 Hz, Hbenzotriazole, 1H), 8.07 (d, J= 8.3 Hz, Hbenzotriazole, 1H). l3CNMR (150
MHz) 8: 12.26 (CHCH3), 18.91 (CH21), 35.63 (CHCH3), 53.00 (NCH2), 109.39 (C
142
Stellenbosch University http://scholar.sun.ac.za
benzotriazole), 120.12 (C benzotriazole), 123.99 (C benzotriazole), 127.50 (C benzotriazole),
133.35 (C benzotriazole), 145.82 (C benzotriazole). MS (EI) m/z (%) 301 M+ (34), 231 (48),
203 (5), 174 (54), 132 (81), 104 (38), 77 (100), 41 (36), 18 (36).
6.3.3.2 Synthesis of the alkylating agents and the 2-methyl-4-nitroimidazole derivatives
1-[(1-Benzoyloxyprop-2-yloxy)methyl] -2-methyl-4-nitroimidazole (2.80)
A mixture of 2-methyl-5-nitroimidazole 2.79 (350 mg, 2.7 mmol), anhydrous K2C03 (1 g) and
acetonitrile (70 ml) was stirred at room temperature for 30 minutes. A solution of freshly
prepared isomerically impure 2-chloromethoxyprop-l-yl benzoate 2.56 (783 mg, 3.4 mmol) in
acetonitrile (9 ml) was added to the resultant yellow suspension. The reaction mixture was
stirred overnight at room temperature, after which it was filtered and the filtrate evaporated to
dryness. The filtrate residue was chromatographed over silica gel (26 g), using ethyl acetate as
mobile phase. The major, least polar product was isolated to give an off-white solid (768 mg).
It was crystallised from methanol to give 1-[(I-benzoyloxyprop-2-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.80 as white crystals (289 mg, 33%) in a purity of 98% [HPLC Method 5],
m.p. 139-139.5°C, IH NMR (300 MHz) 8: 1.27-1.30 (d, J = 6.4 Hz, OCHCH3, 3H), 2.47 (s,
CH3 imidazole, 3H), 3.93-4.02 (m, OCHCH3, IH), 4.27-4.40 (m, CH20CO, 2H), 5.40, 5.43
(AB spin system, 2Jgem = 11.0 Hz, NCHb 2H), 7.48-7.53 [t (with fine structure), H-3, H-5
phenyl, 2H], 7.61-7.66 [t (with fine structure), H-4 phenyl, IH], 7.83 (s, H imidazole, IH),
7.99-8.02 [d (with fine structure), H-2, H-6 phenyl, 2H]. l3C NMR (75 MHz) 8: 12.83
(imidazole CH3), 16.66 (CHCH3), 67.04 (CH20CO), 72.98 (CHCH3), 74.88 (NCH2), 119.56
(C-5 imidazole), 128.73 (phenyl C), 129.50 (phenyl C), 129.63 (phenyl C), 133.65 (phenyl C),
145.46 (C imidazole), 147.08 (C imidazole), 166.48 (C=O). MS (EI) m/z (%) 319 M+ (1), 193
(7), 163 (15), 141 (7), 105 (100), 77 (22), 43 (8).
1-[(1-Hydroxyprop-2-yloxy)methyl] -2-methyl-4-nitroimidazole (2.82)
Concentrated ammonia solution (25%, 8 ml) was added to a solution of 1-[(1-benzoyloxyprop-
2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.80 (200 mg, 0.62 mmol) in methanol (15 ml),
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and the mixture was stirred overnight at room temperature after which the reaction mixture was
evaporated to near dryness under reduced pressure at 60°C. Residual water was azeotropically
distilled off with acetonitrile. The residue was triturated with CHCl3 (20 ml), the residue was
filtered off and the filtrate evaporated to dryness. The brownish filtrate residue was
chromatographed over silica gel (4 g), using ethyl acetate as mobile phase, to give pure 1-[(1-
hydroxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.82 (126 mg, 93%). IH NMR (300
MHz) 8: 1.12-1.14 (d, J = 6.4 Hz, OCHCH3, 3H), 2.51 (s, CH3 imidazole, 3H), 3.58-3.67 (m,
CH20H, 2H), 3.70-3.79 (m, OCHCH3, IH), 5.44, 5.53 (AB spin system, 2Jgem = 10.8 Hz,
NCH2, 2H), 7.89 (s, H imidazole, IH). l3C NMR (75 MHz) 8: 12.82 (imidazole CH3), 16.12
(CHCH3), 66.68 (CH20H), 75.28 (NCH2), 75.78 (CHCH3), 119.98 (C-5 imidazole), 145.62 (C
imidazole), 146.57 (C imidazole). MS (EI) m/z (%) 215 M+ (4), 185 (3), 156 (2), 141 (11), 127
(18),98 (4), 81 (13),59 (100), 43 (53),28 (4).
2-Methyl-4-nitro-l-[(l-p-toluenesulphonyloxyprop-2-yloxy )methyl] imidazole (2.83)
This compound was prepared from 1-[(I-hydroxyprop-2-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.82 (97 mg, 0.45 mmol) and p-toluenesulphonyl chloride (112 mg, 0.58 mmol)
according to the procedure used for the preparation of 1-[(I-p-toluenesulphonyl-oxyprop-2-
yloxy)methyl]benzotriazole 2.69. The reaction mixture was refluxed in an oil bath at 100°C for
4.5 hours, and column chromatography was carried out over silica gel (6 g), using initially
petroleum ether/ethyl acetate (1: 1) as the mobile phase. The first fraction (13 ml) was
discarded, and elution was continued with petroleum ether/ethyl acetate (1:3). The second
fraction (15 ml) was discarded, and the product was collected in the subsequent fraction (24
ml). 2-Methyl-4-nitro-l-[(1-p-toluenesulphonyloxyprop-2-yloxy)methyl]imidazole 2.83 was
obtained as a white solid (152 mg, 91%), m.p. 97.5-98°C, IH NMR (600 MHz) 8: 1.12 (d, J =
6.4 Hz, OCHCH3, 3H), 2.46 (2s, CH3 imidazole and Ts-CH3 overlap, 6H), 3.82-3.87 (m,
OCHCH3, IH), 3.95 (AB spin system, dd, Jgem = 10.9 Hz, Jyic = 7.5 Hz, CHHOTs, IH), 4.01
(AB spin system, dd, Jgem = 10.9 Hz, Jyic = 3.2 Hz, CHHOTs, IH), 5.33, 5.35 (AB spin system,
2Jgem = 11.0 Hz, NCH], 2H), 7.37, 7.76 (m, AA'BB' spin system, Ts aromatic H, 4H), 7.73 (s,
H imidazole, IH). l3C NMR (150 MHz) 8: 13.02 (imidazole CH3), 16.64 (CHCH3), 21.63 (Ts-
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CH3), 72.39 (CH20Ts), 72.72 (CHCH3), 75.32 (NCH2), 119.48 (C-5 imidazole), 127.77 (Ts
aromatic C), 130.02 (Ts aromatic C), 132.41 (Ts aromatic C), 145.32 (C imidazole), 145.45 (Ts
aromatic C), 146.56 (C imidazole). HRMS: m/z M+ = 369.0997, calc. for ClsH1906N3S =
369.0994. MS (EI) m/z (%) 369 M+ (3), 243 (16), 213 (60), 198 (5), 155 (100), 141 (10), 91
(23).
2-Methyl-4-nitro-1-[(1 -trifluoromethanesulphonyloxyprop-2-yloxy )methyl] imidazole (2.85)
Neat trifluoromethanesulphonic anhydride (14 JlI, 0.08 mmol) was added to a chilled (-10°C)
solution of 1-[(1-hydroxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.82 (15 mg, 0.07
mmol) in dry acetonitrile (0.3 ml). The reaction mixture was refrigerated at -10°C for
approximately 1 hour, after which the solvent was evaporated with a stream of nitrogen. Ice
water (1 ml) and dichloromethane (1 ml) was added to the residue, the aqueous phase was
made basic with sodium carbonate solution, the mixture stirred well and the layers separated.
The aqueous phase was extracted three times with dichloromethane (0.5 ml) and the combined
dichloromethane extracts were dried over anhydrous MgS04. The drying agent was filtered off
and the filtrate concentrated with a stream of nitrogen to give 2-methyl-4-nitro-I-[(I-
trifluoromethanesulphonyloxyprop-2-yloxy)methyl]imidazole 2.85 as a white solid (25 mg,
100% yield). This solid was immediately dissolved in dry dichloromethane (1.25 ml) and
refrigerated at -10°C.
1-[(1-Iodoprop-2-yloxy) methyl] -2-methyl-4-nitroimidazole (2.87)
A mixture of 2-methyl-4-nitro-I-[(1-p-toluenesulphonyloxyprop-2-yloxy)methyl]imidazole
2.83 (25 mg, 0.07 mmol) and sodium iodide (12 mg, 0.08 mol) in acetone (1.5 ml) was heated
under reflux in an oil bath at 120-140°C for 1.5 hours. Additional sodium iodide (5.8 mg) in
acetone (0.3 ml) was added to the reaction mixture and heating was continued for a further 45
minutes. The reaction mixture was chromatographed over silica gel (5 g), using ethyl
acetate/hexane/chloroform (70: 15:15) as mobile phase, to give pure I-[(I-iodoprop-2-
yloxy)methyl]-2-methyl-4-nitroimidazole 2.87 (18 mg, 82%). IH NMR (600 MHz) 8: 1.27 (d, J
= 6.2 Hz, OCHCH3, 3H), 2.54 (s, CH3 imidazole, 3H), 3.15-3.21 (m, CH21, 2H), 3.59-3.64 (m,
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OCHCH3, IH), 5.34, 5.37 (AB spin system, 2Jgem = 11.0 Hz, NCH], 2H), 7.80 (s, H imidazole,
IH). "c NMR (150 MHz) 0: 9.03 (CH2I), 13.35 (imidazole CH3), 20.43 (CHCH3), 74.58
(NCH2), 74.70 (CHCH3), 119.52 (C-5 imidazole), 145.52 (C imidazole), 146.63 (C imidazole).
MS (EI) m/z (%) 325 M+ (3),295 (1), 199 (19), 169 (100), 141 (18), 127 (1), 98 (2),41 (20),39
(3).
2-Bromo-l-propanol (2.53)
A solution of lithium aluminium hydride (LAH) in tetrahydrofuran (1M, 70 ml, 70 mmol) was
placed in a thoroughly dried 250 ml Erlenmeyer flask and cooled to -10°C. Concentrated
sulphuric acid (1.9 ml, 35 mmol) was added dropwise with stirring to the LAH at such a rate
that the temperature of the mixture did not exceed 4°C. After the addition was completed, the
mixture was cooled to -5°C while being stirred and treated with a solution of 2-bromopropionic
acid (4.5 g, 29.4 mmol) in anhydrous tetrahydrofuran (30 ml) at such a rate that the temperature
of the mixture did not exceed 12°C. After the addition was completed, the temperature was
allowed to increase to room temperature and stirring was continued for 2.5 hours. The mixture
was cooled to 5°C, and water/THF (1: 1, 10 ml) was added dropwise to the mixture while
maintaining the temperature of the mixture at 0-5°C. Stirring was continued for 10-15 minutes.
Diethyl ether (100ml) and sodium hydroxide solution (15%, 13 ml) were added to the reaction
mixture, and stirring was continued for another 10 minutes. The mixture was filtered and the
filtrate concentrated at 45-50°C under reduced pressure to a volume of approximately 2 ml.
Dichloromethane (20 ml) and anhydrous MgS04 were added, the mixture was stirred for 25
minutes, filtered, and the filtrate concentrated at 30-35°C under reduced pressure to give a
colourless liquid. Residual solvent was removed by drying the liquid under vacuum at 55°C for
a few hours, giving 2-bromo-l-propanoI2.53 (0.86 g, 21%) in an isomeric purity of95% (GC
Method 1). The product and its isomeric impurity were identified by comparing the retention
times on the GC chromatogram with those obtained from a commercially available mixture of
the isomers l-bromo-Z-propanol LSz and 2-bromo-l-propanoI2.53.
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I-Hydroxyprop-2-yl benzoate (2.55) from 95% isomerically pure 2-bromo-1-propanol 2.53
A mixture of sodium benzoate (0.3 g, 2.08 mmol) and 2-bromo-1-propanol 2.53 (460 mg, 3.3
mmol) in dimethylformamide (5 ml) was heated and stirred in a sealed vial (lO ml) in an oil
bath at 80-100°C for an hour. Additional 2-bromo-I-propanol (240 mg) and sodium benzoate
(0.3 g) were added to the reaction mixture which was heated at 100-117°C for a further 6 hours
and then allowed to cool to room temperature. The solid matrerial was filtered off, and the
filtrate evaporated to dryness under reduced pressure at 100°C. Further work-up and
purification, carried out as described for the preparation of 2-hydroxyprop-1-yl benzoate 2.54,
gave 1-hydroxyprop-2-yl benzoate 2.55 (542 mg, 75%) in an isomeric purity of 66% [HPLC
Method 3(a)]. IH NMR (300 MHz) 8: 1.37-1.39 (d, J= 6.5 Hz, CHCH3, 3H), 2.1 (bs, OH, 1H),
3.75-3.86 (m, CH20H, 2H), 5.25-5.31 (m, COrCH, lH), 7.46-7.51 (t, with fine structure, H-3,
H-5 phenyl, 2H), 7.58-7.64 (t, with fine structure, H-4 phenyl, 1H), 8.08-8.11 (d, with fine
structure, H-2, H-6 phenyl, 2H). 13C NMR (75 MHz) 8: 16.12 (CHCH3), 66.05 (CH20H),
72.71 (CHCH3), 128.52 (phenyl C), 129.79 (phenyl C), 130.41 [phenyl C (ipso)], 133.25
(phenyl C), 166.90 (C=O). MS (EI) rn/z (%) 180 M+ (0.2), 162 (2), 150 (3), 136 (5), 123 (11),
105 (100), 77 (37), 51 (13),31 (5), 18 (4).
l-Chloromethoxyprop-2-yl benzoate (2.57) from 2.55 of 70% isomeric purity
This reagent was prepared from 1-hydroxyprop-2-yl benzoate 2.55 (595 mg, 3.3 mmol) and
paraformaldehyde (113 mg, 3.76 mmol) according to the procedure used for the preparation of
2-chloromethoxyprop-1-yl benzoate 2.56. The final product was recovered in dichloromethane
(24 ml), with a solid content, calculated as described in the preparation of 2-
chloromethoxyprop-l-yl benzoate 2.56, of approximately 720 mg. The solution was
refrigerated at -10°C.
1-[(2-Benzoyloxyprop-l-yloxy )rnethylJ-2-rnethyl-4-nitroirnidazole (2.88)
A mixture of 2-methyl-5-nitroimidazole 2.79 (255 mg, 2.0 mmol), anhydrous K2C03 (765 mg)
and acetonitrile (50 ml) was stirred at room temperature for 50 minutes. A solution of freshly
prepared 1-chloromethoxyprop-2-yl benzoate 2.57 (approximately 720 mg, ~3.1 mmol) in
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dichloromethane (24 ml) was added to the yellow suspension. The mixture was stirred for
approximately 4.5 hours at room temperature, after which it was filtered and the filtrate
evaporated to dryness. The crude reaction product was chromatographed over silica gel (8 g),
using ethyl acetate as mobile phase. The fractions containing the target compound 2.88 were
combined, evaporated to near dryness, and the residue dissolved in methanol (2.5 ml). On
refrigerating this solution overnight at -10°C some crystals of the isomer 1-[(1-
benzoyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.80 were formed. The mother
liquor was carefully removed with a pasteur pipette, the crystals washed with a small portion of
cold methanol, and the combined mother and wash liquors evaporated to dryness. The residue,
highly enriched in 2.88, was chromatographed over silica gel (20 g), using ethyl
acetate/chloroform (1: 1) as mobile phase. Pure fractions were combined to give 1-[(2-
benzoyloxyprop-1-yloxy)methyl]-2-methyl-4-nitroimidazole 2.88 as an oil (200 mg, 31%), in
90% isomeric purity (HPLC Method 4). IH NMR (300 MHz) 8: 1.37 (d, J = 6.5Hz, CHCH3,
3H), 2.47 (s, CH3 imidazole, 3H), 3.67 (d, J= 5.0 Hz, OCH2CH, 2H), 5.32-5.42 (m, NCH2 and
CHCH3 overlapping, 3H), 7.47-7.53 [t (with fine structure), H-3, H-5 phenyl, 2H], 7.60-7.66 [t
(with fine structure), H-4 phenyl, 1H], 7.82 (s, H imidazole, 1H), 8.02-8.05 [d (with fine
structure), H-2, H-6 phenyl, 2H]. 13CNMR (75 MHz) 8: 12.82 (imidazole CH3), 16.35
(CHCH3), 68.91 (CHCH3), 71.51 (OCH2), 76.49 (NCH2), 119.64 (C-5 imidazole), 128.63
(phenyl C), 129.68 (phenyl C), 130.00 (phenyl C), 133.46 (phenyl C), 145.56 (C imidazole),
146.87 (C imidazole), 166.18 (C=O). MS (EI) m/z (%) 319 M+ (1), 193 (10), 163 (17), 105
(100), 77 (12).
1-[(2-Hydroxyprop-l-yloxy )methyl] -2-methyl-4-nitroimidazole (2.89)
This compound was prepared from 1-[(2-benzoyloxyprop-1-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.88 (184 mg, 0.57 mmol) according to the procedure used for the preparation
of 1-[(1-hydroxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazoIe 2.82, except for using
double the molar excess of 25% ammonia that was required for the synthesis of 2.82. The
CHCh extract was chromatographed over silica gel, using ethyl acetate, followed by ethyl
acetate/methanol (20: I) as mobile phase. The target compound 1-[(2-hydroxyprop-1-
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yloxy)methyl]-2-methyl-4-nitroimidazole 2.89 was obtained as a white crystalline substance
(l12 mg, 90%) in an isomeric purity of 89% (HPLC, Method 6). Recrystallisation from ethyl
acetate (1.5 ml) at -10°C gave 2.89 as white crystals (68 mg) in 94% isomeric purity, m.p. 96.5-
97.5°C, IH NMR (600 MHz) 8: 1.17 (d, J= 6.6 Hz, CHCH3, 3H), 2.50 (s, CH3 imidazole, 3H),
3.32-3.35 (dd, Jgem = 9.5 Hz, Jyic = 7.3 Hz, OCHHCH, IH), 3.46-3.48 (dd, Jgem = 9.5 Hz, Jyic =
3.2 Hz, OCHHCH, IH), 4.0 (m, CHOH, IH), 5.36, 5.40 (AB spin system, 2Jgem = 10.9 Hz,
NCH], 2H), 7.81 (s, H imidazole, IH). l3C NMR (l50 MHz) 8: 13.06 (imidazole CH3), 19.06
(CHCH3), 66.47 (CHCH3), 74.50 (OCH2), 76.71 (NCH2), 119.70 (C-5 imidazole), 145.38 (C
imidazole), 146.52 (C imidazole). MS (EI) m/z (%) 215 M+ (7), 171 (9), 141 (43), 127 (24), 89
(12), 59 (100), 43 (49), 28 (l8).
2-Methyl-4-nitro-l-[ (2-trifluoromethanesulphonyloxyprop-l-yloxy )methylJ imidazole (2.90)
This compound was prepared from 1-[(2-hydroxyprop-l-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.89 (15 mg, 0.07 mmol) and triflic anhydride (19 ul) and worked up according
to the procedure used for the preparation and work-up of 2-methyl-4-nitro-l-[(l-
trifluoromethanesulphonyloxyprop-2-yloxy)methyl]imidazole 2.85. The target compound 2-
methyl-4-nitro-l-[(2-trifluoromethanesulphonyloxyprop-l-yloxy)methyl]imidazole 2.90 was
obtained as an oil (24 mg, 100%). It was immediately dissolved in dry dichloromethane (1.2
ml), and refrigerated at -10°C.
1-[(2-Iodoprop-l-yloxy)methyl} -2-methyl-4-nitroimidazole (2.92)
A solution of of 1-[(2-hydroxyprop-l-yloxy)methyl]-2-methyl-4-nitroimidazole 2.89 (12 mg,
0.056 mmol) in dry acetonitrile (0.24 ml) was treated with neat triflic anhydride (18 ul, 0.1
mmol) at -10°C. The mixture was refrigerated for 2.5 hours at -10°C. The solvent was
evaporated at room temperature with a stream of nitrogen and the residue dissolved in acetone
(0.5 ml). A solution of sodium iodide (10 mg, 0.067 mmol) in acetone (0.34 ml) was added to
the solution of the residue in acetone, and the reaction mixture was stirred at room temperature
for 20 minutes. The reaction product was chromatographed over silica gel (3 g), using ethyl
acetate/hexane/chloroform (70:15:15) as mobile phase. Pure fractions were combined and
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evaporated to dryness. The residue was dissolved in dichloromethane (5 ml), the solution
washed with sodium carbonate solution (1%, 2 ml), dried over anhydrous MgS04, and filtered.
The filtrate was filtered through a short column of aluminium oxide to remove residual traces
of triflic acid. The filtrate was evaporated to dryness to give 1-[(2-iodoprop-l-yloxy)methyl]-2-
methyl-4-nitroimidazole 2.92 as an oil (20 mg, 100%) in 95% isomeric purity. (HPLC Method
6). IH NMR (300 MHz) 8: 1.87 (d, J = 7.0 Hz, ICHCH3, 3H), 2.55 (s, CH3 imidazole, 3H),
3.57-3.70 (m, OCH2CH, 2H), 4.11-4.22 (m, CH2CHI, IH), 5.4 (s, NCH], 2H), 7.83 (s, H
imidazole, IH). l3C NMR (75 MHz) 8: 13.05 (imidazole CH3), 20.96 (CHCH3), 24.31 (1-
CHCH3), 76.21, 76.22 (NCH2 and OCH2), 119.62 (C-5 imidazole), 145.67 (C imidazole),
146.85 (C imidazole). MS (EI) m/z (%) 325 M+ (11),281 (8),221 (12), 199 (20),169 (100), 97
(12), 73 (22), 41 (73).
1,3-Dibenzoyloxy-2-propanol (2.59)
Method 1: A mixture of benzoic acid (1.76 g, 14.4 mmol) and sodium hydride (55-65%
dispersion in oil", 1.0 g, 23-27 mmol) in HMPA (30 ml) was stirred at room temperature for 30
minutes, followed by the addition of a solution of 1,3-dibromo-2-propanol (1.5 g, 6.88 mmol)
in HMPA (5 ml). The mixture was stirred in an oil bath at 110°C for 2.5 hours during which
time its colour turned dark. The reaction mixture was cooled, a 5% HCI solution (80 ml) was
added slowly to the mixture, and the mixture was extracted with diethyl ether (50 ml). The
ethereal extract was washed with sodium hydrogen carbonate solution (5%, 30 ml), followed
by water (30 ml), dried over anhydrous MgS04, filtered, and the filtrate evaporated to dryness
to give a crude product containing 1,3-dibenzoyloxy-2-propanoI2.59 (1.67 g).
Method 2 : A mixture of sodium benzoate (2.08 g, 14.4 mmol) and 1,3-dibromo-2-propanol
(1.5 g, 6.88 mmol) in DMF (50 ml) was stirred in an oil bath at 130-135°C for 1.5 hours.
Additional sodium benzoate (1.0 g) was added to the yellow solution and the temperature was
gradually increased to 165°C to achieve complete dissolution of the solid material. Heating was
continued for another 20 minutes, after which the warm reaction mixture was filtered to
remove unreacted sodium benzoate. The filtrate was concentrated to near dryness at 100°C
7 The dispersion was not pre-washed to remove the oil
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under reduced pressure. CHCl3 (50 ml) and NaHC03 solution (5%, 40 ml) were added to the
residue and the mixture well shaken in a separating funnel. The CHCl3 layer was washed with
water (40 ml), dried over anhydrous MgS04, the drying agent filtered off, and the filtrate
evaporated to dryness to give a crude product containing 1,3-dibenzoyloxy-2-propanol 2.59
(1.74 g).
The crude extracts obtained from the two methods were combined and chromatographed over
silica gel (30 g), using petroleum ether/ethyl acetate (2: 1) as mobile phase. Fractions highly
enriched in the target compound 2.59 were combined to give 1,3-dibenzoyloxy-2-propanol
2.59 as an oil (985 mg, 24%) in a purity of 95% (HPLC Method 4). 'n NMR (300 MHz) 8:
2.91 (d, J = 4.9 Hz, OH, IH), 4.38-4.44 (m, CHOH, IH), 4.49-4.59 (ABX spin system, dd,
2Jgem = 11.7 Hz, 3Jvic = 5.3 Hz, 3Jvic = 4.9 Hz, CH20CO (2), 4H), 7.45-7.50 (m, H-3, H-5 phenyl
(2), 4H), 7.59-7.64 (m, H-4 phenyl (2), 2H), 8.08-8.11 (m, H-2, H-6 phenyl (2), 4H). l3C NMR
(75 MHz) 8: 65.82 (C02CH2), 68.53 (CHOH), 128.64 (phenyl C), 129.74 (phenyl C), 129.92
(phenyl C), 133.52 (phenyl C), 166.99 (C=O). MS (EI) m/z (%) 227 (2), 165 (13), 122 (8), 105
(100),77 (31),51 (lO), 18 (15).
1,3-Dibenzoyloxy- 2-chloromethoxypropane (2.61)
This reagent was prepared from 1,3-dibenzoyloxy-2-propanol 2.59 (313 mg, 1.0 mmol) and
paraformaldehyde (37 mg, 1.23 mmol) according to the procedure used for the preparation of
2-chloromethoxyethyl benzoate 2.51, except for allowing a slightly longer reaction time (20
minutes after introduction of 2.59) and using a slightly higher temperature (-5 to -8°C). 1,3-
Dibenzoyloxy-2-chloromethoxypropane 2.61 was obtained in a dichloromethane solution that
was concentrated to a volume of 5 ml.
1-[(1 ,3-Dibenzoyloxyprop-2-yloxy )methylJ -2-methyl-4-nitroimidazole (2.93)
This compound was prepared from 2-methyl-5-nitroimidazole 2.79 (95 mg, 0.75 mmol),
anhydrous K2C03 (285 mg) and 1,3-dibenzoyloxy-2-chloromethoxypropane 2.61 in
dichloromethane (5 ml, -1 mmol based on the 1,3-dibenzoyloxy-2-propanol 2.59 content)
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according to the procedure used for the preparation of 1-[(2-benzoyloxyprop-1-yloxy)methyl]-
2-methyl-4-nitroimidazole 2.88. Repeated column chromatography (twice) over silica gel (20
g, 8 g), using petroleum ether/ethyl acetate (2:1) and ethyl acetate as mobile phases for each
procedure, gave 1-[(1,3-dibenzoyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.93
(92 mg, 28%) in a purity of 96% (HPLC, Method 5). IH NMR (300 MHz) 8: 2.45 (s, CH3
imidazole, 3H), 4.18-4.25 (m, OCH(CH2)2), 1H), 4.45-4.52 (dd, 2Jgem = 12.1 Hz, 3Jvic = 6.1 Hz,
CHHOCO, 1H), 4.55-4.61 (dd, 2Jgem = 12.1 Hz, 3Jvic = 4.4 Hz, CHHOCO, 1H), 5.52 (s, NCH2,
2H), 7.47-7.52 (t, J = 7.6 Hz, H-3, H-5 phenyl (2), 4H), 7.61-7.67 (t, J = 7.5 Hz, H-4 phenyl
(2), 2H), 7.86 (s, H imidazole, 1H), 7.98-8.02 (m, H-2, H-6 phenyl (2), 4H). l3C NMR (75
MHz) 8: 12.74 (imidazole CH3), 63.16 (C02CH2), 74.77 (CH-O), 75.21 (NCH2), 119.72 (C-5
imidazole), 128.77 (phenyl C), 129.13 (phenyl C), 129.69 (phenyl C), 133.83 (phenyl C),
145.54 (C imidazole), 146.82 (C imidazole), 166.42 (C=O). MS (EI) mlz (%) 439 M+ (1), 409
(0.5),313 (13), 283 (9),195 (3),141 (7), 105 (100), 77 (15), 43 (3).
1-[(l-Benzoyloxy-3 -hydroxyprop-2 -yloxy) methyl] -2-methyl-ë-nitroimidazole (2.94)
A solution of concentrated ammonia (25%, 0.9 ml, ~ 13 mmol) was added to a solution of 1-
[(I,3-dibenzoyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.93 (122 mg, 0.27 mmol)
in methanol (9 ml) and the mixture was stirred at room temperature for 3 hours. The reaction
mixture was diluted with water (9 ml), chloroform (I5 ml) was added, and the mixture was
vigorously stirred for 5 minutes. The layers were separated, and the aqueous layer was again
extracted with CHCl3 (5 ml). The combined organic extracts were dried over anhydrous
MgS04, the drying agent filtered off, and the filtrate evaporated to dryness. The residue was
chromatographed over silica gel (7 g), using ethyl acetate and ethyl acetate/methanol (20:1) as
mobile phases, to grve 1-[(1-benzoyloxy-3-hydroxyprop-2-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.94 (48 mg, 57%) in a purity of 96% [HPLC Method 2(b)]. IH NMR (300
MHz) 8: 2.48 (s, CH3 imidazole, 3H), 3.77-3.83 (dd, 2Jgem = 11.9 Hz, 3Jvic = 6.5 Hz, CHHOH,
1H), 3.84-3.89 (dd, 2Jgem = 11.8 Hz, 'i: = 4.0 Hz, CHHOH, 1H), 3.94-4.0 (m, OCH(CH2)2,
1H), 4.36-4.42 (dd, 2Jgem = 12.1 Hz, 3Jvic = 6.0 Hz, CHHOCO, 1H), 4.44-4.5 (dd, 2Jgem = 12.1
Hz, 3Jvic = 4.2 Hz, CHHOCO, 1H), 5.51, 5.58 (AB spin system, 2Jgem = 10.9 Hz, NCH2, 2H),
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7.47-7.53 (t, J= 7.6 Hz, H-3, H-5 phenyl, 2H), 7.61-7.67 (t, J= 7.5 Hz, H-4 phenyl, IH), 7.88
(s, H imidazole, IH), 7.97-8.0 (m, H-2, H-6 phenyl, 2H). 13C NMR (75 MHz) 8: 12.80
(imidazole CH3), 62.57 (CH20H), 63.25 (C02CH2), 75.69 (NCH2), 77.48 (CH-O), 119.96 (C-5
imidazole), 128.78 (phenyl C), 129.29 (phenyl C), 129.69 (phenyl C), 133.79 (phenyl C),
145.69 (C imidazole), 146.69 (C imidazole), 166.66 (C=O). MS (EI) m/z (%) 335 M+ (1),318
(1),209 (13),179 (6),141 (7), 105 (100), 77 (18), 43 (8), 31 (2).
1-[ (l-Benzoyloxy- 3-trifluoromethanesulphonyloxyprop- 2-yloxy )methyl] -2-methyl-4-nitro-
imidazole (2.95) and 1-[(1-benzoyloxy-3-iodoprop-2-yloxy)methyl] -Z-methyl-s-nitroimidazole
(2.99)
A solution of 1-[(I-benzoyloxy-3-hydroxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole
2.94 (23 mg, 0.068 mmol) in dry acetonitrile (0.5 ml) was treated with neat trif1ic anhydride
(18 JlI, 0.1 mmol) at -10°C. The mixture was refrigerated for 30 minutes at -10°C, the solvent
evaporated with a stream of nitrogen at room temperature and the intermediate 1-[(1-
benzoyloxy-3-trifluoromethanesulphonyloxyprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole
2.95 dissolved in dry acetone (0.9 ml). This solution was treated with a solution of sodium
iodide (18 mg, 0.12 mmol) in dry acetone (0.6 ml) and the mixture was stirred at room
temperature for 1 hour. The acetone was evaporated with a stream of nitrogen, the reaction
product dissolved in CHCl3 (2 ml) and washed with sodium hydrogen carbonate (1%, 2 ml).
The organic layer was dried over anhydrous MgS04, the drying agent filtered off, and the
product chromatographed over silica gel (3 g), using CHCl3 and then ethyl acetate as mobile
phases, giving 1-[(I-benzoyloxy-3-iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.99
(15 mg, 50% based on 2.94). 'n NMR (300 MHz) 8: 2.53 (s, CH3 imidazole, 3H), 3.22-3.28
(dd, 2Jgem = 11.1 Hz, 3Jvic = 6.9 Hz, CHHI, lH), 3.30-3.35 (dd, 2Jgem = 11.2 Hz, 3Jvic = 4.7 Hz,
CHHI, IH), 3.89-3.97 (m, OCH(CH2h, IH), 4.37-4.43 (dd, 2Jgem = 12.1 Hz, 3Jvic = 5.8 Hz,
CHHOCO, IH), 4.47-4.53 (dd, 2Jgem = 12.1 Hz, 3Jvic = 4.5 Hz, CHHOCO, IH), 5.48 (s, NCH2,
2H), 7.47-7.53 (CC'-component of AA'BCC' spin system, H-3, H-5 phenyl, 2H), 7.62-7.67 (B-
component of AA'BCC' spin system, H-4 phenyl, IH), 7.85 (s, H imidazole, lH), 7.98-8.02
(AA'-component of AA'BCC' spin system, H-2, H-6 phenyl, 2H). l3C NMR (75 MHz) 8: 2.44
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(CH21), 13.06 (imidazole CH3), 65.07 (C02CH2), 75.30 (NCH2), 76.73 (CH-O), 119.77 (C-5
imidazole), 128.84 (phenyl C), 129.05 (phenyl C), 129.74 (phenyl C), l33.95 (phenyl C),
145.76 (C imidazole), 146.85 (C imidazole), 166.37 (C=O). MS (EI) mlz (%) 445 M+ (1), 318
(12),289 (34), 232 (2), 191 (3), 149 (2), 105 (100), 77 (17), 43 (22).
1-[(1-Benzoyloxy- 3-p-toluenesulphonyloxyprop-2 -yloxy) methyl] -2-methyl-4-nitroimidazole
(2.97)
A mixture of 1-[(1-benzoyloxy- 3-hydroxyprop- 2-yloxy)methyl]- 2-methyl-4-nitroimidazole
2.94 (21 mg, 0.06 mmol) and p-toluenesulphonyl chloride (36 mg, 0.19 mmol) in dry pyridine
(1 ml) was stirred at room temperature for 4 hours and then refrigerated overnight at -10°C.
The reaction mixture was diluted with ethyl acetate (3 ml), and washed twice with water (3
ml). The combined aqueous phase was extracted with ethyl acetate (3 ml), and the combined
organic extracts dried over anhydrous MgS04. The drying agent was filtered off, and the
solvent evaporated at 70°C under reduced pressure. The residue was chromatographed over
silica gel (6 g), using petroleum ether/ethyl acetate (2: 1), followed by ethyl acetate, as mobile
phases. Fractions showing essentially only one spot were combined, evaporated to dryness,
dissolved in CHCl3 (4 ml), and washed twice with 0.1 N H2S04 (4 ml) to remove traces of
pyridine. The CHCl3 layer was filtered through a pad of anhydrous MgS04 and the filtrate
evaporated to dryness. The residue was finally dried in vacuum at 60°C to give 1-[(1-
benzoyloxy-3-p- toluenesulphonyloxyprop- 2-yloxy)methyl]- 2-methyl-4- nitro imidazole 2.97 (24
mg, 79%). IH NMR (300 MHz) 0: 2.45 (2 s, CH3 imidazole and Ts-CH3 overlap, 6H), 4.06-
4.43 (m, OCH2CHCH20 overlap, 5H), 5.45 (s, NCH], 2H), 7.36-7.39 (m, BB'-component of
AA'BB' spin system, Ts aromatic H, 2H), 7.46-7.52 (CC'-component of AA'BCC' spin system,
H-3, H-5 phenyl, 2H), 7.62-7.67 (B-component of AA'BCC' spin system, H-4 phenyl, 1H),
7.79-7.81 (m, H imidazole, AA'-component of AA'BB' spin system, Ts aromatic H overlap,
3H), 7.92-7.95 (AA'-component of AA'BCC' spin system, H-2, H-6 phenyl, 2H). 13C NMR (75
MHz) 0: 12.74 (imidazole CH3), 21.46 (Ts-CH3), 62.25 (C02CH2), 68.43 (CH20Ts), 74.54
(NCH2), 75.52 (CH-O), 119.70 (C-5 imidazole), 128.00 (Ts aromatic C), 128.79 (phenyl C),
128.92 (phenyl C), 129.70 (phenyl C), l30.28 (Ts aromatic C), l32.27 (Ts aromatic C), l33.93
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(phenyl C), 145.62 (C imidazole), 145.92 (Ts aromatic C), 146.87 (C imidazole), 166.22
(C=O). MS (EI) m/z (%) 489 M+(1),363 (3),333 (9), 177 (1), 155 (11), 105 (100),91 (22),77
(20), 18 (8).
1-[(I-Hydroxy- 3-iodoprop- 2-yloxy)methylJ -2-methyl-A-nitroimidazole (2.100)
A solution of sodium hydroxide (1 N, 0.15 ml, 0.15 mmol) was mixed with a solution of 1-[(1-
benzoyloxy-3-iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.99 (12 mg, 0.027 mmol)
in methanol (1.2 ml) and the mixture was stirred at room temperature for 50 minutes. The
methanol was evaporated with a stream of nitrogen, water (1 ml) and CHCl3 (2 ml) was added
to the residue, and the mixture was stirred for 5 minutes. The layers were separated, the
aqueous phase extracted twice with CHCl3 (1 ml) and the combined CHCl3 extracts dried over
anhydrous MgS04. The drying agent was filtered off, and the filtrate evaporated to dryness.
The filtrate residue was chromatographed over silica gel (3 g), using ethyl acetate as mobile
phase, to give 1-[(1-hydroxy-3-iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.100
(6.5 mg, 70%). IH NMR (600 MHz) 8: 2.55 (s, CH3 imidazole, 3H), 3.13-3.16 (dd, 2Jgem = 11.0
Hz, 'i:= 6.6 Hz, CHHI, IH), 3.19-3.22 (dd, 2Jgem = 11.0 Hz, 3Jvic = 4.6 Hz, CHHI, IH), 3.66-
3.81 (m, CH20H, OCH(CH2)2) overlap, 3H), 5.47, 5.54 (AB spin system, dd, 2Jgem = 11.0 Hz,
NCH2, 2H), 7.84 (s, H imidazole, IH). 13C NMR (150 MHz) 8: 2.88 (CH21), 13.32 (imidazole
CH3), 65.01 (CH20H), 75.70 (NCH2), 79.18 (CH-O), 119.84 (C-5 imidazole), 145.65 (C
imidazole), 146.53 (C imidazole). MS (EI) m/z (%) 341 M+ (6), 214 (10), 185 (100), 184 (63),
128 (24), 111 (7),87 (43), 57 (79), 29 (40).
6.4 RADIOSYNTHESES
Radioactivity quantities are all given within ranges due to the varymg radioactivity
concentrations of the radioiodine sources.
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6.4.1 General Method for the Radiosynthesis of ~-Iodoalkylether Model Compounds 2.4, 2.7,
2.12, 2.15, 2.19, 2.22 and Reference Compounds 2.26 and 2.30
A radioiodide solution [0.5-5.0 Ill, 30-100 IlCi (1.1-3.7 MBq) 1311] and a solution of sodium
sulphite (0.5 mg) in water (20 Ill) were placed in a 5 ml pear-shaped vessel or a 2 ml
ReactiVial with a screw cap. The mixture was evaporated to dryness with a stream of argon or
nitrogen with mild heating. A solution of the respective tosylate (5-10 mg) [30-50 mg in the
case of the tosylate 2-methoxy-2-phenylethyl p-toluenesulphonate 2.21] in acetone/dioxane
(4: 1) or acetone (0.5 ml) was added to the dried mixture, the vessel fitted with a reflux
condenser (or the vial was sealed) and the mixture was heated and stirred in an oil bath at 120-
180DC. The reaction progress was monitored by means of radio-thin layer chromatography
(radio- TLC), using Method 1 and autoradiography as imaging tool. Small amounts of the
corresponding cold iodinated compounds were used as reference compounds to distinguish the
authentic radioiodinated compounds from radiochemical impurities. Some reactions were also
monitored by means of radio- HPLC, using Method 8 or 9. After completion of the reaction,
indicated by the consumption of most of the radioiodide and the formation of the desired
radioiodinated compound, the volume of the reaction mixture was reduced to approximately
0.2 ml with a slow stream of argon or nitrogen. Hexane (1 ml) was added and the mixture was
transferred to a silica gel column (3 - 4g silica gel equilibrated with hexane/chloroform (90: 10),
column diameter = 1-1.5 cm). Fractions were eluted with hexane/Cl+Cl, (90: 10) or (70:30).
The purities of these fractions were determined by means of autoradiography as described
above. Pure fractions were combined, evaporated to dryness under reduced pressure at
approximately 20DC, and the residue dissolved in a small amount of human serum (50-90 Ill)
by means of a strong vortex action.
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6.4.2 General Method for the Radiosynthesis of Benzamide Derivatives 2.42, 2.44, 2.46 and
2.48
6.4.2.1 From tosylate precursors 3-methoxy-N-(2-piperidin-I-ylethyl)-2-[2-(p-
toluenesulphonyloxy)ethoxy]benzamide 2.41, 3-methoxy-N-(2-piperidin-I-
ylethyl)-2-[I-(p-toluenesulphonyloxy)prop-2-yloxy ]benzamide 2.43 and 3-
methoxy-N-(2-piperidin-l- ylethyl)-2-[2-(p-toluenesulphonyloxy )prop-I- yloxy]-
benzamide 2.45
A radioiodide solution [50 ul, 12-19 mCi (444-703 MBq) 1231] was placed in a 1 ml ReactiVial
and evaporated to dryness with a stream of nitrogen with mild heating. A solution of the
tosylate (1 mg) in acetone (0.1 ml) was added to the radioiodide, the vial was capped and
heated in an oil bath at a temperature of 150°C (150-170°C for tosylate 2.45) for 15-20
minutes. The vial was cooled, a small aliquot was taken for HPLC analysis (Method 1), and the
acetone was evaporated with a stream of nitrogen. The residue was dissolved in diisopropyl
ether/methanol/25% ammonia (85:15:0.2) (0.3 ml) and transferred to a small (~1 cm diameter)
silica gel column (2 g silica gel equilibrated with the same solvent mixture). Residual activity
was washed into the column (0.3 ml), and the product was eluted with diisopropyl
ether/methanol/25% aqueous ammonia (85: 15:0.2). Approximately ten fractions of 2 ml each
were collected and the activity in each, fraction was measured. Fractions containing the highest
activities were combined, and evaporated to dryness with a stream of nitrogen. The resulting
residue was dissolved in a small amount of serum (90 ul) as described previously.
6.4.2.2 Radiosynthesis of 2-(3-[1231]iodoprop-2-en-I-yloxy)-3-methoxy-N-(2-piperidin-l-
ylethyl)benzamide 2.48 from precursor 3-methoxy-N-(2-piperidin-I-ylethyl)-2-[3-
(tributylstannyl)prop-2-en-I-yloxy]benzamide 2.47
A radioiodide solution [50 ul, 14 mCi (518 MBq) 1231] and a solution of precursor 2.47 (1 mg)
in acetonitrile (195 ul) were placed in aIO ml borosilicate glass vial. A solution of H2S04
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(10%, 105 ul), and a solution of chloramine- T8 (30 ug) in water (30 ul) was added to the
contents in the vial and the mixture was stirred for 5 minutes at room temperature. The reaction
was quenched with a solution of sodium metabisulphite (145 ug) in water (145 ul), the reaction
mixture neutralized to a pH of 6-7 with a solution of sodium carbonate (30 mg) in water (1 ml),
and extracted with dichloromethane (3 ml). The dichloromethane extract was evaporated to
dryness with a stream of nitrogen, and the residue dissolved in a mixture of diisopropyl
ether!methanol/25% ammonia (70:30:0.5) (0.2 ml). The solution was transferred to a silica gel
column prepared as before and the product was eluted with diisopropyl ether!methano1l25%
ammonia (70:30:0.5). Ten fractions of I ml each were collected and the activity in each
fraction was measured. Fractions containing the highest activities were combined, and
evaporated to dryness with a stream of nitrogen. The residue was dissolved in a small amount
of serum (90 ul) as previously described.
6.4.3 General Methods for the Radiosynthesis of Heterocyclic Amine Derivatives
6.4.3.1 Radiosynthesis of benzotriazole derivatives 1-[(2-[123I]iodoethoxy)methyl]benzotria-
zole 2.66b and 1-[(I-C23I]iodoprop-2-yloxy)methyl]benzotriazole 2.70
A radioiodide solution [50 ul, 15-19 mCi (555-703 MBq] was placed in a I ml ReactiVial and
evaporated to dryness with a stream of nitrogen with mild heating. A solution of the respective
tosylates 1-[(2-p-toluenesulphonyloxyethoxy)methyl]benzotriazole 2.65 and 1-[(1-p-
toluenesulphonyl-oxyprop-2-yloxy)methyl]benzotriazole 2.69 (1 mg) in acetone (0.1 ml) was
added to the radioiodide, the vial was capped and heated for 10 minutes in an oil bath at a
temperature of 130°C (for the radio synthesis of2.66b) or 130°-150°C (for the radio synthesis of
2.70). The vial was cooled, a small aliquot was taken for HPLC analysis [Method 2(a) or 2(b)],
and the reaction mixture diluted with petroleum ether (0.3 ml). The mixture was transferred to
a small column of silica gel [2 g, equilibrated with petroleum ether!ethyl acetate (5: 1)]. The
reaction vial was rinsed with the same solvent mixture (0.3 ml), the liquid transferred to the
8 The sodium salt of N-chloro-p-toluenesulphonamide
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column and the product eluted with petroleum ether/ethyl acetate (5: 1). Thirteen fractions of 2
ml each were collected, and the activity in each fraction was measured. Fractions containing
the highest activities were combined, and evaporated to dryness with a stream of nitrogen. The
residue was dissolved in a small amount of serum (90 ul) as previously described.
6.4.3.2 Radiosynthesis of Benzotriazole derivatives 1-(2-[1231]iodoprop-l-yl)benzotriazole
2.74 and 1-(3-[1231]iodo-2-methylprop-l-yl)benzotriazole 2.78
The radiosynthesis and purification of these compounds were carried out according to the
procedure used for the preparation of [1231]2.66band [1231]2.70,except for using an oil bath
temperature of 150De, and petroleum ether/ethyl acetate (3: 1) as mobile phase for the
chromatography over silica gel.
6.4.3.3 Radiosynthesis of 2-methyl-4-nitroimidazole derivative 1-[(1-[1231]iodoprop-2-
yloxy)methyl]-2-methyl-4-nitroimidazole 2.87
6.4.3.3.1 From 2-methyl-4-nitro-l-[(I-p-toluenesulphonyloxyprop-2-yloxy)methyl]imidazole
2.83
The radio synthesis and purification of [1231]2.87,using the tosylate precursor 2.83, was carried
out according to the procedure used for the preparation of 1-[(1-[1231]iodoprop-2-
yloxy)methyl]benzotriazole 2.70, except for the following differences:
Volume and activity of radio iodide solution: 65 ul, 19-20 mei (703-740 MBq).
Oil bath temperature: 130De.
Mobile phase for chromatography over silica gel: Ethyl acetate/hexane/Cl+Cl, (70: 15:15).
Fraction volumes: 1ml (Nine fractions).
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6.4.3.3.2 From 2-methyl-4-nitro-I-[(I-trifluoromethanesulphonyloxyprop-2-
yloxy)methyl ]imidazole 2.85
A radioiodide solution [50 ul, 11-14 mCi (407-518 MBq) 1231] was placed in a lO ml
borosilicate glass vial and the solution was evaporated to dryness with a stream of nitrogen
with mild heating. A solution of the triflate 2.85 (1-5 mg) in dichloromethane (50-250 ul) was
dried with a stream of nitrogen, the dried triflate re-dissolved in dry acetone (200 ul) and the
solution transferred to the vial containing the dried radioiodide. The mixture was stirred at
room temperature for 10-30 minutes. A small aliquot was taken for HPLC analysis [Method
2(b], the reaction mixture diluted with the mobile phase, ethyl acetate/hexane/ClfCl,
(70: 15:15) (0.3 ml), and chromatographed over a small silica gel column equilibrated with the
mobile phase. Ten I ml fractions were collected. Fractions containing the highest activities
were combined, evaporated and the residue dissolved in serum as before.
6.4.3.4 Radiosynthesis of 2-methyl-4-nitroimidazole derivative 1-[(2-[1231]iodoprop-l-
yloxy)methyl]-2-methyl-4-nitroimidazole 2.92
The radiosynthesis and purification of [1231]2.92 from 2-methyl-4-nitro-I-[(2-
trifluoromethanesulphonyloxyprop-I-yloxy)methyl]imidazole 2.90 was carried out according
to the procedure used for the preparation of 1-[(1-[1231]iodoprop-2-yloxy)methyl]-2-methyl-4-
nitroimidazole 2.87 from 2-methyl-4-nitro-I-[( I-trifluoromethanesulphonyloxyprop-2-
yloxy)methyl]imidazole 2.85, except for the following differences:
Volume and activity of radio iodide solution: 30-75 ul, 7-22 mCi (259-814 MBq).
Mass of triflate used: 1-9 mg.
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6.4.3.5 Radiosynthesis of 2-methyl-4-nitroimidazole derivative I-[(1-hydroxy-3-e231]iodo-
prop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.100 via I-[(1-benzoyloxy-3-
[1231]iodoprop-2-yloxy)methyl]-2-methyl-4-nitroimidazole 2.99
A radioiodide solution [50 JlI, 14 mCi (518 MBq) 1231] was placed in a 1 ml ReactiVial and
evaporated to dryness with a stream of nitrogen with mild heating. A solution of the tosylate
precursor 1-[(1-benzoyloxy- 3-p-toluenesulphonyloxyprop- 2-yloxy)methyl]- 2-methyl-4-
nitroimidazole 2.97 (1 mg) in acetone (0.1 ml) was added to the radioiodide, the vial was
capped and heated in an oil bath at 150°C for 30 minutes. The vial was cooled, a small aliquot
was taken for RPLC analysis [Method 2(b)], and the reaction mixture transferred with a small
syringe to a 10 ml borosilicate glass vial. The reaction vial was rinsed with acetone (0.3 ml)
and the liquid transferred to the 10 ml vial. The acetone solution was evaporated to dryness at
room temperature with a stream of nitrogen, and the residue, containing [1231]2.99, was
dissolved in 96% ethanol (0.2 ml). Water (0.1 ml) and 1M NaOR (50 ul) were added to the
ethanol solution, and the mixture was stirred at room temperature for approximately 30
minutes. The mixture was then filtered through a small column containing a small amount of a
water-moistened cation exchange resin [AGMP-50 hydrogen form (BioRad), 200-400 mesh,
approximately 100 mg]. The reaction vial was rinsed with ethanol (0.2 ml), and the liquid
transferred to the resin column. The filtrate was evaporated to near dryness with a stream of
nitrogen and mild heating, the residue dissolved in ethyl acetate (0.2 ml) and the solution
transferred to a small silica gel (2 g) column, equilibrated with ethyl acetate. The product,
[1231]2.100, was eluted with ethyl acetate, and nine 2 ml fractions were collected. Fractions
containing the highest activities were combined and evaporated to dryness under nitrogen with
mild heating. The residue was dissolved in serum as before.
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6.5 STABILITY EVALUATION
6.5.1 Stability Evaluation of the Labelled Pilot Study Compounds 2.4, 2.7, 2.12, 2.15, 2.19,
2.22 and the Reference Compounds 2.26 and 2.30
A small amount of the labelled compound (5 - 20 JlCi, 0.185 - 0.74 MBq), dissolved in human
blood serum (50-90 JlI), was placed in a small Eppendorff vial or a 5 ml round bottom glass
vessel and diluted further with blood serum (110 - 250 ul), An aliquot (30-45 ul) of the serum
solution was taken and diluted with acetonitrile (40-60 ul) containing 40-45 ug of the
corresponding cold iodinated compound. This aliquot represented the time 0 sample. The vial
or vessel was sealed and placed in a waterbath or incubator at 37°C. Aliquots (30-45 ul) of the
incubation mixture were taken after 3 and 21 hours incubation time and diluted with
acetonitrile in the same way as for the time 0 sample. The diluted mixtures were thoroughly
mixed by a vortex action, and the supernatent was analysed for free radioiodide. In most cases,
both radio-HPLC and -TLC were used to determine the amount of released free radioiodide.
In the radio-HPLC analysis, an aliquot (15 - 30 ul) of the supernatent was injected into the
HPLC, and the areas of the peaks processed on a chromatogram. Retention times were as
follows:
Method 8: Free radioiodide, 2.1 - 2.4 min; labelled compound, 7 - 9 min.
Method 9: Free radioiodide, 1.4 - 1.6 min; labelled compound, 7.5 - 12 min.
In the radio-Tl.C analysis, a small aliquot (6 - 20 JlI) of the supernatent solution was applied to
a silica gel TLC plate in the presence of approximately 30 ug stable sodium iodide. The plate
was developed by using TLC Method 12. The plate was then allowed to dry and imaged by
means of autoradiography. The intensities of the spots were automatically processed and
expressed as area percentages in the same way as in an HPLC chromatogram. The relative
retention factors were as follows:
Free radioiodide, 0.4-0.5; labelled compound, 1.
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The amount of free radioiodide was defined as the area of the radioactive component
associated with free radioiodide expressed as a percentage of the total area associated with free
radioiodide as well as that associated with the labelled compound displayed in a
chromatogram.
6.5.2 Stability Evaluation of the Labelled Benzamide and Heterocyclic Amine Derivatives
2.42,2.44,2.46,2.48, 2.66b, 2.70, 2.74, 2.78, 2.87, 2.92 and 2.100
A small amount of the labelled compound (0.5 - 2 mCi, 18.5 - 74 MBq), dissolved in human
blood serum (80 Ill), was placed in a 5 ml round bottom glass vessel and diluted further with
blood serum (220 or 320 Ill). An aliquot (30 Ill) of the serum solution was taken and diluted
with acetonitrile (60 Ill). This aliquot represented the time 0 sample. The vessel was sealed and
placed in an incubator oven at 37°C. Aliquots (30 Ill) of the incubation mixture were taken
after 2, 5 and 24 hours incubation time and diluted with acetonitrile in the same way as for the
time 0 sample. The diluted mixtures were thoroughly mixed by a vortex action, and the
supernatent liquid was analysed for free radioiodide by means of HPLC. An aliquot of the
supernatent solution (5-20 Ill) was co-injected with a small amount of stable sodium iodide (40
ug),
In the analysis of the labelled benzamide derivatives, HPLC Method 1 was used. The retention
times of the various compounds were as follows:
Free radioiodide, 2.0 - 2.2 min.
Labelled compound 2.42, 12.8 - 13.4 min.
2.44, 14.2 - 14.8 min.
2.46, 14.2 - 15.5 min.
2.48, 14.6 - 15.3 min.
In the analyses of the labelled heterocyclic amine derivatives, both Methods 2(a) and 2(b) were
used for labelled compounds 2.66b and 2.70, while only Method 2(b) was used for the other
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compounds in this series. No differences in retention times were observed when using these
two methods. The following retention times were recorded for the various compounds:
Free radioiodide, 2.0 - 3.0 min.
Labelled compound 2.66b, 15.1 - 16.2 min.
2.70, 17.6 - 18.3 min.
2.74, 16.5 - 16.9 min.
2.78, 18.9 - 19.1 min.
2.87, 12.4 - 12.9 min.
2.92, 13.2 - 13.9 min.
2.100,6.0 - 6.5 min.
The amount of free radioiodide was defined in the same way as described in section 6.5.1.
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APPENDIX A
CHROMATOGRAPHIC PARAMETERS FOR THE BENZAMIDE
DERIV ATIVES
Compound HPLC HPLC Retention Time TLC TLC Retention Factor
No. Method (Rt) Method (Rf)
No. (min.) No. (min.)
2.33 1 2.4 5 0.1
,
2.41 1 12.2 -
2.42 1 13.3 -
2.43 1 16.1 5 0.48
2.44 1 14.8 5 0.66
2.45 1 15.0 5 0.37
2.46 1 14.8 5 0.57
2.47 - 4 0.75
2.48 1 14.6 4 0.53
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APPENDIXB
CHROMATOGRAPHIC PARAMETERS FOR THE BENZOTRIAZOLE
DERIVATIVES
Compound HPLC HPLC Retention Time TLC TLC Retention Factor
No. Method (Rt) Method (Rf)
No. (min.) No. (min.)
2.62 2b 4.8 6 0.63
2.63 2b 17.5 6 0.75
2.64 2b 4.2 6 0.15
2.64 6 14.3
2.65 2a 17.8 6 0.61
2.66a 2b 12.2 - -
2.66b 2b 15.4 - -
2.67 2b 18.8 7 0.51
2.68 2b 5.2 6 0.31
2.68 6 15.7
2.69 2b 19.0 6 0.63
2.70 2b 18.0 7 0.63
2.71 7 7.5 6 0.37
2.72 7 12.5 6 0.57
2.73 2b 17.0 7 0.37
2.74 2b 16.7 - -
2.76 7 12.0 6 0.34
2.77 2b 19.1 7 0.46
2.78 2b 18.9 7 0.62
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APPENDIXC
CHROMATOGRAPHIC PARAMETERS FOR THE 2-METHYL-4-
NITRO IMIDAZOLE DERIVATIVES
Compound No. HPLC HPLC Retention Time TLC TLC Retention Factor
Method (Rt) Method (Rf)
No. (min.) No. (min.)
2.79 5 2.9 - -
2.80 5 8.5 9 0.67
2.80 4 13.6
2.82 5 3.1 9 0.2
2.82 6 10.9
2.83 2b 16.2 10 0.45
2.85 - - 11 0.66
2.87 2b 12.5 - -
2.88 5 7.6 9 0.71
2.88 4 15.3
2.89 4 3.1 11 0.24
2.89 6 10.1
2.90 - - 11 0.66
2.92 2b 13.3 - -
2.93 5 13.5 9 0.73
2-Methyl-5-nitro- 5 14.6 9 0.58
imidazole
derivative of 2.93
2.94 2b 9.5 11 0.36
2.95 2b 19.5 9 0.74
2.97 - - 9 0.68
2.99 2b 18.3 9 0.66
2.100 2b 6.0 9 0.37
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